e424b5
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of
|
|
|
|
|
Maximum Aggregate
|
|
|
|
Registration
|
|
Title of Each Class of Securities Offered
|
|
|
Offering Price
|
|
|
|
Fee (1)(2)
|
|
Common Stock, par value $0.01
|
|
|
$
|
6,349,520,044
|
|
|
|
$
|
737,179.28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Calculated in accordance with Rule 457(r) under the
Securities Act of 1933 as amended (the Securities
Act).
|
|
(2)
|
A registration fee of $737,179.28 has been paid with respect to
this offering.
|
Filed
pursuant to Rule 424(b)(5)
Registration No. 333-170876
(To Prospectus dated November 30, 2010)
146,809,712 Shares
Common Stock
This is an offering of 146,809,712 shares of common stock
of MetLife, Inc. MetLife, Inc. is offering
68,570,000 shares of its common stock, par value $0.01 per
share (the common stock), and ALICO Holdings
LLC, the selling stockholder (the Selling
Stockholder), and a subsidiary of American
International Group, Inc. (AIG), is offering
78,239,712 shares of the common stock. If fewer than
146,809,712 shares of the common stock can be sold in this
offering, the number of shares sold will be allocated first, to
the shares of common stock that MetLife, Inc. proposes to sell,
and second, to the shares of common stock that the Selling
Stockholder proposes to sell. See
Underwriting.
The common stock is listed on the New York Stock Exchange under
the symbol MET. On March 2, 2011, the last
reported sales price of the common stock on the New York Stock
Exchange was $43.41 per share.
Concurrently with this offering, the Selling Stockholder is
offering, by means of a separate prospectus supplement,
40,000,000 common equity units of MetLife, Inc. (the
concurrent offering). This offering of common
stock is not conditioned on the completion of the concurrent
offering. There can be no assurance that the concurrent offering
will be completed. It is a condition to the closing of the
MetLife, Inc. offering of common stock that all of the closing
conditions of the Repurchase transaction (as more fully
described herein) (except the condition that the offering of the
shares of common stock by MetLife, Inc. pursuant to this
prospectus supplement has been consummated) under the
Coordination Agreement (as defined below) will need to be
satisfied or waived. It is a condition to the closing of the
Selling Stockholder offering of common stock that the
Coordination Agreement is in full force and effect.
See Risk Factors beginning on
page S-12
of this prospectus supplement to read about important factors
you should consider before buying shares of the common stock.
Neither the Securities and Exchange Commission nor any other
regulatory body has approved or disapproved of these securities
or passed upon the accuracy or adequacy of this prospectus
supplement or the accompanying prospectus. Any representation to
the contrary is a criminal offense.
|
|
|
|
|
|
|
|
|
|
|
Per Share
|
|
Total
|
|
Public offering price
|
|
$
|
43.25000
|
|
|
$
|
6,349,520,044.00
|
|
Underwriting discounts and commissions
|
|
$
|
0.21625
|
|
|
$
|
31,747,600.22
|
|
Proceeds, before expenses, to MetLife, Inc.
|
|
$
|
43.03375
|
|
|
$
|
2,950,824,237.50
|
|
Proceeds, before expenses, to the Selling Stockholder
|
|
$
|
43.03375
|
|
|
$
|
3,366,948,206.28
|
|
The underwriters expect to deliver the shares of common stock
against payment in New York, New York on March 8, 2011.
|
|
|
Goldman,
Sachs & Co. |
Citi |
Credit
Suisse |
|
|
|
|
|
|
|
BofA
Merrill Lynch |
Barclays
Capital |
Deutsche
Bank Securities |
J.P.
Morgan |
Morgan
Stanley |
UBS
Investment Bank |
Wells
Fargo Securities |
|
|
|
|
|
|
BNP
PARIBAS |
HSBC |
Mizuho Securities USA Inc. |
Nomura |
Piper Jaffray |
PNC Capital Markets LLC |
|
|
|
|
|
|
RBC
Capital Markets |
RBS |
Scotia Capital |
SOCIETE GENERALE |
SMBC Nikko |
Cabrera Capital Markets, LLC |
|
|
|
|
|
|
CastleOak
Securities, L.P. |
Guzman & Company |
Lebenthal Capital Markets |
Loop Capital Markets |
MFR Securities, Inc. |
M.R. Beal & Company |
|
|
|
|
|
Ramirez
& Co., Inc. |
Siebert Capital Markets |
The Williams Capital Group,
L.P. |
Toussaint Capital Partners,
LLC |
Blaylock Robert Van, LLC |
Prospectus Supplement dated March 3, 2011.
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
Prospectus Supplement
|
|
|
|
S-3
|
|
|
|
|
S-3
|
|
|
|
|
S-5
|
|
|
|
|
S-7
|
|
|
|
|
S-8
|
|
|
|
|
S-12
|
|
|
|
|
S-51
|
|
|
|
|
S-54
|
|
|
|
|
S-62
|
|
|
|
|
S-63
|
|
|
|
|
S-64
|
|
|
|
|
S-65
|
|
|
|
|
S-66
|
|
|
|
|
S-68
|
|
|
|
|
S-72
|
|
|
|
|
S-78
|
|
|
|
|
S-78
|
|
|
Prospectus
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
15
|
|
|
|
|
21
|
|
|
|
|
23
|
|
|
|
|
24
|
|
|
|
|
25
|
|
|
|
|
25
|
|
|
|
|
28
|
|
|
|
|
30
|
|
|
|
|
32
|
|
|
|
|
32
|
|
You should rely only on the information contained or
incorporated by reference in this prospectus supplement and the
accompanying prospectus. Neither we nor the underwriters have
authorized anyone to provide you with additional or different
information. If anyone provided you with additional or different
information, you should not rely on it. Neither we nor the
underwriters are making an offer to sell these securities in any
jurisdiction where the offer or sale is not permitted. You
should assume that the information contained in this prospectus
supplement, the accompanying prospectus and the documents
incorporated by reference, is accurate only as of their
respective dates. MetLifes business, financial condition,
results of operations and prospects may have changed since those
dates.
S-2
The common stock is offered for sale in those jurisdictions in
the United States, Europe, Asia and elsewhere where it is lawful
to make such offers. The distribution of this prospectus
supplement and the accompanying prospectus and the offering or
sale of the common stock in some jurisdictions may be restricted
by law. Persons into whose possession this prospectus supplement
and the accompanying prospectus come are required by us, the
Selling Stockholder and the underwriters to inform themselves
about and to observe any applicable restrictions. This
prospectus supplement and the accompanying prospectus may not be
used for or in connection with an offer or solicitation by any
person in any jurisdiction in which that offer or solicitation
is not authorized or to any person to whom it is unlawful to
make that offer or solicitation. See
Underwriting in this prospectus supplement.
ABOUT
THIS PROSPECTUS SUPPLEMENT
You should read this prospectus supplement along with the
accompanying prospectus carefully before investing in the common
stock. This prospectus supplement and the accompanying
prospectus contain the terms of this offering of common stock.
This prospectus supplement may add, update or change information
in the accompanying prospectus. In addition, the information
incorporated by reference in the accompanying prospectus may
have added, updated or changed information in the accompanying
prospectus. If information in this prospectus supplement is
inconsistent with any information in the accompanying prospectus
(or any information incorporated therein by reference), this
prospectus supplement will apply and will supersede such
information.
It is important for you to read and consider all information
contained in this prospectus supplement and the accompanying
prospectus in making your investment decision. You should also
read and consider the additional information under the caption
Where You Can Find More Information in this
prospectus supplement and the accompanying prospectus.
Unless otherwise stated or the context otherwise requires,
references in this prospectus supplement and the accompanying
prospectus to MetLife, we,
our, or us refer to
MetLife, Inc., together with its direct and indirect
subsidiaries, while references to MetLife,
Inc. refer only to the holding company on an
unconsolidated basis.
WHERE YOU
CAN FIND MORE INFORMATION
MetLife, Inc. files reports, proxy statements and other
information with the Securities and Exchange Commission (the
SEC). These reports, proxy statements and
other information can be read and copied at the SECs
public reference room at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the SEC
at 1-800-SEC-0330
for further information on the operation of the public reference
room. The SEC maintains an internet site at www.sec.gov
that contains reports, proxy and information statements and
other information regarding companies that file electronically
with the SEC, including MetLife, Inc. MetLife, Inc.s
common stock is listed and trading on the New York Stock
Exchange under the symbol MET. These reports, proxy
statements and other information can also be read at the offices
of the New York Stock Exchange, 11 Wall Street, New York, New
York 10005.
The SEC allows incorporation by reference into this
prospectus supplement and the accompanying prospectus of
information that MetLife, Inc. files with the SEC. This permits
MetLife, Inc. to disclose important information to you by
referencing these filed documents. Any information referenced
this way is considered part of this prospectus supplement and
accompanying prospectus, and any information filed with the SEC
subsequent to the date of this prospectus supplement will
automatically be deemed to update and supersede this
information. Information furnished under Item 2.02 and
Item 7.01 of MetLife, Inc.s Current Reports on
Form 8-K
is not incorporated by reference in this prospectus supplement
and accompanying prospectus. MetLife, Inc. incorporates by
reference the following documents which have been filed with the
SEC:
|
|
|
|
|
Annual Report on
Form 10-K
for the year ended December 31, 2010 and Amendment
No. 1 on
Form 10-K/A,
filed on March 1, 2011 (as so amended, the 2010
Form 10-K); and
|
|
|
|
Current Reports on
Form 8-K
filed on August 2, 2010, November 30, 2010,
March 1, 2011 and March 2, 2011.
|
MetLife, Inc. incorporates by reference the documents listed
above and any future filings made with the SEC in accordance
with Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934, as amended (the
S-3
Exchange Act), until MetLife, Inc. files a
post-effective amendment which indicates the termination of the
offering of common stock made by this prospectus supplement and
accompanying prospectus. Any reports filed by MetLife, Inc. with
the SEC after the date of this prospectus supplement and before
the date that the offering of common stock by means of this
prospectus supplement and accompanying prospectus is terminated
will automatically update and, where applicable, supersede any
information contained or incorporated by reference in this
prospectus supplement and accompanying prospectus.
MetLife, Inc. will provide without charge upon written or oral
request, a copy of any or all of the documents that are
incorporated by reference into this prospectus supplement and
accompanying prospectus, other than exhibits to those documents,
unless those exhibits are specifically incorporated by reference
into those documents. Requests should be directed to Investor
Relations, MetLife, Inc., 1095 Avenue of the Americas, New York,
New York 10036, by electronic mail (metir@metlife.com), or
by telephone
(212-578-2211).
You may also obtain the documents incorporated by reference into
this document as of the date hereof at MetLifes website,
www.metlife.com. All other information contained on
MetLifes website is not a part of this document.
S-4
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement and the accompanying prospectus may
contain or incorporate by reference information that includes or
is based upon forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements give expectations or forecasts of
future events. These statements can be identified by the fact
that they do not relate strictly to historical or current facts.
They use words such as anticipate,
estimate, expect, project,
intend, plan, believe and
other words and terms of similar meaning in connection with a
discussion of future operating or financial performance. In
particular, these include statements relating to future actions,
prospective services or products, future performance or results
of current and anticipated services or products, sales efforts,
expenses, the outcome of contingencies such as legal
proceedings, trends in operations and financial results.
Any or all forward-looking statements may turn out to be wrong.
They can be affected by inaccurate assumptions or by known or
unknown risks and uncertainties. Many such factors will be
important in determining the actual future results of MetLife,
Inc., its subsidiaries and affiliates. These statements are
based on current expectations and the current economic
environment. They involve a number of risks and uncertainties
that are difficult to predict. These statements are not
guarantees of future performance. Actual results could differ
materially from those expressed or implied in the
forward-looking statements. Risks, uncertainties, and other
factors that might cause such differences include the risks,
uncertainties and other factors identified in MetLife,
Inc.s filings with the SEC. These factors include:
(1) difficult conditions in the global capital markets;
(2) increased volatility and disruption of the capital and
credit markets, which may affect our ability to seek financing
or access our credit facilities; (3) uncertainty about the
effectiveness of the United States (U.S.)
governments programs to stabilize the financial system,
the imposition of fees relating thereto, or the promulgation of
additional regulations; (4) impact of comprehensive
financial services regulation reform on us; (5) exposure to
financial and capital market risk; (6) changes in general
economic conditions, including the performance of financial
markets and interest rates, which may affect our ability to
raise capital, generate fee income and market-related revenue
and finance statutory reserve requirements and may require us to
pledge collateral or make payments related to declines in value
of specified assets; (7) potential liquidity and other
risks resulting from our participation in a securities lending
program and other transactions; (8) investment losses and
defaults, and changes to investment valuations;
(9) impairments of goodwill and realized losses or market
value impairments to illiquid assets; (10) defaults on our
mortgage loans; (11) the impairment of other financial
institutions that could adversely affect our investments or
business; (12) our ability to address unforeseen
liabilities, asset impairments, loss of key contractual
relationships, or rating actions arising from acquisitions or
dispositions, including our acquisition of American Life
Insurance Company (American Life), a
subsidiary of the Selling Stockholder, and Delaware American
Life Insurance Company (DelAm, together with
American Life, collectively ALICO) (the
Acquisition) and to successfully integrate
and manage the growth of acquired businesses with minimal
disruption; (13) uncertainty with respect to the outcome of
the closing agreement entered into between American Life and the
United States Internal Revenue Service in connection with the
Acquisition; (14) uncertainty with respect to any
incremental tax benefits resulting from the planned elections
for ALICO and certain of its subsidiaries under Section 338
of the U.S. Internal Revenue Code of 1986, as amended (the
Section 338 Elections); (15) the
dilutive impact of the settlement of the stock purchase
contracts forming part of the common equity units issued to the
Selling Stockholder and the issuance of common stock upon
conversion of any Series B Contingent Convertible Junior
Participating Non-Cumulative Perpetual Preferred Stock (the
Series B Preferred Stock) of MetLife,
Inc. not repurchased and cancelled by MetLife, Inc.;
(16) downward pressure on MetLife, Inc.s stock price
as a result of the Selling Stockholders ability to sell
its equity securities; (17) the conditional payment
obligation of up to approximately $300 million to the
Selling Stockholder, to the extent any of the Series B
Preferred Stock is not repurchased and cancelled by MetLife,
Inc. and the conversion of the Series B Preferred Stock is
not approved; (18) economic, political, currency and other
risks relating to our international operations, including with
respect to fluctuations of exchange rates; (19) MetLife,
Inc.s primary reliance, as a holding company, on dividends
from its subsidiaries to meet debt payment obligations and the
applicable regulatory restrictions on the ability of the
subsidiaries to pay such dividends; (20) downgrades in our
claims paying ability, financial strength or credit ratings;
(21) ineffectiveness of risk management policies and
procedures; (22) availability and effectiveness of
reinsurance or indemnification arrangements, as well as default
or failure of counterparties to perform; (23) discrepancies
between actual claims experience and assumptions used in setting
prices for our products and establishing the liabilities for our
obligations for future policy benefits and
S-5
claims; (24) catastrophe losses; (25) heightened
competition, including with respect to pricing, entry of new
competitors, consolidation of distributors, the development of
new products by new and existing competitors, distribution of
amounts available under U.S. government programs, and for
personnel; (26) unanticipated changes in industry trends;
(27) changes in accounting standards, practices
and/or
policies; (28) changes in assumptions related to deferred
policy acquisition costs, deferred sales inducements, value of
business acquired or goodwill; (29) increased expenses
relating to pension and postretirement benefit plans, as well as
health care and other employee benefits; (30) exposure to
losses related to variable annuity guarantee benefits, including
from significant and sustained downturns or extreme volatility
in equity markets, reduced interest rates, unanticipated
policyholder behavior, mortality or longevity, and the
adjustment for nonperformance risk; (31) deterioration in
the experience of the closed block established in
connection with the reorganization of Metropolitan Life
Insurance Company (MLIC); (32) adverse
results or other consequences from litigation, arbitration or
regulatory investigations; (33) inability to protect our
intellectual property rights or claims of infringement of the
intellectual property rights of others, (34) discrepancies
between actual experience and assumptions used in establishing
liabilities related to other contingencies or obligations;
(35) regulatory, legislative or tax changes relating to our
insurance, banking, international, or other operations that may
affect the cost of, or demand for, our products or services,
impair our ability to attract and retain talented and
experienced management and other employees, or increase the cost
or administrative burdens of providing benefits to employees;
(36) the effects of business disruption or economic
contraction due to terrorism, other hostilities, or natural
catastrophes, including any related impact on our disaster
recovery systems and management continuity planning which could
impair our ability to conduct business effectively;
(37) the effectiveness of our programs and practices in
avoiding giving our associates incentives to take excessive
risks; and (38) other risks and uncertainties described
from time to time in MetLife, Inc.s filings with the SEC.
MetLife, Inc. does not undertake any obligation to publicly
correct or update any forward-looking statement if MetLife, Inc.
later becomes aware that such statement is not likely to be
achieved. Please consult any further disclosures MetLife, Inc.
makes on related subjects in reports to the SEC.
S-6
NOTE REGARDING
RELIANCE ON STATEMENTS IN OUR CONTRACTS
In reviewing the agreements included as exhibits to any of the
documents incorporated by reference into this prospectus
supplement and the accompanying prospectus, please remember that
they are incorporated to provide you with information regarding
their terms and are not intended to provide any other factual or
disclosure information about MetLife, Inc., its subsidiaries or
the other parties to the agreements. The agreements contain
representations and warranties by each of the parties to the
applicable agreement. These representations and warranties have
been made solely for the benefit of the other parties to the
applicable agreement and:
|
|
|
|
|
should not in all instances be treated as categorical statements
of fact, but rather as a way of allocating the risk to one of
the parties to the agreement if those statements prove to be
inaccurate;
|
|
|
|
have been qualified by disclosures that were made to the other
party in connection with the negotiation of the applicable
agreement, which disclosures are not necessarily reflected in
the agreement;
|
|
|
|
may apply standards of materiality in a way that is different
from what may be viewed as material to investors; and
|
|
|
|
were made only as of the date of the applicable agreement or
such other date or dates as may be specified in the agreement
and are subject to more recent developments.
|
Accordingly, these representations and warranties may not
describe the actual state of affairs as of the date they were
made or at any other time.
S-7
SUMMARY
This summary contains basic information about us and this
offering. Because it is a summary, it does not contain all of
the information that you should consider before investing in the
common stock. You should read this entire prospectus supplement
carefully, including the sections entitled Risk
Factors, our financial statements and the notes thereto
incorporated by reference into this prospectus supplement, and
the accompanying prospectus, before making an investment
decision.
MetLife
MetLife, Inc. is a leading provider of insurance, employee
benefits and financial services with operations throughout the
United States and the regions of Latin America, Asia Pacific,
Europe and the Middle East. Through subsidiaries and affiliates,
MetLife, Inc. reaches more than 90 million customers around
the world and MetLife is the largest life insurer in the
U.S. (based on life insurance in-force), and holds leading
market positions in the U.S., Japan, Latin America, Asia
Pacific, Europe and the Middle East. The MetLife companies offer
life insurance, annuities, auto and home insurance, retail
banking and other financial services to individuals, as well as
group insurance and retirement & savings products and
services to corporations and other institutions.
MetLife is one of the largest insurance and financial services
companies in the United States. MetLife believes that its
franchises and brand names uniquely position it to be the
preeminent provider of protection and savings and investment
products in the United States. In addition, its international
operations are focused on markets where the demand for insurance
and savings and investment products is expected to grow rapidly
in the future.
Over the past several years, we have grown our core businesses,
as well as successfully executed on our growth strategy. This
has included completing a number of transactions that have
resulted in the acquisition and, in some cases, divestiture of
certain businesses while also further strengthening our balance
sheet to position MetLife for continued growth. On
November 1, 2010 (the Acquisition Date),
MetLife, Inc. completed the acquisition (the
Acquisition) of American Life Insurance
Company (American Life), from the Selling
Stockholder, a subsidiary of AIG, and Delaware American Life
Insurance Company (DelAm and, together with
American Life, ALICO) from AIG for a total
purchase price of $16.4 billion subject to adjustment,
including $7.2 billion of cash, 78,239,712 shares of
MetLife, Inc.s common stock, 6,857,000 shares of the
Series B Preferred Stock (convertible into
68,570,000 shares of MetLife, Inc.s common stock
(subject to anti-dilution adjustments) upon a favorable vote of
MetLife, Inc.s common shareholders) and 40 million
equity units with an aggregate stated value of
$3.0 billion. The business acquired in the Acquisition
provides consumers and businesses with products and services,
life insurance, accident and health insurance, retirement and
wealth management solutions. This transaction delivers on our
global growth strategies, adding significant scale and reach to
MetLifes international footprint, furthering our
diversification in geographic mix and product offerings, as well
as increasing our distribution strength.
MetLife is organized into five operating segments: Insurance
Products, Retirement Products, Corporate Benefit Funding,
Auto & Home (collectively,
U.S. Business) and International. The
assets and liabilities of ALICO as of November 30, 2010 and
the operating results of ALICO from the Acquisition Date through
November 30, 2010 are included in the International
segment. For reporting periods beginning in 2011, our
non-U.S. Business
results will be presented within two separate segments: Japan
and Other International Region. MetLifes management
continues to evaluate its segment performance and allocated
resources and may adjust such measurements in the future to
better reflect segment profitability.
|
|
|
|
|
Insurance Products. The Insurance
Products segment offers a broad range of protection products and
services aimed at serving the financial needs of MetLifes
customers throughout their lives. These products are sold to
individuals and corporations, as well as other institutions and
their respective employees. MetLife has built a leading position
in the U.S. group insurance market through long-standing
relationships with many of the largest corporate employers in
the United States, and is one of the largest issuers of
individual life insurance products in the United States.
|
|
|
|
Retirement Products. The Retirement
products segment includes a variety of variable and fixed
annuities that are primarily sold to individuals and employees
of corporations and other institutions.
|
S-8
|
|
|
|
|
Corporate Benefit Funding. The
Corporate Benefit Funding segment includes an array of annuity
and investment products, including guaranteed interest products
and other stable value products, income annuities, and separate
account contracts for the investment management of defined
benefit and defined contribution plan assets. This segment also
includes certain products to fund postretirement benefits and
company, bank or trust owned life insurance used to finance
non-qualified benefit programs for executives.
|
|
|
|
Auto & Home. The
Auto & Home segment includes personal lines property
and casualty insurance offered directly to employees at their
employers worksite, as well as to individuals through a
variety of retail distribution channels, including independent
agents, property and casualty specialists, direct response
marketing and the individual distribution sales group.
|
|
|
|
International. International provides
life insurance, accident and health insurance, credit insurance,
annuities, endowment and retirement & savings products
to both individuals and groups. MetLife focuses on markets
primarily within Japan, Latin America, Asia Pacific, Europe and
the Middle East. MetLife operates in international markets
through subsidiaries and affiliates. MetLifes
International segment is the fastest-growing of MetLifes
businesses, and we believe it will be one of the largest future
growth areas.
|
Banking, Corporate & Other contains the excess capital
not allocated to the segments, which is invested to optimize
investment spread and to fund company initiatives, various
start-up
entities and run-off entities. Banking, Corporate &
Other also includes interest expense related to the majority of
MetLifes outstanding debt and expenses associated with
certain legal proceedings, as well as the financial results of
MetLife Bank, National Association (MetLife
Bank), which offers a variety of residential mortgage
and deposit products, including forward and reverse residential
mortgage loans and consumer deposits. The elimination of
transactions from activity between U.S. Business,
International and Banking, Corporate & Other occurs
within Banking, Corporate & Other.
Accounting
Treatment of Repurchase
In connection with the repurchase of the Series B Preferred
Stock, in the first quarter of 2011 MetLife will recognize a
reduction in net income available to common shareholders of
approximately $145 million (approximately $0.14 per common
share), representing a return to the Selling Stockholder
calculated as the excess of the repurchase price over the
carrying value of the Series B Preferred Stock. This return to
the Selling Stockholder will have no effect on MetLifes
operating earnings, operating earnings available to common
shareholders, operating earnings per common share or operating
earnings available to common shareholders per common share.
MetLife, Inc. is incorporated under the laws of the State of
Delaware. MetLife, Inc.s principal executive offices are
located at 200 Park Avenue, New York, New York
10166-0188
and its telephone number is
(212) 578-2211.
S-9
The
Offering
|
|
|
Common stock offered by MetLife, Inc. |
|
68,570,000 shares of common stock |
|
Common stock offered by the Selling Stockholder |
|
78,239,712 shares of common stock. Any unsold shares of
common stock will be allocated to the Selling Stockholder. |
|
Common stock outstanding at February 18, 2011, as adjusted
for this offering |
|
1,055,155,463 shares of common stock (all shares of common
stock held by the Selling Stockholder are already issued and
outstanding). |
|
|
|
If fewer than 146,809,712 shares of the common stock can be
sold in this offering, the number of shares sold will be
allocated first, to the shares of common stock that MetLife,
Inc. proposes to sell, and second, to the shares of common stock
that the Selling Stockholder proposes to sell. |
|
Use of proceeds |
|
MetLife, Inc. estimates that its net proceeds of this offering
will be $2,950,824,237.50. Pursuant to the Coordination
Agreement, dated as of March 1, 2011 (the
Coordination Agreement), by and among
MetLife, Inc., the Selling Stockholder and AIG, MetLife, Inc.
intends to use all of its net proceeds from this offering to
fund the repurchase (the Repurchase) from the
Selling Stockholder of the Series B Preferred Stock issued
and delivered to the Selling Stockholder on the Acquisition Date
as part of the consideration for the Acquisition, for a purchase
price equal to such net proceeds. Each share of Series B
Preferred Stock is convertible into ten shares of common stock
(subject to anti-dilution adjustments), subject to a favorable
vote of MetLife, Inc.s common shareholders. To the extent
MetLife, Inc. sells fewer than 68,570,000 shares of common
stock in this offering, it will use all of the net proceeds that
it receives in this offering to repurchase a proportionate
number of shares of the Series B Preferred Stock (on an
as-converted basis) from the Selling Stockholder, for a purchase
price equal to such net proceeds. Upon receipt, any shares of
the Series B Preferred Stock will be cancelled by MetLife,
Inc. |
|
|
|
MetLife, Inc. will not receive any proceeds from the sale of
common stock by the Selling Stockholder. |
|
New York Stock Exchange symbol |
|
MET |
|
Concurrent Offering |
|
Concurrent with this offering, the Selling Stockholder will
offer, by means of a separate prospectus supplement, 40,000,000
common equity units of MetLife, Inc. The common equity units
consist of (x) stock purchase contracts obligating the
holder to purchase a variable number of shares of MetLife,
Inc.s common stock on each of three specified future
settlement dates (approximately two, three and four years after
the closing of the Acquisition, subject to deferral under
certain circumstances) for a fixed amount per stock purchase
contract (an aggregate of $1.0 billion on each settlement
date) and (y) an interest in each of three series of debt
securities of MetLife, Inc. The aggregate amount of MetLife,
Inc.s common stock expected to be issued upon settlement
of the stock purchase contracts is expected to be approximately
67,764,000 to 84,696,000 shares. This offering of common
stock is not conditioned on the completion of the concurrent |
S-10
|
|
|
|
|
offering. There can be no assurance that the concurrent offering
will be completed. |
|
|
|
It is a condition to the closing of the MetLife, Inc. offering
of common stock pursuant to this prospectus supplement that all
of the closing conditions of the Repurchase transaction (except
the condition that the offering of the shares of common stock by
MetLife, Inc. pursuant to this prospectus supplement has been
consummated) under the Coordination Agreement will need to be
satisfied or waived. It is a condition to the closing of the
Selling Stockholder offering of common stock that the
Coordination Agreement is in full force and effect. |
S-11
RISK
FACTORS
In considering whether to purchase common stock, you should
carefully consider all the information included or incorporated
by reference in this prospectus supplement and in the
accompanying prospectus. In particular, you should carefully
consider the following risk factors.
Risks
Related to our Business
Difficult Conditions in the Global Capital Markets and the
Economy Generally May Materially Adversely Affect Our Business
and Results of Operations and These Conditions May Not Improve
in the Near Future
Our business and results of operations are materially affected
by conditions in the global capital markets and the economy
generally, both in the United States and elsewhere around the
world. Stressed conditions, volatility and disruptions in global
capital markets or in particular markets or financial asset
classes can have an adverse effect on us, in part because we
have a large investment portfolio and our insurance liabilities
are sensitive to changing market factors. Disruptions in one
market or asset class can also spread to other markets or asset
classes. Although the disruption in the global financial markets
that began in late 2007 has moderated, not all global financial
markets are functioning normally, and some remain reliant upon
government intervention and liquidity. Upheavals in the
financial markets can also affect our business through their
effects on general levels of economic activity, employment and
customer behavior. Although the recent recession in the United
States ended in June of 2009, the recovery from the recession
has been below historic averages and the unemployment rate is
expected to remain high for some time. In addition, inflation is
expected to remain at low levels for some time. Some economists
believe that some level of disinflation and deflation risk
remains in the U.S. economy. The global recession and
disruption of the financial markets has led to concerns over
capital markets access and the solvency of certain European
Union member states, including Portugal, Ireland, Italy, Greece
and Spain. The Japanese economy, to which we face increased
exposure as a result of the Acquisition, continues to experience
low nominal growth, a deflationary environment, and weak
consumer spending.
Our revenues and net investment income are likely to remain
under pressure in such circumstances and our profit margins
could erode. Also, in the event of extreme prolonged market
events, such as the recent global credit crisis, we could incur
significant capital
and/or
operating losses. Even in the absence of a market downturn, we
are exposed to substantial risk of loss due to market volatility.
We are a significant writer of variable annuity products. The
account values of these products decrease as a result of
downturns in capital markets. Decreases in account values reduce
the fees generated by our variable annuity products, cause the
amortization of deferred policy acquisition costs
(DAC) to accelerate and could increase the
level of insurance liabilities we must carry to support those
variable annuities issued with any associated guarantees.
Factors such as consumer spending, business investment,
government spending, the volatility and strength of the capital
markets, and inflation all affect the business and economic
environment and, ultimately, the amount and profitability of our
business. In an economic downturn characterized by higher
unemployment, lower family income, lower corporate earnings,
lower business investment and lower consumer spending, the
demand for our financial and insurance products could be
adversely affected. Group insurance, in particular, is affected
by the higher unemployment rate. In addition, we may experience
an elevated incidence of claims and lapses or surrenders of
policies. Our policyholders may choose to defer paying insurance
premiums or stop paying insurance premiums altogether. Adverse
changes in the economy could affect earnings negatively and
could have a material adverse effect on our business, results of
operations and financial condition. The recent market turmoil
has precipitated, and may continue to raise the possibility of,
legislative, regulatory and governmental actions. We cannot
predict whether or when such actions may occur, or what impact,
if any, such actions could have on our business, results of
operations and financial condition. See
Actions of the U.S. Government,
Federal Reserve Bank of New York and Other Governmental and
Regulatory Bodies for the Purpose of Stabilizing and
Revitalizing the Financial Markets and Protecting Investors and
Consumers May Not Achieve the Intended Effect or Could Adversely
Affect MetLifes Competitive Position,
Various Aspects of Dodd-Frank Could Impact Our
Business Operations, Capital Requirements and Profitability and
Limit Our Growth, Our Insurance,
Brokerage and Banking
S-12
Businesses Are Heavily Regulated, and Changes in
Regulation May Reduce Our Profitability and Limit Our
Growth and Competitive Factors May
Adversely Affect Our Market Share and Profitability.
Adverse Capital and Credit Market Conditions May
Significantly Affect Our Ability to Meet Liquidity Needs, Access
to Capital and Cost of Capital
The capital and credit markets are sometimes subject to periods
of extreme volatility and disruption. Such volatility and
disruption could cause liquidity and credit capacity for certain
issuers to be limited.
We need liquidity to pay our operating expenses, interest on our
debt and dividends on our capital stock, maintain our securities
lending activities and replace certain maturing liabilities.
Without sufficient liquidity, we will be forced to curtail our
operations, and our business will suffer. The principal sources
of our liquidity are insurance premiums, annuity considerations,
deposit funds, and cash flow from our investment portfolio and
assets, consisting mainly of cash or assets that are readily
convertible into cash. Sources of liquidity in normal markets
also include short-term instruments such as funding agreements
and commercial paper. Sources of capital in normal markets
include long-term instruments, medium- and long-term debt,
junior subordinated debt securities, capital securities and
equity securities.
In the event market or other conditions have an adverse impact
on our capital and liquidity beyond expectations and our current
resources do not satisfy our needs, we may have to seek
additional financing. The availability of additional financing
will depend on a variety of factors such as market conditions,
regulatory considerations, the general availability of credit,
the volume of trading activities, the overall availability of
credit to the financial services industry, our credit ratings
and credit capacity, as well as the possibility that customers
or lenders could develop a negative perception of our long- or
short-term financial prospects if we incur large investment
losses or if the level of our business activity decreases due to
a market downturn. Similarly, our access to funds may be
impaired if regulatory authorities or rating agencies take
negative actions against us. Our internal sources of liquidity
may prove to be insufficient and, in such case, we may not be
able to successfully obtain additional financing on favorable
terms, or at all.
Our liquidity requirements may change if, among other things, we
are required to return significant amounts of cash collateral on
short notice under securities lending agreements.
Disruptions, uncertainty or volatility in the capital and credit
markets may also limit our access to capital required to operate
our business, most significantly our insurance operations. Such
market conditions may limit our ability to replace, in a timely
manner, maturing liabilities; satisfy regulatory capital
requirements (under both insurance and banking laws); and access
the capital necessary to grow our business. The possible impact
of Basel II and Basel III on MetLife is discussed in
the 2010
Form 10-K.
As such, we may be forced to delay raising capital, issue
different types of securities than we would otherwise, less
effectively deploy such capital, issue shorter tenor securities
than we prefer, or bear an unattractive cost of capital which
could decrease our profitability and significantly reduce our
financial flexibility. Our results of operations, financial
condition, cash flows and statutory capital position could be
materially adversely affected by disruptions in the financial
markets.
Actions of the U.S. Government, Federal Reserve Bank of
New York and Other Governmental and Regulatory Bodies for the
Purpose of Stabilizing and Revitalizing the Financial Markets
and Protecting Investors and Consumers May Not Achieve the
Intended Effect or Could Adversely Affect MetLifes
Competitive Position
In recent years, Congress, the Federal Reserve Bank of New York,
the FDIC, the U.S. Treasury and other agencies of the
U.S. federal government took a number of increasingly
aggressive actions (in addition to continuing a series of
interest rate reductions that began in the second half of
2007) intended to provide liquidity to financial
institutions and markets, to avert a loss of investor confidence
in particular troubled institutions, to prevent or contain the
spread of the financial crisis and to spur economic growth. Most
of these programs have largely run their course or been
discontinued. More likely to be relevant to MetLife, Inc. is the
monetary policy implemented by the Federal Reserve Board, as
well as Dodd-Frank, which will significantly change financial
regulation in the U.S. in a number of areas that could
affect MetLife. Given the large number of provisions that must
be implemented through regulatory action, we cannot predict what
impact this could have on our business, results of operations
and financial condition.
S-13
It is not certain what effect the enactment of Dodd-Frank will
have on the financial markets, the availability of credit, asset
prices and MetLifes operations. See
Various Aspects of Dodd-Frank Could Impact
Our Business Operations, Capital Requirements and Profitability
and Limit Our Growth. In addition, the U.S. federal
government (including the FDIC) and private lenders have
instituted programs to reduce the monthly payment obligations of
mortgagors
and/or
reduce the principal payable on residential mortgage loans. As a
result of such programs or of any legislation requiring loan
modifications, we may need to maintain or increase our
engagement in similar activities in order to comply with program
or statutory requirements and to remain competitive. We cannot
predict whether the funds made available by the
U.S. federal government and its agencies will be enough to
continue stabilizing or to further revive the financial markets
or, if additional amounts are necessary, whether the Federal
Reserve Board will make funds available, whether Congress will
be willing to make the necessary appropriations, what the
publics sentiment would be towards any such
appropriations, or what additional requirements or conditions
might be imposed on the use of any such additional funds.
The choices made by the U.S. Treasury, the Federal Reserve
Board and the FDIC in their distribution of funds under EESA and
any future asset purchase programs, as well as any decisions
made regarding the imposition of additional regulation on large
financial institutions may have, over time, the effect of
supporting or burdening some aspects of the financial services
industry more than others. Some of our competitors have
received, or may in the future receive, benefits under one or
more of the federal governments programs. This could
adversely affect our competitive position. See
Competitive Factors May Adversely Affect
Our Market Share and Profitability. See also
New and Impending Compensation and Corporate
Governance Regulations Could Hinder or Prevent Us From
Attracting and Retaining Management and Other Employees with the
Talent and Experience to Manage and Conduct Our Business
Effectively and Our Insurance, Brokerage
and Banking Businesses Are Heavily Regulated, and Changes in
Regulation May Reduce Our Profitability and Limit Our
Growth.
Our Insurance, Brokerage and Banking Businesses Are Highly
Regulated, and Changes in Regulation and in Supervisory and
Enforcement Policies May Reduce Our Profitability and Limit Our
Growth
Our insurance operations are subject to a wide variety of
insurance and other laws and regulations. State insurance laws
regulate most aspects of our U.S. insurance businesses, and
our insurance subsidiaries are regulated by the insurance
departments of the states in which they are domiciled and the
states in which they are licensed. Our
non-U.S. insurance
operations are principally regulated by insurance regulatory
authorities in the jurisdictions in which they are domiciled or
operate.
State laws in the United States grant insurance regulatory
authorities broad administrative powers with respect to, among
other things:
|
|
|
|
|
licensing companies and agents to transact business;
|
|
|
|
calculating the value of assets to determine compliance with
statutory requirements;
|
|
|
|
mandating certain insurance benefits;
|
|
|
|
regulating certain premium rates;
|
|
|
|
reviewing and approving policy forms;
|
|
|
|
regulating unfair trade and claims practices, including through
the imposition of restrictions on marketing and sales practices,
distribution arrangements and payment of inducements;
|
|
|
|
regulating advertising;
|
|
|
|
protecting privacy;
|
|
|
|
establishing statutory capital and reserve requirements and
solvency standards;
|
|
|
|
fixing maximum interest rates on insurance policy loans and
minimum rates for guaranteed crediting rates on life insurance
policies and annuity contracts;
|
|
|
|
approving changes in control of insurance companies;
|
|
|
|
restricting the payment of dividends and other transactions
between affiliates; and
|
|
|
|
regulating the types, amounts and valuation of investments.
|
S-14
State insurance guaranty associations have the right to assess
insurance companies doing business in their state for funds to
help pay the obligations of insolvent insurance companies to
policyholders and claimants. Because the amount and timing of an
assessment is beyond our control, the liabilities that we have
currently established for these potential liabilities may not be
adequate.
State insurance regulators and the National Association of
Insurance Commissioners (NAIC) regularly
reexamine existing laws and regulations applicable to insurance
companies and their products. Changes in these laws and
regulations, or in interpretations thereof, are often made for
the benefit of the consumer at the expense of the insurer and,
thus, could have a material adverse effect on our financial
condition and results of operations.
Currently, the U.S. federal government does not directly
regulate the business of insurance. However,
Dodd-Frank
allows federal regulators to compel state insurance regulators
to liquidate an insolvent insurer under some circumstances if
the state regulators have not acted within a specific period. It
also establishes the Federal Insurance Office which has the
authority to participate in the negotiations of international
insurance agreements with foreign regulators for the United
States. The Federal Insurance Office is also authorized to
collect information about the insurance industry and recommend
prudential standards.
Federal legislation and administrative policies in several areas
can significantly and adversely affect insurance companies.
These areas include financial services regulation, securities
regulation, pension regulation, health care regulation, privacy,
tort reform legislation and taxation. In addition, various forms
of direct and indirect federal regulation of insurance have been
proposed from time to time, including proposals for the
establishment of an optional federal charter for insurance
companies. Other aspects of our insurance operations could also
be affected by Dodd-Frank. For example, Dodd-Frank imposes new
restrictions on the ability of affiliates of insured depository
institutions (such as MetLife Bank) to engage in proprietary
trading or sponsor or invest in hedge funds or private equity
funds. See Various Aspects of
Dodd-Frank Could Impact Our Business Operations, Capital
Requirements and Profitability and Limit Our Growth.
As a federally chartered national association, MetLife Bank is
subject to a wide variety of banking laws, regulations and
guidelines. Federal banking laws regulate most aspects of the
business of MetLife Bank, but certain state laws may apply as
well. MetLife Bank is principally regulated by the Office of the
Comptroller of the Currency, the Federal Reserve and the FDIC.
Federal banking laws and regulations address various aspects of
MetLife Banks business and operations with respect to,
among other things:
|
|
|
|
|
chartering to carry on business as a bank;
|
|
|
|
the permissibility of certain activities;
|
|
|
|
maintaining minimum capital ratios;
|
|
|
|
capital management in relation to the banks assets;
|
|
|
|
dividend payments;
|
|
|
|
safety and soundness standards;
|
|
|
|
loan loss and other related liabilities;
|
|
|
|
liquidity;
|
|
|
|
financial reporting and disclosure standards;
|
|
|
|
counterparty credit concentration;
|
|
|
|
restrictions on related party and affiliate transactions;
|
|
|
|
lending limits (and, in addition, Dodd-Frank includes the credit
exposures arising from securities lending by MetLife Bank within
lending limits otherwise applicable to loans);
|
|
|
|
payment of interest;
|
S-15
|
|
|
|
|
unfair or deceptive acts or practices;
|
|
|
|
privacy; and
|
|
|
|
bank holding company and bank change of control.
|
Federal and state banking regulators regularly re-examine
existing laws and regulations applicable to banks and their
products. Changes in these laws and regulations, or in
interpretations thereof, are often made for the benefit of the
consumer at the expense of the bank and, thus, could have a
material adverse effect on the financial condition and results
of operations of MetLife Bank.
Since 2008, MetLife, through its MetLife Bank affiliate, has
significantly increased its mortgage servicing activities by
acquiring servicing portfolios. Currently, MetLife Bank services
approximately 1% of the aggregate principal amount of the
mortgage loans serviced in the United States.
State and federal regulatory and law enforcement authorities
have initiated various inquiries, investigations or examinations
of alleged irregularities in the foreclosure practices of the
residential mortgage servicing industry. Mortgage servicing
practices have also been the subject of Congressional attention.
Authorities have publicly stated that the scope of the
investigations extends beyond foreclosure documentation
practices to include mortgage loan modification and loss
mitigation practices.
MetLife Banks mortgage servicing has been the subject of
recent inquiries and requests by such authorities. The Acting
Comptroller of the Currency disclosed in testimony before
Congress that 14 mortgage servicing businesses affiliated with
banking organizations, including that of MetLife Bank, have been
the subject of an intra-agency confidential horizontal
examination of mortgage servicing and foreclosure
activities. The Acting Comptroller testified that federal
banking regulators expect to issue administrative enforcement
orders to such businesses and to seek civil money penalties. The
Acting Comptrollers testimony also indicated that other
federal agencies, including the Department of Justice and the
Federal Trade Commission, were examining potential actions with
respect to such businesses.
MetLife is cooperating with the authorities review of this
business. MetLife cannot predict the outcome of the pending
reviews. It is also possible that additional state or federal
authorities may pursue similar investigations or make related
inquiries.
In view of widespread attention to foreclosure practices within
the industry, MetLife Bank undertook a review of its servicing
procedures. Based on its review of its foreclosure practices and
procedures, MetLife Bank does not believe that its mortgage
servicing practices improperly adversely affected the obligors
of mortgages that it services.
Nevertheless, these inquiries or investigations could adversely
affect MetLifes reputation or result in material fines,
penalties, equitable remedies (including requiring default
servicing or other process changes), or other enforcement
actions, and result in significant legal costs in responding to
governmental investigations or other litigation. In addition,
any changes to the mortgage servicing business that are required
in connection with the resolution of such matters may affect the
profitability of such business.
In addition, Dodd-Frank establishes a new Bureau of Consumer
Financial Protection that supervises and regulates institutions
providing certain financial products and services to consumers.
Although the consumer financial services to which this
legislation applies exclude insurance business of the kind in
which we engage, the new Bureau has authority to regulate
consumer services provided by MetLife Bank and non-insurance
consumer services provided elsewhere throughout MetLife.
Dodd-Frank established a statutory standard for Federal
pre-emption of state consumer financial protection laws, which
standard will require national banks to comply with many state
consumer financial protection laws that previously were
considered preempted by Federal law. As a result, the regulatory
and compliance burden on MetLife Bank may increase and could
adversely affect its business and results of operations.
Dodd-Frank also includes provisions on mortgage lending,
anti-predatory lending and other regulatory and supervisory
provisions that could impact the business and operations of
MetLife Bank.
Dodd-Frank also authorizes the SEC to establish a standard of
conduct applicable to brokers and dealers when providing
personalized investment advice to retail and other customers.
This standard of conduct would be to act in
S-16
the best interest of the customer without regard to the
financial or other interest of the broker or dealer providing
the advice. See Changes in
U.S. Federal and State Securities Laws and Regulations, and
State Insurance Regulations Regarding Suitability of Annuity
Product Sales, May Affect Our Operations and Our
Profitability.
In December 2010, the Basel Committee on Banking Supervision
published Basel III for banks and bank holding companies,
such as MetLife, Inc. Assuming regulators in the United States
endorse and adopt Basel III, it will require banks and bank
holding companies to hold greater amounts of capital, to comply
with requirements for short-term liquidity and to reduce
reliance on short-term funding sources. It is not clear how
these new requirements will compare to the enhanced prudential
standards that may apply to us under Dodd-Frank. See
Various Aspects of Dodd-Frank Could Impact
Our Business Operations, Capital Requirements and Profitability
and Limit Our Growth.
As a bank holding company, MetLife, Inc.s ability to pay
dividends may be restricted by the Federal Reserve Bank of New
York. In addition, the ability of MetLife Bank and MetLife, Inc.
to pay dividends could be restricted by any additional capital
requirements that might be imposed as a result of the enactment
of Dodd-Frank
and/or the
endorsement and adoption by the United States of Basel III.
The FDIC has the right to assess FDIC-insured banks for funds to
help pay the obligations of insolvent banks to depositors.
Because the amount and timing of an assessment is beyond our
control, the reserves that we have currently established for
these potential liabilities may not be adequate. In addition,
Dodd-Frank will result in increased assessment for banks with
assets of $10.0 billion or more, which includes MetLife
Bank.
Our international operations are subject to regulation in the
jurisdictions in which they operate. A significant portion of
our revenues are generated through operations in foreign
jurisdictions, including many countries in early stages of
economic and political development. Our international operations
may be materially adversely affected by foreign authorities and
regulators, such as through nationalization or expropriation of
assets, the imposition of limits on foreign ownership, changes
in laws or their interpretation or application, political
instability, dividend limitations, price controls, currency
exchange controls or other restrictions that prevent us from
transferring funds from these operations out of the countries in
which they operate or converting local currencies we hold to
U.S. dollars or other currencies, as well as adverse
actions by foreign governmental authorities and regulators. This
may also impact many of our customers and independent sales
intermediaries. Changes in the regulations that affect their
operations also may affect our business relationships with them
and their ability to purchase or distribute our products.
Accordingly, these changes could have a material adverse effect
on our financial condition and results of operations.
Our international operations are subject to local laws and
regulations, and we expect the scope and extent of regulation
outside of the United States, as well as regulatory oversight,
generally to continue to increase. The authority of our
international operations to conduct business is subject to
licensing requirements, permits and approvals, and these
authorizations are subject to modification and revocation. The
regulatory environment in the countries in which we operate and
changes in laws could have a material adverse effect on us and
our foreign operations. See Our
International Operations Face Political, Legal, Operational and
Other Risks, Including Exposure to Local and Regional Economic
Conditions, that Could Negatively Affect Those Operations or Our
Profitability.
Furthermore, the increase in our international operations as a
result of the acquisition of ALICO may also subject us to
increased supervision by the Federal Reserve Board, since the
size of a bank holding companys foreign activities is
taken as an indication of the holding companys complexity.
It may also have an effect on the manner in which MetLife, Inc.
is required to calculate its risk-based capital
(RBC).
Compliance with applicable laws and regulations is time
consuming and personnel-intensive, and changes in these laws and
regulations may materially increase our direct and indirect
compliance and other expenses of doing business, thus having a
material adverse effect on our financial condition and results
of operations.
From time to time, regulators raise issues during examinations
or audits of MetLife, Inc.s regulated subsidiaries that
could, if determined adversely, have a material impact on us. We
cannot predict whether or when regulatory actions may be taken
that could adversely affect our operations. In addition, the
interpretations of
S-17
regulations by regulators may change and statutes may be enacted
with retroactive impact, particularly in areas such as
accounting or statutory reserve requirements.
We are also subject to other regulations and may in the future
become subject to additional regulations.
Various Aspects of Dodd-Frank Could Impact Our Business
Operations, Capital Requirements and Profitability and Limit Our
Growth
On July 21, 2010, President Obama signed Dodd-Frank.
Various provisions of Dodd-Frank could affect our business
operations and our profitability and limit our growth. For
example:
|
|
|
|
|
As a large, interconnected bank holding company with assets of
$50 billion or more, or possibly as an otherwise
systemically important financial company, MetLife, Inc. will be
subject to enhanced prudential standards imposed on systemically
significant financial companies. Enhanced standards will be
applied to RBC, liquidity, leverage (unless another, similar,
standard is appropriate), resolution plan and credit exposure
reporting, concentration limits, and risk management.
Off-balance sheet activities are required to be accounted for in
meeting capital requirements. In addition, if it were determined
that MetLife posed a substantial threat to U.S. financial
stability, the applicable federal regulators would have the
right to require it to take one or more other mitigating actions
to reduce that risk, including limiting its ability to merge
with or acquire another company, terminating activities,
restricting its ability to offer financial products or requiring
it to sell assets or off-balance sheet items to unaffiliated
entities. Enhanced standards would also permit, but not require,
regulators to establish requirements with respect to contingent
capital, enhanced public disclosures and short-term debt limits.
These standards are described as being more stringent than those
otherwise imposed on bank holding companies; however, the
Federal Reserve Board is permitted to apply them on an
institution-by-institution
basis, depending on its determination of the institutions
riskiness. In addition, under Dodd-Frank, all bank holding
companies that have elected to be treated as financial holding
companies, such as MetLife, Inc. will be required to be
well capitalized and well managed as
defined by the Federal Reserve Board, on a consolidated basis
and not just at their depository institution(s), a higher
standard than was applicable to financial holding companies
before Dodd-Frank.
|
|
|
|
MetLife, Inc., as a bank holding company, will have to meet
minimum leverage ratio and RBC requirements on a consolidated
basis to be established by the Federal Reserve Board that are
not less than those applicable to insured depository
institutions under so-called prompt corrective action
regulations as in effect on the date of the enactment of
Dodd-Frank. One consequence of these new rules will ultimately
be the inability of bank holding companies to include
trust-preferred securities as part of their Tier 1 capital.
Because of the phase-in period for these new rules, they should
have little practical effect on MetLifes ability to treat
its currently outstanding trust-preferred securities as part of
its Tier 1 capital, but they do prevent MetLife, Inc. from
treating the common equity units issued as part of the
consideration for the Acquisition as Tier 1 capital, since
the new rules apply immediately to instruments issued after
May 19, 2010.
|
|
|
|
Under the provisions of Dodd-Frank relating to the resolution or
liquidation of certain types of financial institutions,
including bank holding companies, if MetLife, Inc. were to
become insolvent or were in danger of defaulting on its
obligations, it could be compelled to undergo liquidation with
the FDIC as receiver. For this new regime to be applicable, a
number of determinations would have to be made, including that a
default by the affected company would have serious adverse
effects on financial stability in the United States. If the FDIC
were to be appointed as the receiver for such a company, the
liquidation of that company would occur under the provisions of
the new liquidation authority, and not under the Bankruptcy
Code. In such a liquidation, the holders of such companys
debt could in certain respects be treated differently than under
the Bankruptcy Code. In particular, unsecured creditors and
shareholders are intended to bear the losses of the company
being liquidated. The FDIC is authorized to establish rules for
the priority of creditors claims and, under certain
circumstances, to treat similarly situated creditors
differently. These provisions could apply to some financial
institutions whose outstanding debt securities we hold in our
investment portfolios. Dodd-Frank also provides for the
assessment of bank holding companies with assets of
$50.0 billion or more, non-bank financial companies
supervised by the Federal Reserve Bank, and other financial
companies with assets of $50.0 billion or more to cover the
costs of liquidating any financial company subject to the new
liquidation authority. Although it is not possible to assess the
full impact of the liquidation authority at this
|
S-18
|
|
|
|
|
time, it could affect the funding costs of large bank holding
companies or financial companies that might be viewed as
systemically significant. It could also lead to an increase in
secured financings.
|
|
|
|
|
|
Dodd-Frank also includes a new framework of regulation of the
OTC derivatives markets which will require clearing of certain
types of transactions currently traded OTC and could potentially
impose additional costs, including new capital, reporting and
margin requirements and additional regulation on MetLife, Inc.
Increased margin requirements on MetLife, Inc.s part and a
smaller universe of securities that will qualify as eligible
collateral could reduce its liquidity and require an increase in
its holdings of cash and government securities with lower yields
causing a reduction in income. However, increased margin
requirements and the expanded ability to transfer trades between
MetLife, Inc.s counterparties could reduce MetLife,
Inc.s exposure to its counterparties default.
MetLife, Inc. uses derivatives to mitigate a wide range of risks
in connection with its businesses, including the impact of
increased benefit exposures from our annuity products that offer
guaranteed benefits. The derivative clearing requirements of
Dodd-Frank could increase the cost of our risk mitigation and
expose us to the risk of a default by a clearinghouse or one of
its members. In addition, we are subject to the risk that
hedging and other management procedures prove ineffective in
reducing the risks to which insurance policies expose us or that
unanticipated policyholder behavior or mortality, combined with
adverse market events, produces economic losses beyond the scope
of the risk management techniques employed. Any such losses
could be increased by any higher costs of writing derivatives
(including customized derivatives) that might result from the
enactment of Dodd-Frank.
|
|
|
|
Dodd-Frank restricts the ability of insured depository
institutions and of companies, such as MetLife, Inc., that
control an insured depository institution and their affiliates,
to engage in proprietary trading and to sponsor or invest in
funds (hedge funds and private equity funds) that rely on
certain exemptions from the Investment Company Act of 1940, as
amended (the Investment Company Act).
Dodd-Frank provides an exemption for investment activity by a
regulated insurance company or its affiliate solely for the
general account of such insurance company if such activity is in
compliance with the insurance company investments laws of the
state or jurisdiction in which such company is domiciled and the
appropriate Federal regulators after consultation with relevant
insurance commissioners have not jointly determined such laws to
be insufficient to protect the safety and soundness of the
institution or the financial stability of the
United States. Notwithstanding the foregoing, the
appropriate Federal regulatory authorities are permitted under
the legislation to impose, as part of rulemaking, additional
capital requirements and other restrictions on any exempted
activity. Dodd-Frank provided for a period of study and rule
making during which the effects of the statutory language may be
clarified. The study has been completed and has assessed and
included recommendations as to how to appropriately accommodate
the business of insurance within an insurance company subject to
regulation in accordance with relevant insurance company
investments laws. However, while these provisions of Dodd-Frank
are supposed to accommodate the business of insurance, until the
rulemaking is completed, it is unclear whether MetLife, Inc. may
have to alter any of its future investment activities to comply.
|
|
|
|
Until various studies are completed and final regulations are
promulgated pursuant to Dodd-Frank, the full impact of
Dodd-Frank on the investments and investment activities and
insurance and annuity products of MetLife, Inc. and its
subsidiaries remains unclear. For example, besides directly
limiting our future investment activities, Dodd-Frank could
potentially negatively impact the market for, the returns from,
or liquidity in, primary and secondary investments in private
equity funds and hedge funds that are connected to (either
through a fund sponsorship or investor relationship) an insured
depository institution. The number of sponsors of such funds
going forward may diminish, which may impact our available fund
investment opportunities. Although Dodd-Frank provides for
various transition periods for coming into compliance, fund
sponsors that are subject to Dodd-Frank, and whose funds we have
invested in, may have to spin off their funds business or reduce
their ownership stakes in their funds, thereby potentially
impacting our related investments in such funds. In addition,
should such funds be required or choose to liquidate or sell
their underlying assets, the market value and liquidity of such
assets or the broader related asset classes could be negatively
affected, including securities and real estate assets that
MetLife, Inc. and its subsidiaries hold or may plan to sell.
Secondary sales of fund interests at significant discounts by
banking institutions and their affiliates, which are not fund
sponsors but nevertheless are subject to the divestment
requirements of Dodd-
|
S-19
|
|
|
|
|
Frank, could reduce the returns realized by investors such as
MetLife, Inc. and its subsidiaries seeking to access liquidity
by selling their fund interests. In addition, our existing
derivatives counterparties and the financial institutions
subject to Dodd-Frank in which we have invested also could be
negatively impacted by Dodd-Frank. See also
New and Impending Compensation and Corporate
Governance Regulations Could Hinder or Prevent Us From
Attracting and Retaining Management and Other Employees with the
Talent and Experience to Manage and Conduct Our Business
Effectively.
|
|
|
|
|
|
In addition, Dodd-Frank statutorily imposes the requirement that
MetLife, Inc. serve as a source of strength for MetLife Bank.
|
The addition of a new regulatory regime over MetLife, Inc. and
its subsidiaries, the likelihood of additional regulations, and
the other changes discussed above could require changes to
MetLife, Inc.s operations. Whether such changes would
affect our competitiveness in comparison to other institutions
is uncertain, since it is possible that at least some of our
competitors, for example insurance holding companies that
control thrifts, rather than banks, will be similarly affected.
Competitive effects are possible, however, if MetLife, Inc. were
required to pay any new or increased assessments and capital
requirements are imposed, and to the extent any new prudential
supervisory standards are imposed on MetLife, Inc. but not on
its competitors. We cannot predict whether other proposals will
be adopted, or what impact, if any, the adoption of Dodd-Frank
or other proposals and the resulting studies and regulations
could have on our business, financial condition or results of
operations or on our dealings with other financial companies.
See also Our Insurance, Brokerage and
Banking Businesses are Heavily Regulated, and Changes in
Regulation May Reduce Our Profitability and Limit Our
Growth and New and Impending
Compensation and Corporate Governance Regulations Could Hinder
or Prevent Us From Attracting and Retaining Management and Other
Employees with the Talent and Experience to Manage and Conduct
Our Business Effectively.
Moreover, Dodd-Frank potentially affects such a wide range of
the activities and markets in which MetLife, Inc. and its
subsidiaries engage and participate that it may not be possible
to anticipate all of the ways in which it could affect us. For
example, many of our methods for managing risk and exposures are
based upon the use of observed historical market behavior or
statistics based on historical models. Historical market
behavior may be altered by the enactment of Dodd-Frank. As a
result of this enactment and otherwise, these methods may not
fully predict future exposures, which could be significantly
greater than our historical measures indicate.
The Resolution of Several Issues Affecting the Financial
Services Industry Could Have a Negative Impact on Our Reported
Results or on Our Relations with Current and Potential
Customers
We will continue to be subject to legal and regulatory actions
in the ordinary course of our business, both in the United
States and internationally. This could result in a review of
business sold in the past under previously acceptable market
practices at the time. Regulators are increasingly interested in
the approach that product providers use to select third-party
distributors and to monitor the appropriateness of sales made by
them. In some cases, product providers can be held responsible
for the deficiencies of third-party distributors.
As a result of publicity relating to widespread perceptions of
industry abuses, there have been numerous regulatory inquiries
and proposals for legislative and regulatory reforms.
In Asia, where MetLife derives and will continue to derive a
significant portion of its income, regulatory regimes are
developing at different speeds, driven by a combination of
global factors and local considerations. New requirements may be
introduced that are retrospectively applied to sales made prior
to their introduction.
We Are Exposed to Significant Financial and Capital
Markets Risk Which May Adversely Affect Our Results of
Operations, Financial Condition and Liquidity, and May Cause Our
Net Investment Income to Vary from Period to Period
We are exposed to significant financial and capital markets
risk, including changes in interest rates, credit spreads,
equity prices, real estate markets, foreign currency exchange
rates, market volatility, the performance of the global economy
in general, the performance of the specific obligors, including
governments, included in our portfolio and other factors outside
our control.
S-20
Our exposure to interest rate risk relates primarily to the
market price and cash flow variability associated with changes
in interest rates. Changes in interest rates will impact the net
unrealized gain or loss position of our fixed income investment
portfolio. If long-term interest rates rise dramatically within
a six to twelve month time period, certain of our life insurance
businesses and fixed annuity business may be exposed to
disintermediation risk. Disintermediation risk refers to the
risk that our policyholders may surrender their contracts in a
rising interest rate environment, requiring us to liquidate
fixed income investments in an unrealized loss position. Due to
the long-term nature of the liabilities associated with certain
of our life insurance businesses, guaranteed benefits on
variable annuities, and structured settlements, sustained
declines in long-term interest rates may subject us to
reinvestment risks and increased hedging costs. In other
situations, declines in interest rates may result in increasing
the duration of certain life insurance liabilities, creating
asset-liability duration mismatches.
Our investment portfolio also contains interest rate sensitive
instruments, such as fixed income securities, which may be
adversely affected by changes in interest rates from
governmental monetary policies, domestic and international
economic and political conditions and other factors beyond our
control. Changes in interest rates will impact both the net
unrealized gain or loss position of our fixed income portfolio
and the rates of return we receive on funds invested. Our
mitigation efforts with respect to interest rate risk are
primarily focused towards maintaining an investment portfolio
with diversified maturities that has a weighted average duration
that is approximately equal to the duration of our estimated
liability cash flow profile. However, our estimate of the
liability cash flow profile may be inaccurate and we may be
forced to liquidate fixed income investments prior to maturity
at a loss in order to cover the cash flow profile of the
liability. Although we take measures to manage the economic
risks of investing in a changing interest rate environment, we
may not be able to mitigate the interest rate risk of our fixed
income investments relative to our liabilities. See also
Changes in Market Interest Rates May
Significantly Affect Our Profitability.
Our exposure to credit spreads primarily relates to market price
volatility and cash flow variability associated with changes in
credit spreads. A widening of credit spreads will adversely
impact both the net unrealized gain or loss position of the
fixed-income investment portfolio, will increase losses
associated with credit-based non-qualifying derivatives where we
assume credit exposure, and, if issuer credit spreads increase
significantly or for an extended period of time, will likely
result in higher
other-than-temporary
impairments. Credit spread tightening will reduce net investment
income associated with new purchases of fixed maturity
securities. In addition, market volatility can make it difficult
to value certain of our securities if trading becomes less
frequent. As such, valuations may include assumptions or
estimates that may have significant period to period changes
which could have a material adverse effect on our results of
operations or financial condition. Credit spreads on both
corporate and structured securities widened significantly during
2008, resulting in continuing depressed pricing. As a result of
improved conditions, credit spreads narrowed in 2009 and changed
to a lesser extent in 2010. If there is a resumption of
significant volatility in the markets, it could cause changes in
credit spreads and defaults and a lack of pricing transparency
which, individually or in tandem, could have a material adverse
effect on our results of operations, financial condition,
liquidity or cash flows through realized investment losses,
impairments, and changes in unrealized loss positions.
Our primary exposure to equity risk relates to the potential for
lower earnings associated with certain of our insurance
businesses where fee income is earned based upon the estimated
fair value of the assets under management. Downturns and
volatility in equity markets can have a material adverse effect
on the revenues and investment returns from our savings and
investment products and services. Because these products and
services generate fees related primarily to the value of assets
under management, a decline in the equity markets could reduce
our revenues from the reduction in the value of the investments
we manage. The retail variable annuity business in particular is
highly sensitive to equity markets, and a sustained weakness in
the equity markets could decrease revenues and earnings in
variable annuity products. Furthermore, certain of our variable
annuity products offer guaranteed benefits which increase our
potential benefit exposure should equity markets decline.
MetLife, Inc. uses derivatives and reinsurance to mitigate the
impact of such increased potential benefit exposures. We are
also exposed to interest rate and equity risk based upon the
discount rate and expected long-term rate of return assumptions
associated with our pension and other postretirement benefit
obligations. Sustained declines in
long-term
interest rates or equity returns likely would have a negative
effect on the funded status of these plans. Lastly, we invest a
portion of our investments in public and private equity
securities, leveraged buy-out funds, hedge
S-21
funds and other private equity funds and the estimated fair
value of such investments may be impacted by downturns or
volatility in equity markets.
Our primary exposure to real estate risk relates to commercial
and agricultural real estate. Our exposure to commercial and
agricultural real estate risk stems from various factors. These
factors include, but are not limited to, market conditions
including the demand and supply of leasable commercial space,
creditworthiness of tenants and partners, capital markets
volatility and the inherent interest rate movement. In addition,
our real estate joint venture development program is subject to
risks, including, but not limited to, reduced property sales and
decreased availability of financing which could adversely impact
the joint venture developments
and/or
operations. The state of the economy and speed of recovery in
fundamental and capital market conditions in the commercial and
agricultural real estate sectors will continue to influence the
performance of our investments in these sectors. These factors
and others beyond our control could have a material adverse
effect on our results of operations, financial condition,
liquidity or cash flows through net investment income, realized
investment losses and levels of valuation allowances.
Our investment portfolio contains investments in government
bonds issued by European nations. Recently, the European Union
member states have experienced above average public debt,
inflation and unemployment as the global economic downturn has
developed. A number of member states are significantly impacted
by the economies of their more influential neighbors, such as
Germany. In addition, financial troubles of one nation can
trigger a domino effect on others. In particular, a number of
large European banks hold significant amounts of sovereign
financial institution debt of other European nations and could
experience difficulties as a result of defaults or declines in
the value of such debt. Our investment portfolio also contains
investments in revenue bonds issued under the auspices of states
and municipalities and a limited amount of general obligation
bonds of states and municipalities (collectively,
Municipal Bonds). Recently, certain states
and municipalities have faced budget deficits and financial
difficulties. There can be no assurance that the financial
difficulties of such states and municipalities would not have an
adverse impact on our Municipal Bond portfolio.
Our primary foreign currency exchange risks are described under
Fluctuations in Foreign Currency Exchange
Rates Could Negatively Affect Our Profitability. Changes
in these factors, which are significant risks to us, can affect
our net investment income in any period, and such changes can be
substantial.
A portion of our investments are made in leveraged buy-out
funds, hedge funds and other private equity funds, many of which
make private equity investments. The amount and timing of net
investment income from such investment funds tends to be uneven
as a result of the performance of the underlying investments,
including private equity investments. The timing of
distributions from the funds, which depends on particular events
relating to the underlying investments, as well as the
funds schedules for making distributions and their needs
for cash, can be difficult to predict. As a result, the amount
of net investment income that we record from these investments
can vary substantially from quarter to quarter.
Recovering private equity markets and stabilizing credit and
real estate markets during 2010 had a positive impact on returns
and net investment income on private equity funds, hedge funds
and real estate joint ventures, which are included within other
limited partnership interests and real estate and real estate
joint venture portfolios. Although volatility in most global
financial markets has moderated, if there is a resumption of
significant volatility, it could adversely impact returns and
net investment income on these alternative investment classes.
Continuing challenges include continued weakness in the
U.S. real estate market and increased residential mortgage
loan and other consumer loan delinquencies, investor anxiety
over the U.S. and European economies, rating agency
downgrades of various structured products and financial issuers,
unresolved issues with structured investment vehicles and
monoline financial guarantee insurers, deleveraging of financial
institutions and hedge funds and the continuing recovery in the
inter-bank market. If there is a resumption of significant
volatility in the markets, it could cause changes in interest
rates, declines in equity prices, and the strengthening or
weakening of foreign currencies against the U.S. dollar
which, individually or in tandem, could have a material adverse
effect on our results of operations, financial condition,
liquidity or cash flows through realized investment losses,
impairments, increased valuation allowances and changes in
unrealized gain or loss positions.
S-22
Changes in Market Interest Rates May Significantly Affect
Our Profitability
Some of our products, principally traditional whole life
insurance, fixed annuities and guaranteed interest contracts,
expose us to the risk that changes in interest rates will reduce
our investment margin or spread, or the difference
between the amounts that we are required to pay under the
contracts in our general account and the rate of return we are
able to earn on general account investments intended to support
obligations under the contracts. Our spread is a key component
of our net income.
As interest rates decrease or remain at low levels, we may be
forced to reinvest proceeds from investments that have matured
or have been prepaid or sold at lower yields, reducing our
investment margin. Moreover, borrowers may prepay or redeem the
fixed income securities, commercial or agricultural mortgage
loans and mortgage-backed securities in our investment portfolio
with greater frequency in order to borrow at lower market rates,
which exacerbates this risk. Lowering interest crediting rates
can help offset decreases in investment margins on some
products. However, our ability to lower these rates could be
limited by competition or contractually guaranteed minimum rates
and may not match the timing or magnitude of changes in asset
yields. As a result, our spread could decrease or potentially
become negative. Our expectation for future spreads is an
important component in the amortization of DAC and value of
business acquired (VOBA), and significantly
lower spreads may cause us to accelerate amortization, thereby
reducing net income in the affected reporting period. In
addition, during periods of declining interest rates, life
insurance and annuity products may be relatively more attractive
investments to consumers, resulting in increased premium
payments on products with flexible premium features, repayment
of policy loans and increased persistency, or a higher
percentage of insurance policies remaining in force from year to
year, during a period when our new investments carry lower
returns. A decline in market interest rates could also reduce
our return on investments that do not support particular policy
obligations. Accordingly, declining interest rates may
materially affect our results of operations, financial position
and cash flows and significantly reduce our profitability. We
recognize that a low interest rate environment will adversely
affect our earnings, but we do not believe any such impact will
be material in 2011.
The sufficiency of our life insurance statutory reserves in
Taiwan is highly sensitive to interest rates and other related
assumptions. This is due to the sustained low interest rate
environment in Taiwan coupled with long-term interest rate
guarantees of approximately 6% embedded in the life and health
contracts sold prior to 2003 and the lack of availability of
long-duration investments in the Taiwanese capital markets to
match such long-duration liabilities. The key assumptions
include current Taiwan government bond yield rates increasing
approximately 1% from current levels over the next ten years,
lapse rates, mortality and morbidity levels remaining consistent
with recent experience, and U.S. dollar-denominated
investments making up to 35% of total assets backing life
insurance statutory reserves. Current reserve adequacy analysis
shows that provisions are adequate; however, adverse
changes in key assumptions for interest rates, lapse experience
and mortality and morbidity levels could lead to a need to
strengthen reserves.
Increases in market interest rates could also negatively affect
our profitability. In periods of rapidly increasing interest
rates, we may not be able to replace, in a timely manner, the
investments in MetLifes general account with higher
yielding investments needed to fund the higher crediting rates
necessary to keep interest sensitive products competitive. We,
therefore, may have to accept a lower spread and, thus, lower
profitability or face a decline in sales and greater loss of
existing contracts and related assets. In addition, policy
loans, surrenders and withdrawals may tend to increase as
policyholders seek investments with higher perceived returns as
interest rates rise. This process may result in cash outflows
requiring that we sell investments at a time when the prices of
those investments are adversely affected by the increase in
market interest rates, which may result in realized investment
losses. Unanticipated withdrawals and terminations may cause us
to accelerate the amortization of DAC, VOBA and negative VOBA,
which reduces net income. An increase in market interest rates
could also have a material adverse effect on the value of our
investment portfolio, for example, by decreasing the estimated
fair values of the fixed income securities that comprise a
substantial portion of our investment portfolio. Lastly, an
increase in interest rates could result in decreased fee income
associated with a decline in the value of variable annuity
account balances invested in fixed income funds.
S-23
Some of Our Investments Are Relatively Illiquid and Are in
Asset Classes That Have Been Experiencing Significant
Market Valuation Fluctuations
We hold certain investments that may lack liquidity, such as
privately-placed fixed maturity securities; mortgage loans;
policy loans and leveraged leases; equity real estate, including
real estate joint ventures and funds; and other limited
partnership interests. These asset classes represented 26.6% of
the carrying value of our total cash and investments at
December 31, 2010. In recent years, even some of our very
high quality investments experienced reduced liquidity during
periods of market volatility or disruption. If we require
significant amounts of cash on short notice in excess of normal
cash requirements or are required to post or return cash
collateral in connection with our investment portfolio,
derivatives transactions or securities lending program, we may
have difficulty selling these investments in a timely manner, be
forced to sell them for less than we otherwise would have been
able to realize, or both. The reported value of our relatively
illiquid types of investments, our investments in the asset
classes described above and, at times, our high quality,
generally liquid asset classes, do not necessarily reflect the
lowest current market price for the asset. If we were forced to
sell certain of our investments in the global market, there can
be no assurance that we will be able to sell them for the prices
at which we have recorded them and we could be forced to sell
them at significantly lower prices.
Our Participation in a Securities Lending Program Subjects
Us to Potential Liquidity and Other Risks
We participate in a securities lending program whereby blocks of
securities, which are included in fixed maturity securities and
short-term investments, are loaned to third parties, primarily
brokerage firms and commercial banks. We generally obtain
collateral in an amount equal to 102% of the estimated fair
value of the loaned securities, which is obtained at the
inception of a loan and maintained at a level greater than or
equal to 100% for the duration of the loan. Returns of loaned
securities by the third parties would require us to return the
collateral associated with such loaned securities. In addition,
in some cases, the maturity of the securities held as invested
collateral (i.e., securities that we have
purchased with cash collateral received from the third parties)
may exceed the term of the related securities on loan and the
estimated fair value may fall below the amount of cash received
as collateral and invested. If we are required to return
significant amounts of cash collateral on short notice and we
are forced to sell securities to meet the return obligation, we
may have difficulty selling such collateral that is invested in
securities in a timely manner, be forced to sell securities in a
volatile or illiquid market for less than we otherwise would
have been able to realize under normal market conditions, or
both. In addition, under stressful capital market and economic
conditions, liquidity broadly deteriorates, which may further
restrict our ability to sell securities. If we decrease the
amount of our securities lending activities over time, the
amount of net investment income generated by these activities
will also likely decline.
Our Requirements to Pledge Collateral or Make Payments
Related to Declines in Estimated Fair Value of Specified Assets
May Adversely Affect Our Liquidity and Expose Us to Counterparty
Credit Risk
Some of our transactions with financial and other institutions
specify the circumstances under which the parties are required
to pledge collateral related to any decline in the estimated
fair value of the specified assets. In addition, under the terms
of some of our transactions, we may be required to make payments
to our counterparties related to any decline in the estimated
fair value of the specified assets. The amount of collateral we
may be required to pledge and the payments we may be required to
make under these agreements may increase under certain
circumstances, which could adversely affect our liquidity.
Gross Unrealized Losses on Fixed Maturity and Equity
Securities May Be Realized or Result in Future Impairments,
Resulting in a Reduction in Our Net Income
Fixed maturity and equity securities classified as
available-for-sale
are reported at their estimated fair value. Unrealized gains or
losses on
available-for-sale
securities are recognized as a component of other comprehensive
income (loss) and are, therefore, excluded from net income. Our
gross unrealized losses on fixed maturity and equity securities
available for sale at December 31, 2010 were
$6.9 billion. The portion of the $6.9 billion of gross
unrealized losses for fixed maturity and equity securities where
the estimated fair value has declined and remained below
amortized cost or cost by 20% or more for six months or greater
was $2.1 billion at December 31, 2010. The accumulated
change in estimated fair value of these
available-for-sale
securities is recognized in net income when the gain or loss is
realized upon the sale of the security or in the event that the
decline in estimated fair value is determined to be
other-than-temporary
and an impairment charge to earnings is taken. Realized losses
or impairments may have a material adverse effect on our net
income in a particular quarterly or annual period.
S-24
The Determination of the Amount of Allowances and
Impairments Taken on Our Investments is Highly Subjective and
Could Materially Impact Our Results of Operations or Financial
Position
The determination of the amount of allowances and impairments
varies by investment type and is based upon our periodic
evaluation and assessment of known and inherent risks associated
with the respective asset class. Such evaluations and
assessments are revised as conditions change and new information
becomes available. We update our evaluations regularly and
reflect changes in allowances and impairments in net investment
losses as such evaluations are revised. Additional impairments
may need to be taken or allowances provided for in the future.
Furthermore, historical trends may not be indicative of future
impairments or allowances.
For example, the cost of our fixed maturity and equity
securities is adjusted for impairments deemed to be
other-than-temporary.
The assessment of whether impairments have occurred is based on
our
case-by-case
evaluation of the underlying reasons for the decline in
estimated fair value. The review of our fixed maturity and
equity securities for impairments includes an analysis of the
total gross unrealized losses by three categories of securities:
(i) securities where the estimated fair value has declined
and remained below cost or amortized cost by less than 20%;
(ii) securities where the estimated fair value has declined
and remained below cost or amortized cost by 20% or more for
less than six months; and (iii) securities where the
estimated fair value has declined and remained below cost or
amortized cost by 20% or more for six months or greater.
Additionally, we consider a wide range of factors about the
security issuer and use our best judgment in evaluating the
cause of the decline in the estimated fair value of the security
and in assessing the prospects for near term recovery. Inherent
in our evaluation of the security are assumptions and estimates
about the operations of the issuer and its future earnings
potential. Considerations in the impairment evaluation process
include, but are not limited to: (i) the length of time and
the extent to which the estimated fair value has been below cost
or amortized cost; (ii) the potential for impairments of
securities when the issuer is experiencing significant financial
difficulties; (iii) the potential for impairments in an
entire industry sector or
sub-sector;
(iv) the potential for impairments in certain economically
depressed geographic locations; (v) the potential for
impairments of securities where the issuer, series of issuers or
industry has suffered a catastrophic type of loss or has
exhausted natural resources; (vi) with respect to fixed
maturity securities, whether we have the intent to sell or will
more likely than not be required to sell a particular security
before recovery of the decline in estimated fair value below
amortized cost; (vii) with respect to equity securities,
whether we have the ability and intent to hold a particular
security for a period of time sufficient to allow for the
recovery of its estimated fair value to an amount at least equal
to its cost; (viii) unfavorable changes in forecasted cash
flows on mortgage-backed and asset-backed securities
(ABS); and (ix) other subjective
factors, including concentrations and information obtained from
regulators and rating agencies.
Defaults on Our Mortgage Loans and Volatility in
Performance May Adversely Affect Our Profitability
Our mortgage loans face default risk and are principally
collateralized by commercial, agricultural and residential
properties. We establish valuation allowances for estimated
impairments at the balance sheet date. Such valuation allowances
are based on the excess carrying value of the loan over the
present value of expected future cash flows discounted at the
loans original effective interest rate, the estimated fair
value of the loans collateral if the loan is in the
process of foreclosure or otherwise collateral dependent, or the
loans observable market price. We also establish valuation
allowances for loan losses for pools of loans with similar risk
characteristics, such as property types, or loans having similar
loan-to-value
ratios and debt service coverage ratios, when based on past
experience, it is probable that a credit event has occurred and
the amount of the loss can be reasonably estimated. These
valuation allowances are based on loan risk characteristics,
historical default rates and loss severities, real estate market
fundamentals and outlook as well as other relevant factors. At
December 31, 2010, mortgage loans that were either
delinquent or in the process of foreclosure totaled less than
0.6% of our mortgage loan investments. The performance of our
mortgage loan investments, however, may fluctuate in the future.
In addition, substantially all of our mortgage loans
held-for-investment
have balloon payment maturities. An increase in the default rate
of our mortgage loan investments could have a material adverse
effect on our business, results of operations and financial
condition through realized investment losses or increases in our
valuation allowances.
Further, any geographic or sector concentration of our mortgage
loans may have adverse effects on our investment portfolios and
consequently on our results of operations or financial
condition. While we seek to
S-25
mitigate this risk by having a broadly diversified portfolio,
events or developments that have a negative effect on any
particular geographic region or sector may have a greater
adverse effect on the investment portfolios to the extent that
the portfolios are concentrated. Moreover, our ability to sell
assets relating to such particular groups of related assets may
be limited if other market participants are seeking to sell at
the same time. In addition, legislative proposals that would
allow or require modifications to the terms of mortgage loans
could be enacted. We cannot predict whether these proposals will
be adopted, or what impact, if any, such proposals or, if
enacted, such laws, could have on our business or investments.
The Impairment of Other Financial Institutions Could
Adversely Affect Us
We have exposure to many different industries and
counterparties, and routinely execute transactions with
counterparties in the financial services industry, including
brokers and dealers, commercial banks, investment banks, hedge
funds and other investment funds and other institutions. Many of
these transactions expose us to credit risk in the event of
default of our counterparty. In addition, with respect to
secured transactions, our credit risk may be exacerbated when
the collateral held by us cannot be realized or is liquidated at
prices not sufficient to recover the full amount of the loan or
derivative exposure due to us. We also have exposure to these
financial institutions in the form of unsecured debt
instruments, non-redeemable and redeemable preferred securities,
derivative transactions, joint venture, hedge fund and equity
investments. Further, potential action by governments and
regulatory bodies in response to the financial crisis affecting
the global banking system and financial markets, such as
investment, nationalization, conservatorship, receivership and
other intervention, whether under existing legal authority or
any new authority that may be created, could negatively impact
these instruments, securities, transactions and investments.
There can be no assurance that any such losses or impairments to
the carrying value of these investments would not materially and
adversely affect our business and results of operations.
We Face Unforeseen Liabilities, Asset Impairments or
Rating Actions Arising from Acquisitions, Including ALICO, and
Dispositions of Businesses or Difficulties Integrating and
Managing Growth of Such Businesses
We have engaged in dispositions and acquisitions of businesses
in the past, and expect to continue to do so in the future.
Acquisition and disposition activity exposes us to a number of
risks.
There could be unforeseen liabilities or asset impairments,
including goodwill impairments, that arise in connection with
the businesses that we may sell or the businesses that we may
acquire in the future.
In addition, there may be liabilities or asset impairments that
we fail, or are unable, to discover in the course of performing
due diligence investigations on each business that we have
acquired or may acquire. Furthermore, even for obligations and
liabilities that we do discover during the due diligence
process, neither the valuation adjustment nor the contractual
protections we negotiate may be sufficient to fully protect us
from losses. For example, in connection with the acquisition of
ALICO, we may be exposed to obligations and liabilities of ALICO
that are not adequately covered, in amount, scope or duration,
by the indemnification provisions in the stock purchase
agreement, dated as of March 7, 2010 (as amended, the
Stock Purchase Agreement), entered into in
connection with the Acquisition, by and among MetLife, Inc., AIG
and the Selling Stockholder, or reflected or reserved for in
ALICOs historical financial statements. Although we have
rights to indemnification from the Selling Stockholder under the
Stock Purchase Agreement for certain losses, our rights are
limited by survival periods for bringing claims and monetary
limitations on the amount we may recover, and we cannot be
certain that indemnification will be, among other things,
collectible or sufficient in amount, scope or duration to fully
offset any loss we may suffer. We are indemnified under the
Stock Purchase Agreement for various tax matters, including
U.S. federal income taxes attributable to periods during
which the ALICO business was included in AIGs consolidated
federal income tax return. We cannot be certain that any such
indemnification will ultimately be fully collectible.
Furthermore, the use of our own funds as consideration in any
acquisition would consume capital resources that would no longer
be available for other corporate purposes. We also may not be
able to raise sufficient funds to consummate an acquisition if,
for example, we are unable to sell our securities or close
related bridge credit facilities. Moreover, as a result of
uncertainty and risks associated with potential acquisitions and
dispositions of businesses, rating agencies may take certain
actions with respect to the ratings assigned to MetLife, Inc.
and/or its
subsidiaries.
S-26
Our ability to achieve certain benefits we anticipate from any
acquisitions of businesses will depend in large part upon our
ability to successfully integrate such businesses in an
efficient and effective manner. We may not be able to integrate
such businesses smoothly or successfully, and the process may
take longer than expected. The integration of operations and
differences in operational culture may require the dedication of
significant management resources, which may distract
managements attention from
day-to-day
business. If we are unable to successfully integrate the
operations of such acquired businesses, we may be unable to
realize the benefits we expect to achieve as a result of such
acquisitions and our business and results of operations may be
less than expected.
The success with which we are able to integrate acquired
operations, will depend on our ability to manage a variety of
issues, including the following:
|
|
|
|
|
Loss of key personnel or higher than expected employee attrition
rates could adversely affect the performance of the acquired
business and our ability to integrate it successfully.
|
|
|
|
Customers of the acquired business may reduce, delay or defer
decisions concerning their use of its products and services as a
result of the acquisition or uncertainty related to the
consummation of the acquisition, including, for example,
potential unfamiliarity with the MetLife brand in regions where
MetLife did not have a market presence prior to the acquisition.
|
|
|
|
If the acquired business relies upon independent distributors to
distribute its products, these distributors may not continue to
generate the same volume of business for MetLife after the
acquisition. Independent distributors may reexamine the scope of
their relationship with the acquired business or MetLife as a
result of the acquisition and decide to curtail or eliminate
distribution of our products.
|
|
|
|
Integrating acquired operations with our existing operations may
require us to coordinate geographically separated organizations,
address possible differences in corporate culture and management
philosophies, merge financial processes and risk and compliance
procedures, combine separate information technology platforms
and integrate operations that were previously closely tied to
the former parent of the acquired business or other service
providers.
|
|
|
|
In cases where we or an acquired business operates in certain
markets through joint ventures, the acquisition may affect the
continued success and prospects of the joint venture. Our
ability to exercise management control or influence over these
joint venture operations and our investment in them will depend
on the continued cooperation between the joint venture
participants and on the terms of the joint venture agreements,
which allocate control among the joint venture participants. We
may face financial or other exposure in the event that any of
these joint venture partners fail to meet their obligations
under the joint venture, encounter financial difficulty or elect
to alter, modify or terminate the relationship.
|
|
|
|
We may incur significant costs in connection with any
acquisition and the related integration. The costs and
liabilities actually incurred in connection with an acquisition
and subsequent integration process may exceed those anticipated.
|
All of these challenges are present in our integration of ALICO,
which we expect to extend over a substantial period.
The prospects of our business also may be materially and
adversely affected if we are not able to manage the growth of
any acquired business successfully. For example, the life
insurance markets in many of the international markets in which
ALICO operates have experienced significant growth in recent
years. Management of ALICOs growth to date has required
significant management and operational resources and is likely
to continue to do so. Future growth of our combined business
will require, among other things, the continued development of
adequate underwriting and claim handling capabilities and
skills, sufficient capital base, increased marketing and sales
activities, and the hiring and training of new personnel.
There can be no assurance that we will be successful in managing
future growth of any acquired business, including ALICO. In
particular, there may be difficulties in hiring and training
sufficient numbers of customer service personnel and agents to
keep pace with any future growth in the number of customers in
our developing or developed markets. In addition, we may
experience difficulties in upgrading, developing and expanding
information technology systems quickly enough to accommodate any
future growth. If we are unable to manage future growth, our
prospects may be materially and adversely affected.
S-27
There Can Be No Assurance That the Closing Agreement
American Life Entered Into With the IRS Will Achieve Its
Intended Effect, or That American Life Will Be Able to Comply
with the Related Agreed Upon Plan
On March 4, 2010, American Life entered into a closing
agreement with the Commissioner of the IRS with respect to a
U.S. withholding tax issue arising from payments by foreign
branches of a life insurance company incorporated under
U.S. law. IRS Revenue Ruling
2004-75,
effective January 1, 2005, requires foreign branches of
U.S. life insurance companies in certain circumstances to
withhold U.S. income taxes on payments of taxable income
made with respect to certain insurance and annuity products paid
to customers resident in a foreign country. The closing
agreement provides transitional relief under
Section 7805(b) of the U.S. Internal Revenue Code of
1986, as amended (the Code), to American
Life, such that American Lifes foreign branches will not
be required to withhold U.S. income tax on the income
portion of payments made pursuant to American Lifes life
insurance and annuity contracts (Covered
Payments) under IRS Revenue Ruling
2004-75 for
any tax periods beginning on January 1, 2005 and ending on
December 31, 2013 (the Deferral Period).
In accordance with the closing agreement, American Life
submitted a plan to the IRS indicating the steps American Life
will take (on a country by country basis) to ensure that no
substantial amount of U.S. withholding tax will arise from
Covered Payments made by American Lifes foreign branches
to foreign customers after the Deferral Period. In addition, the
closing agreement requires that such plan be updated in
quarterly filings with the IRS. The closing agreement is final
and binding upon American Life and the IRS; provided, however,
that the agreement can be reopened in the event of malfeasance,
fraud or a misrepresentation of a material fact, and is subject
to change of law risk that occurs after the effective date of
the closing agreement (with certain exceptions). In addition,
the closing agreement provides that no legislative amendment to
Section 861(a)(1)(A) of the Code shall shorten the Deferral
Period, regardless of when such amendment is enacted. The plan
American Life delivered to the IRS involves the transfer of
businesses from certain of the foreign branches of American Life
to one or more existing or newly-formed foreign affiliates of
American Life; however, the plan is subject to change pursuant
to the quarterly updates that American Life will provide to the
IRS. An estimate of the costs to comply with the plan has been
recorded in the financial statements. Also the achievement of
the plan presented to the IRS within the required time frame of
December 31, 2013 is contingent upon regulatory approvals
and other requirements. Failure to achieve the plan in a timely
manner could cause American Life to be required to withhold
U.S. income taxes on the taxable portion of payments made
by American Lifes foreign branches after December 31,
2013 to customers resident in a foreign country, which could put
American Life at a competitive disadvantage with its competitors
that sell similar products through foreign entities and could
have a material adverse effect on American Lifes future
revenues or expenses or both.
There Can Be No Assurance That Any Incremental Tax Benefit
Will Result From the Currently Planned Elections Under
Section 338 of the Code
MetLife, Inc. currently plans to make Section 338 Elections
with respect to ALICO and certain of its subsidiaries, and
MetLife, Inc. believes that ALICO and such subsidiaries should
have additional amortizable basis in their assets for
U.S. tax purposes as a result of such elections. No
assurance can be given, however, as to the incremental tax
benefit, if any, that will result from any such elections if
made.
To the Extent MetLife, Inc. Does Not Repurchase All of the
Series B Preferred Stock, If MetLife, Inc.s
Stockholders Do Not Vote to Approve the Conversion of the
Series B Preferred Stock Into Common Stock, MetLife, Inc.
Will Be Required to Pay Up To Approximately $300 Million to the
Selling Stockholder
The Selling Stockholder received the shares of the Series B
Preferred Stock upon completion of the Acquisition. Each share
of Series B Preferred Stock will convert into
10 shares of MetLife, Inc.s common stock (subject to
anti-dilution adjustments) if conversion is approved by MetLife,
Inc.s common stockholders. If MetLife, Inc. fails to
obtain such approval prior to the first anniversary of the
closing of the Acquisition, November 1, 2011, MetLife, Inc.
will be required to pay up to approximately $300 million to
the Selling Stockholder, assuming no purchase price adjustments,
and, upon request, register the Series B Preferred Stock
for sale by the Selling Stockholder in a public offering and
list the Series B Preferred Stock on the NYSE.
Fluctuations in Foreign Currency Exchange Rates Could
Negatively Affect Our Profitability
We are exposed to risks associated with fluctuations in foreign
currency exchange rates against the U.S. dollar resulting
from our holdings of
non-U.S. dollar
denominated investments, investments in foreign subsidiaries and
net
S-28
income from foreign operations and issuance of
non-U.S. dollar
denominated instruments, including guaranteed interest contracts
and funding agreements. These risks relate to potential
decreases in estimated fair value and income resulting from a
strengthening or weakening in foreign exchange rates versus the
U.S. dollar. In general, the weakening of foreign
currencies versus the U.S. dollar will adversely affect the
estimated fair value of our
non-U.S. dollar
denominated investments, our investments in foreign
subsidiaries, and our net income from foreign operations.
Although we use foreign currency swaps and forward contracts to
mitigate foreign currency exchange rate risk, we cannot provide
assurance that these methods will be effective or that our
counterparties will perform their obligations.
From time to time, various emerging market countries have
experienced severe economic and financial disruptions, including
significant devaluations of their currencies. Our exposure to
foreign exchange rate risk is exacerbated by our investments in
certain emerging markets.
Historically, we have matched substantially all of our foreign
currency liabilities in our foreign subsidiaries with
investments denominated in their respective foreign currency,
which limits the effect of currency exchange rate fluctuation on
local operating results; however, fluctuations in such rates
affect the translation of these results into our
U.S. dollar basis consolidated financial statements.
Although we take certain actions to address this risk, foreign
currency exchange rate fluctuation could materially adversely
affect our reported results due to unhedged positions or the
failure of hedges to effectively offset the impact of the
foreign currency exchange rate fluctuation.
The Acquisition has increased our exposure to risks associated
with fluctuations in foreign currency exchange rates against the
U.S. dollar and increased our exposure to emerging markets.
Fluctuations in the yen/ U.S. dollar exchange rate can have
a significant effect on our reported financial position and
results of operations because ALICO has substantial operations
in Japan and a significant portion of its premiums and
investment income are received in yen. Claims and expenses are
also paid in yen and ALICO primarily purchases yen-denominated
assets to support yen-denominated policy liabilities. These and
other yen-denominated financial statement items are, however,
translated into U.S. dollars for financial reporting
purposes. Accordingly, fluctuations in the yen/U.S. dollar
exchange rate can have a significant effect on our reported
financial position and results of operations.
Due to our significant international operations, during periods
when any foreign currency in which we derive our revenues (such
as the Japanese yen) weakens, translating amounts expressed in
that currency into U.S. dollars causes fewer
U.S. dollars to be reported. When the relevant foreign
currency strengthens, translating such currency into
U.S. dollars causes more U.S. dollars to be reported.
Between September 30, 2010 and December 31, 2010, the
Japanese yen has strengthened against the U.S. dollar,
which fluctuated from a low point of ¥80.40 to the
U.S. dollar on October 29, 2010 to a high point of
¥84.26 to the U.S. dollar on November 29, 2010,
which has been somewhat offset by the weakening of the euro,
which fluctuated from a high point of 0.7702 euro to the
U.S. dollar on November 30, 2010, to 0.7039 euro to
the U.S. dollar on November 4, 2010. Any unrealized
foreign currency translation adjustments are reported in
accumulated other comprehensive income (loss). The weakening of
a foreign currency relative to the U.S. dollar will
generally adversely affect the value of investments in
U.S. dollar terms and reduce the level of reserves
denominated in that currency.
Our International Operations Face Political, Legal,
Operational and Other Risks, Including Exposure to Local and
Regional Economic Conditions, That Could Negatively Affect Those
Operations or Our Profitability
Our international operations face political, legal, operational
and other risks that we do not face in our domestic operations.
We face the risk of discriminatory regulation, nationalization
or expropriation of assets, price controls and exchange controls
or other restrictions that prevent us from transferring funds
from these operations out of the countries in which they operate
or converting local currencies we hold into U.S. dollars or
other currencies. Some of our foreign insurance operations are,
and are likely to continue to be, in emerging markets where
these risks are heightened. In addition, we rely on local sales
forces in these countries and may encounter labor problems
resulting from workers associations and trade unions in
some countries. In several countries, including Japan, China and
India we operate with local business partners with the resulting
risk of managing partner relationships to the business
objectives. If our business model is not successful in a
particular country, we may lose all or most of our investment in
building and training the sales force in that country.
S-29
We are expanding our international operations in certain markets
where we operate and in selected new markets. This may require
considerable management time, as well as
start-up
expenses for market development before any significant revenues
and earnings are generated. Operations in new foreign markets
may achieve low margins or may be unprofitable, and expansion in
existing markets may be affected by local economic and market
conditions. Therefore, as we expand internationally, we may not
achieve expected operating margins and our results of operations
may be negatively impacted.
In addition, in recent years, the operating environment in
Argentina has been very challenging. In Argentina, we were
formerly principally engaged in the pension business. In
December 2008, the Argentine government nationalized private
pensions and seized the pension funds investments,
eliminating the private pensions business in Argentina. As a
result, we have experienced and will continue to experience
reductions in the operations revenues and cash flows. The
Argentine government now controls all assets which previously
were managed by our Argentine pension operations. Further
governmental or legal actions related to our operations in
Argentina could negatively impact our operations in Argentina
and result in future losses.
We have market presence in over 60 different countries, and
increased exposure to risks posed by local and regional economic
conditions. Europe has recently experienced a deep recession and
countries such as Italy, Spain, Portugal and, in particular,
Greece and Ireland, have been particularly affected by the
recession, resulting in increased national debts and depressed
economic activity. We have significant operations and
investments in these countries which could be adversely affected
by economic developments such as higher taxes, growing
inflation, decreasing government spending, rising unemployment
and currency instability.
In addition to fluctuations in the yen/U.S. dollar exchange
rate discussed above, we face increased exposure to the Japanese
markets as a result of ALICOs considerable presence there.
Deterioration in Japans economic recovery could have an
adverse effect on our results of operations and financial
condition.
We also have operations in the Middle East where the legal and
political systems and regulatory frameworks are subject to
instability and disruptions. Lack of legal certainty and
stability in the region exposes our operations to increased risk
of disruption and to adverse or unpredictable actions by
regulators and may make it more difficult for us to enforce our
contracts, which may negatively impact our business in this
region. See also Changes in Market
Interest Rates May Significantly Affect Our Profitability
regarding the impact of low interest rates on our Taiwanese
operations.
As a Holding Company, MetLife, Inc. Depends on the Ability
of Its Subsidiaries to Transfer Funds to It to Meet Its
Obligations and Pay Dividends
MetLife, Inc. is a holding company for its insurance and
financial subsidiaries and does not have any significant
operations of its own. Dividends from its subsidiaries and
permitted payments to it under its tax sharing arrangements with
its subsidiaries are its principal sources of cash to meet its
obligations and to pay preferred and common stock dividends. If
the cash MetLife, Inc. receives from its subsidiaries is
insufficient for it to fund its debt service and other holding
company obligations, MetLife, Inc. may be required to raise cash
through the incurrence of debt, the issuance of additional
equity or the sale of assets.
The payment of dividends and other distributions to MetLife,
Inc. by its insurance subsidiaries is regulated by insurance
laws and regulations. In general, dividends in excess of
prescribed limits require insurance regulatory approval. In
addition, insurance regulators may prohibit the payment of
dividends or other payments by its insurance subsidiaries to
MetLife, Inc. if they determine that the payment could be
adverse to our policyholders or contractholders. The payment of
dividends and other distributions by insurance companies is also
influenced by business conditions and rating agency
considerations. The ability of MetLife Bank to pay dividends is
also subject to regulation by the OCC.
Any payment of interest, dividends, distributions, loans or
advances by our foreign subsidiaries and branches to MetLife,
Inc. could be subject to taxation or other restrictions on
dividends or repatriation of earnings under applicable law,
monetary transfer restrictions and foreign currency exchange
regulations in the jurisdiction in which such foreign
subsidiaries operate. See Our
International Operations Face Political, Legal, Operational and
Other Risks, Including Exposure to Local and Regional Economic
Conditions, That Could Negatively Affect Those Operations or Our
Profitability.
S-30
A Downgrade or a Potential Downgrade in Our Financial
Strength or Credit Ratings Could Result in a Loss of Business
and Materially Adversely Affect Our Financial Condition and
Results of Operations
Financial strength ratings, which various Nationally Recognized
Statistical Rating Organizations (NRSRO)
publish as indicators of an insurance companys ability to
meet contractholder and policyholder obligations, are important
to maintaining public confidence in our products, our ability to
market our products and our competitive position.
Downgrades in our financial strength ratings could have a
material adverse effect on our financial condition and results
of operations in many ways, including:
|
|
|
|
|
reducing new sales of insurance products, annuities and other
investment products;
|
|
|
|
adversely affecting our relationships with our sales force and
independent sales intermediaries;
|
|
|
|
materially increasing the number or amount of policy surrenders
and withdrawals by contractholders and policyholders;
|
|
|
|
requiring us to reduce prices for many of our products and
services to remain competitive; and
|
|
|
|
adversely affecting our ability to obtain reinsurance at
reasonable prices or at all.
|
In addition to the financial strength ratings of our insurance
subsidiaries, various NRSROs also publish credit ratings for
MetLife, Inc. and several of its subsidiaries. Credit ratings
are indicators of a debt issuers ability to meet the terms
of debt obligations in a timely manner and are important factors
in our overall funding profile and ability to access certain
types of liquidity. Downgrades in our credit ratings could have
a material adverse effect on our financial condition and results
of operations in many ways, including adversely limiting our
access to capital markets, potentially increasing the cost of
debt, and requiring us to post collateral. For example, with
respect to derivative transactions with credit ratings downgrade
triggers, a one-notch downgrade would have increased our
derivative collateral requirements by $99 million at
December 31, 2010. Also, $375 million of liabilities
associated with funding agreements and other capital market
products were subject to credit ratings downgrade triggers that
permit early termination subject to a notice period of
90 days.
In view of the difficulties experienced during 2008 and 2009 by
many financial institutions, including our competitors in the
insurance industry, we believe it is possible that the NRSROs
will continue to heighten the level of scrutiny that they apply
to such institutions, will continue to increase the frequency
and scope of their credit reviews, will continue to request
additional information from the companies that they rate, and
may adjust upward the capital and other requirements employed in
the NRSRO models for maintenance of certain ratings levels.
Rating agencies use an outlook statement of
positive, stable, negative
or developing to indicate a medium- or long-term
trend in credit fundamentals which, if continued, may lead to a
ratings change. A rating may have a stable outlook
to indicate that the rating is not expected to change; however,
a stable rating does not preclude a rating agency
from changing a rating at any time, without notice. Certain
rating agencies assign rating modifiers such as
CreditWatch or Under Review to indicate
their opinion regarding the potential direction of a rating.
These ratings modifiers are generally assigned in connection
with certain events such as potential mergers and acquisitions,
or material changes in a companys results, in order for
the rating agencies to perform their analyses to fully determine
the rating implications of the event. Certain rating agencies
have recently implemented rating actions, including downgrades,
outlook changes and modifiers, for MetLife, Inc.s and
certain of its subsidiaries insurer financial strength and
credit ratings.
Based on the announcement in February 2010 that MetLife was in
discussions to acquire ALICO, in February 2010, S&P and
A.M. Best placed the ratings of MetLife, Inc. and its
subsidiaries on CreditWatch with negative
implications and under review with negative
implications, respectively. Also in connection with the
announcement, in March 2010, Moodys changed the ratings
outlook of MetLife, Inc. and its subsidiaries from
stable to negative outlook. Upon
completion of the public financing transactions related to the
Acquisition, in August 2010, S&P affirmed the ratings of
MetLife, Inc. and subsidiaries with a negative
outlook, and removed them from CreditWatch. On
November 1, 2010, upon closing of the Acquisition, S&P
changed the rating outlook of American Life to
positive from negative and affirmed its
financial strength rating; the ratings of MetLife, Inc. and its
other subsidiaries were unaffected by this ratings action. Also
on November 1, 2010, Fitch Ratings upgraded
S-31
by one notch (and changed the rating outlook from Rating
Watch Positive to stable) the financial
strength rating of American Life and affirmed all existing
ratings for MetLife, Inc. and its other subsidiaries. On
November 4, 2010, A.M. Best upgraded by one notch the
financial strength rating of American Life and changed the
rating outlook from under review with positive
implications to negative. A.M. Best also
changed the outlook for MetLife, Inc. and certain of its other
subsidiaries to negative from under review
with negative implications. Effective as of January 2011,
MetLife withdrew the American Life financial strength ratings by
A.M. Best and Fitch Ratings as once it became a subsidiary
of MetLife it was not deemed necessary to maintain stand-alone
ratings.
On July 1, 2010, Moodys published revised guidance
called Revisions to Moodys Hybrid Tool Kit
(the Guidance) for assigning equity credit to
so-called hybrid securities, i.e., securities with
both debt and equity characteristics
(Hybrids). Moodys evaluates Hybrids
using certain specified criteria and then places each such
security into a basket, with a specific percentage
of debt and equity being associated with each basket, which is
then used to adjust full sets of financial statements for
purposes of, among other things, calculating the issuing
companys financial leverage. Under the Guidance, Hybrids
are one element that Moodys considers within the context
of an issuers overall credit profile. As of
December 31, 2010, we have approximately $11.1 billion
of Hybrids outstanding, which includes approximately
$6.2 billion of debt securities and $4.9 billion of
equity securities. Application of the Guidance has resulted in
Moodys significantly reducing the amount of equity credit
it assigns to these securities, including the common equity
units issued to the Selling Stockholder in connection with the
Acquisition. We do not expect at this time, as a result of the
Guidance, that a reduction in Moodys equity treatment of
our Hybrids, including the common equity units, would result in
any material negative impact on MetLife, Inc.s credit
rating or the financial strength ratings of its insurance
company subsidiaries. However, if we decided to increase our
adjusted capital as a result of the application of the Guidance,
we may seek to (i) issue additional common equity or higher
equity content Hybrids satisfying the Guidances revised
rating criteria,
and/or
(ii) redeem, repurchase or restructure existing Hybrids.
Any sale of additional common equity would have a dilutive
effect on our common stockholders.
We cannot predict what actions rating agencies may take, or what
actions we may take in response to the actions of rating
agencies, which could adversely affect our business. As with
other companies in the financial services industry, our ratings
could be downgraded at any time and without any notice by any
NRSRO.
An Inability to Access Our Credit Facilities Could Result
in a Reduction in Our Liquidity and Lead to Downgrades in Our
Credit and Financial Strength Ratings
In October 2010, we entered into two senior unsecured credit
facilities: a three-year $3 billion facility and a
364-day
$1 billion facility. We also have other facilities which we
enter into in the ordinary course of business.
We rely on our credit facilities as a potential source of
liquidity. The availability of these facilities could be
critical to our credit and financial strength ratings and our
ability to meet our obligations as they come due in a market
when alternative sources of credit are tight. The credit
facilities contain certain administrative, reporting, legal and
financial covenants. We must comply with covenants under our
credit facilities, including a requirement to maintain a
specified minimum consolidated net worth.
Our right to make borrowings under these facilities is subject
to the fulfillment of certain important conditions, including
our compliance with all covenants, and our ability to borrow
under these facilities is also subject to the continued
willingness and ability of the lenders that are parties to the
facilities to provide funds. Our failure to comply with the
covenants in the credit facilities or fulfill the conditions to
borrowings, or the failure of lenders to fund their lending
commitments (whether due to insolvency, illiquidity or other
reasons) in the amounts provided for under the terms of the
facilities, would restrict our ability to access these credit
facilities when needed and, consequently, could have a material
adverse effect on our financial condition and results of
operations.
Defaults, Downgrades or Other Events Impairing the
Carrying Value of Our Fixed Maturity or Equity Securities
Portfolio May Reduce Our Earnings
We are subject to the risk that the issuers, or guarantors, of
fixed maturity securities we own may default on principal and
interest payments they owe us. We are also subject to the risk
that the underlying collateral within loan-backed securities,
including mortgage-backed securities, may default on principal
and interest payments causing an adverse change in cash flows.
Fixed maturity securities represent a significant portion of our
investment
S-32
portfolio. The occurrence of a major economic downturn, acts of
corporate malfeasance, widening risk spreads, or other events
that adversely affect the issuers, guarantors or underlying
collateral of these securities could cause the estimated fair
value of our fixed maturity securities portfolio and our
earnings to decline and the default rate of the fixed maturity
securities in our investment portfolio to increase. A ratings
downgrade affecting issuers or guarantors of particular
securities, or similar trends that could worsen the credit
quality of issuers, such as the corporate issuers of securities
in our investment portfolio, could also have a similar effect.
With economic uncertainty, credit quality of issuers or
guarantors could be adversely affected. Similarly, a ratings
downgrade affecting a security we hold could indicate the credit
quality of that security has deteriorated and could increase the
capital we must hold to support that security to maintain our
RBC levels. Any event reducing the estimated fair value of these
securities other than on a temporary basis could have a material
adverse effect on our business, results of operations and
financial condition. Levels of writedowns or impairments are
impacted by our assessment of intent to sell, or whether it is
more likely than not that we will be required to sell, fixed
maturity securities and the intent and ability to hold equity
securities which have declined in value until recovery. If we
determine to reposition or realign portions of the portfolio so
as not to hold certain equity securities, or intend to sell or
determine that it is more likely than not that we will be
required to sell, certain fixed maturity securities in an
unrealized loss position prior to recovery, then we will incur
an
other-than-temporary
impairment charge in the period that the decision was made not
to hold the equity security to recovery, or to sell, or the
determination was made it is more likely than not that we will
be required to sell the fixed maturity security.
Our Risk Management Policies and Procedures May Leave Us
Exposed to Unidentified or Unanticipated Risk, Which Could
Negatively Affect Our Business
Management of risk requires, among other things, policies and
procedures to record properly and verify a large number of
transactions and events. We have devoted significant resources
to develop our risk management policies and procedures and
expect to continue to do so in the future. Nonetheless, our
policies and procedures may not be comprehensive. Many of our
methods for managing risk and exposures are based upon the use
of observed historical market behavior or statistics based on
historical models. As a result, these methods may not fully
predict future exposures, which can be significantly greater
than our historical measures indicate. Other risk management
methods depend upon the evaluation of information regarding
markets, clients, catastrophe occurrence or other matters that
is publicly available or otherwise accessible to us. This
information may not always be accurate, complete,
up-to-date
or properly evaluated.
Reinsurance May Not Be Available, Affordable or Adequate
to Protect Us Against Losses
As part of our overall risk management strategy, we purchase
reinsurance for certain risks underwritten by our various
business segments. While reinsurance agreements generally bind
the reinsurer for the life of the business reinsured at
generally fixed pricing, market conditions beyond our control
determine the availability and cost of the reinsurance
protection for new business. In certain circumstances, the price
of reinsurance for business already reinsured may also increase.
Any decrease in the amount of reinsurance will increase our risk
of loss and any increase in the cost of reinsurance will, absent
a decrease in the amount of reinsurance, reduce our earnings.
Accordingly, we may be forced to incur additional expenses for
reinsurance or may not be able to obtain sufficient reinsurance
on acceptable terms, which could adversely affect our ability to
write future business or result in the assumption of more risk
with respect to those policies we issue.
If the Counterparties to Our Reinsurance or
Indemnification Arrangements or to the Derivative Instruments We
Use to Hedge Our Business Risks Default or Fail to Perform, We
May Be Exposed to Risks We Had Sought to Mitigate, Which Could
Materially Adversely Affect Our Financial Condition and Results
of Operations
We use reinsurance, indemnification and derivative instruments
to mitigate our risks in various circumstances. In general,
reinsurance does not relieve us of our direct liability to our
policyholders, even when the reinsurer is liable to us.
Accordingly, we bear credit risk with respect to our reinsurers
and indemnitors. We cannot provide assurance that our reinsurers
will pay the reinsurance recoverables owed to us or that
indemnitors will honor their obligations now or in the future or
that they will pay these recoverables on a timely basis. A
reinsurers or indemnitors insolvency, inability or
unwillingness to make payments under the terms of reinsurance
agreements or indemnity agreements with us could have a material
adverse effect on our financial condition and results of
operations.
S-33
In addition, we use derivative instruments to hedge various
business risks. We enter into a variety of derivative
instruments, including options, forwards, interest rate, credit
default and currency swaps with a number of counterparties. If
our counterparties fail or refuse to honor their obligations
under these derivative instruments, our hedges of the related
risk will be ineffective. This is a more pronounced risk to us
in view of the stresses suffered by financial institutions over
the past few years. Such failure could have a material adverse
effect on our financial condition and results of operations.
Differences Between Actual Claims Experience and
Underwriting and Reserving Assumptions May Adversely Affect Our
Financial Results
Our earnings significantly depend upon the extent to which our
actual claims experience is consistent with the assumptions we
use in setting prices for our products and establishing
liabilities for future policy benefits and claims. Our
liabilities for future policy benefits and claims are
established based on estimates by actuaries of how much we will
need to pay for future benefits and claims. For life insurance
and annuity products, we calculate these liabilities based on
many assumptions and estimates, including estimated premiums to
be received over the assumed life of the policy, the timing of
the event covered by the insurance policy, the amount of
benefits or claims to be paid and the investment returns on the
investments we make with the premiums we receive. We establish
liabilities for property and casualty claims and benefits based
on assumptions and estimates of damages and liabilities
incurred. To the extent that actual claims experience is less
favorable than the underlying assumptions we used in
establishing such liabilities, we could be required to increase
our liabilities.
Due to the nature of the underlying risks and the high degree of
uncertainty associated with the determination of liabilities for
future policy benefits and claims, we cannot determine precisely
the amounts which we will ultimately pay to settle our
liabilities. Such amounts may vary from the estimated amounts,
particularly when those payments may not occur until well into
the future. We evaluate our liabilities periodically based on
accounting requirements, which change from time to time, the
assumptions used to establish the liabilities, as well as our
actual experience. We charge or credit changes in our
liabilities to expenses in the period the liabilities are
established or re-estimated. If the liabilities originally
established for future benefit payments prove inadequate, we
must increase them. Such increases could affect earnings
negatively and have a material adverse effect on our business,
results of operations and financial condition.
Catastrophes May Adversely Impact Liabilities for
Policyholder Claims and Reinsurance Availability
Our life insurance operations are exposed to the risk of
catastrophic mortality, such as a pandemic or other event that
causes a large number of deaths. Significant influenza pandemics
have occurred three times in the last century, but neither the
likelihood, timing, nor the severity of a future pandemic can be
predicted. A significant pandemic could have a major impact on
the global economy or the economies of particular countries or
regions, including travel, trade, tourism, the health system,
food supply, consumption, overall economic output and,
eventually, on the financial markets. In addition, a pandemic
that affected our employees or the employees of our distributors
or of other companies with which we do business could disrupt
our business operations. The effectiveness of external parties,
including governmental and non-governmental organizations, in
combating the spread and severity of such a pandemic could have
a material impact on the losses experienced by us. In our group
insurance operations, a localized event that affects the
workplace of one or more of our group insurance customers could
cause a significant loss due to mortality or morbidity claims.
These events could cause a material adverse effect on our
results of operations in any period and, depending on their
severity, could also materially and adversely affect our
financial condition.
Our Auto & Home business has experienced, and will
likely in the future experience, catastrophe losses that may
have a material adverse impact on the business, results of
operations and financial condition of the Auto & Home
segment. Although Auto & Home makes every effort to
manage our exposure to catastrophic risks through volatility
management and reinsurance programs, these efforts do not
eliminate all risk. Catastrophes can be caused by various
events, including hurricanes, windstorms, earthquakes, hail,
tornadoes, explosions, severe winter weather (including snow,
freezing water, ice storms and blizzards), fires and man-made
events such as terrorist attacks. Historically, substantially
all of our catastrophe-related claims have related to homeowners
coverages. However, catastrophes may also affect other
Auto & Home coverages. Due to their nature, we cannot
predict the incidence, timing and severity of catastrophes. In
addition, changing climate conditions, primarily rising global
S-34
temperatures, may be increasing, or may in the future increase,
the frequency and severity of natural catastrophes such as
hurricanes.
Hurricanes and earthquakes are of particular note for our
homeowners coverages. Areas of major hurricane exposure include
coastal sections of the northeastern United States (including
lower New York, Connecticut, Rhode Island and Massachusetts),
the Gulf Coast (including Alabama, Mississippi, Louisiana and
Texas) and Florida. We also have some earthquake exposure,
primarily along the New Madrid fault line in the central United
States and in the Pacific Northwest.
The extent of losses from a catastrophe is a function of both
the total amount of insured exposure in the area affected by the
event and the severity of the event. Most catastrophes are
restricted to small geographic areas; however, hurricanes,
earthquakes and man-made catastrophes may produce significant
damage or loss of life in larger areas, especially those that
are heavily populated. Claims resulting from natural or man-made
catastrophic events could cause substantial volatility in our
financial results for any fiscal quarter or year and could
materially reduce our profitability or harm our financial
condition. Also, catastrophic events could harm the financial
condition of our reinsurers and thereby increase the probability
of default on reinsurance recoveries. Our ability to write new
business could also be affected. It is possible that increases
in the value, caused by the effects of inflation or other
factors, and geographic concentration of insured property, could
increase the severity of claims from catastrophic events in the
future.
Most of the jurisdictions in which our insurance subsidiaries
are admitted to transact business require life and property and
casualty insurers doing business within the jurisdiction to
participate in guaranty associations, which are organized to pay
contractual benefits owed pursuant to insurance policies issued
by impaired, insolvent or failed insurers. These associations
levy assessments, up to prescribed limits, on all member
insurers in a particular state on the basis of the proportionate
share of the premiums written by member insurers in the lines of
business in which the impaired, insolvent or failed insurer is
engaged. In addition, certain states have government owned or
controlled organizations providing life and property and
casualty insurance to their citizens. The activities of such
organizations could also place additional stress on the adequacy
of guaranty fund assessments. Many of these organizations also
have the power to levy assessments similar to those of the
guaranty associations described above. Some states permit member
insurers to recover assessments paid through full or partial
premium tax offsets.
While in the past five years, the aggregate assessments levied
against MetLife, Inc.s insurance subsidiaries have not
been material, it is possible that a large catastrophic event
could render such guaranty funds inadequate and we may be called
upon to contribute additional amounts, which may have a material
impact on our financial condition or results of operations in a
particular period. We have established liabilities for guaranty
fund assessments that we consider adequate for assessments with
respect to insurers that are currently subject to insolvency
proceedings, but additional liabilities may be necessary.
Consistent with industry practice and accounting standards, we
establish liabilities for claims arising from a catastrophe only
after assessing the probable losses arising from the event. We
cannot be certain that the liabilities we have established will
be adequate to cover actual claim liabilities. From time to
time, states have passed legislation that has the effect of
limiting the ability of insurers to manage risk, such as
legislation restricting an insurers ability to withdraw
from catastrophe-prone areas. While we attempt to limit our
exposure to acceptable levels, subject to restrictions imposed
by insurance regulatory authorities, a catastrophic event or
multiple catastrophic events could have a material adverse
effect on our business, results of operations and financial
condition.
Our ability to manage this risk and the profitability of our
property and casualty and life insurance businesses depends in
part on our ability to obtain catastrophe reinsurance, which may
not be available at commercially acceptable rates in the future.
See Reinsurance May Not Be Available,
Affordable or Adequate to Protect Us Against Losses.
Our Statutory Reserve Financings May Be Subject to Cost
Increases and New Financings May Be Subject to Limited Market
Capacity
To support statutory reserves for several products, including,
but not limited to, our level premium term life and universal
life with secondary guarantees and MLICs closed block, we
currently utilize capital markets solutions for
S-35
financing a portion of our statutory reserve requirements. While
we have financing facilities in place for our previously written
business and have remaining capacity in existing facilities to
support writings through the end of 2010 or later, certain of
these facilities are subject to cost increases upon the
occurrence of specified ratings downgrades of MetLife or are
subject to periodic repricing. Any resulting cost increases
could negatively impact our financial results.
Future capacity for these statutory reserve funding structures
in the marketplace is not guaranteed. If capacity becomes
unavailable for a prolonged period of time, hindering our
ability to obtain funding for these new structures, our ability
to write additional business in a cost effective manner may be
impacted.
Competitive Factors May Adversely Affect Our Market Share
and Profitability
Our segments are subject to intense competition. We believe that
this competition is based on a number of factors, including
service, product features, scale, price, financial strength,
claims-paying ratings, credit ratings,
e-business
capabilities and name recognition. We compete with a large
number of other insurers, as well as non-insurance financial
services companies, such as banks, broker-dealers and asset
managers, for individual consumers, employers and other group
customers and agents and other distributors of insurance and
investment products. Some of these companies offer a broader
array of products, have more competitive pricing or more
attractive features in their products or, with respect to other
insurers, have higher claims paying ability ratings. Some may
also have greater financial resources with which to compete.
National banks, which may sell annuity products of life insurers
in some circumstances, also have pre-existing customer bases for
financial services products. Many of our group insurance
products are underwritten annually, and, accordingly, there is a
risk that group purchasers may be able to obtain more favorable
terms from competitors rather than renewing coverage with us.
The effect of competition may, as a result, adversely affect the
persistency of these and other products, as well as our ability
to sell products in the future.
In addition, the investment management and securities brokerage
businesses have relatively few barriers to entry and continually
attract new entrants.
Finally, the new requirements imposed on the financial industry
by Dodd-Frank could similarly have differential effects. See
Various Aspects of Dodd-Frank Could Impact
Our Business Operations, Capital Requirements and Profitability
and Limit Our Growth.
Industry Trends Could Adversely Affect the Profitability
of Our Businesses
Our segments continue to be influenced by a variety of trends
that affect the insurance industry, including competition with
respect to product features, price, distribution capability,
customer service and information technology. The impact on our
business and on the life insurance industry generally of the
volatility and instability of the financial markets is difficult
to predict, and our business plans, financial condition and
results of operations may be negatively impacted or affected in
other unexpected ways. In addition, the life insurance industry
is subject to state regulation, and, as complex products are
introduced, regulators may refine capital requirements and
introduce new reserving standards. Dodd-Frank, Basel III
and the market environment in general may also lead to changes
in regulation that may benefit or disadvantage us relative to
some of our competitors. See Our
Insurance, Brokerage and Banking Businesses Are Heavily
Regulated, and Changes in Regulation May Reduce Our
Profitability and Limit Our Growth and
Competitive Factors May Adversely Affect Our
Market Share and Profitability.
Consolidation of Distributors of Insurance Products May
Adversely Affect the Insurance Industry and the Profitability of
Our Business
The insurance industry distributes many of its individual
products through other financial institutions such as banks and
broker-dealers. An increase in bank and broker-dealer
consolidation activity may negatively impact the industrys
sales, and such consolidation could increase competition for
access to distributors, result in greater distribution expenses
and impair our ability to market insurance products to our
current customer base or to expand our customer base.
Consolidation of distributors
and/or other
industry changes may also increase the likelihood that
distributors will try to renegotiate the terms of any existing
selling agreements to terms less favorable to us.
S-36
Our Valuation of Fixed Maturity, Equity and Trading and
Other Securities and Short-Term Investments May Include
Methodologies, Estimations and Assumptions Which Are Subject to
Differing Interpretations and Could Result in Changes to
Investment Valuations That May Materially Adversely Affect Our
Results of Operations or Financial Condition
Fixed maturity, equity, and trading and other securities and
short-term investments which are reported at estimated fair
value on the consolidated balance sheets represent the majority
of our total cash and investments. We have categorized these
securities into a three-level hierarchy, based on the priority
of the inputs to the respective valuation technique.
The fair value hierarchy gives the highest priority to quoted
prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable
inputs (Level 3). An asset or liabilitys
classification within the fair value hierarchy is based on the
lowest level of significant input to its valuation. The input
levels are as follows:
Level 1 Unadjusted quoted prices in active
markets for identical assets or liabilities. We define active
markets based on average trading volume for equity securities.
The size of the bid/ask spread is used as an indicator of market
activity for fixed maturity securities.
Level 2 Quoted prices in markets that are not
active or inputs that are observable either directly or
indirectly. Level 2 inputs include quoted prices for
similar assets or liabilities other than quoted prices in
Level 1; quoted prices in markets that are not active; or
other significant inputs that are observable or can be derived
principally from or corroborated by observable market data for
substantially the full term of the assets or liabilities.
Level 3 Unobservable inputs that are supported
by little or no market activity and are significant to the
estimated fair value of the assets or liabilities. Unobservable
inputs reflect the reporting entitys own assumptions about
the assumptions that market participants would use in pricing
the asset or liability. Level 3 assets and liabilities
include financial instruments whose values are determined using
pricing models, discounted cash flow methodologies, or similar
techniques, as well as instruments for which the determination
of the estimated fair value requires significant management
judgment or estimation.
At December 31, 2010, 7.0%, 85.8% and 7.2% of these
securities represented Level 1, Level 2 and
Level 3, respectively. The Level 1 securities
primarily consist of certain U.S. Treasury, agency and
government guaranteed fixed maturity securities; certain foreign
government fixed maturity securities; exchange-traded common
stock; certain trading securities; certain fair value option
securities and certain short-term investments. The Level 2
assets include fixed maturity and equity securities priced
principally through independent pricing services using
observable inputs. These fixed maturity securities include most
U.S. Treasury, agency and government guaranteed securities,
as well as the majority of U.S. and foreign corporate
securities, RMBS, CMBS, state and political subdivision
securities, foreign government securities, and ABS. Equity
securities classified as Level 2 primarily consist of non-
redeemable preferred securities and certain equity securities
where market quotes are available but are not considered
actively traded and are priced by independent pricing services.
We review the valuation methodologies used by the independent
pricing services on an ongoing basis and ensure that any changes
to valuation methodologies are justified. Level 3 assets
include fixed maturity securities priced principally through
independent non-binding broker quotations or market standard
valuation methodologies using inputs that are not market
observable or cannot be derived principally from or corroborated
by observable market data. Level 3 consists of less liquid
fixed maturity securities with very limited trading activity or
where less price transparency exists around the inputs to the
valuation methodologies including: U.S. and foreign
corporate securities including below investment
grade private placements; RMBS; CMBS; and ABS
including all of those supported by
sub-prime
mortgage loans. Equity securities classified as Level 3
securities consist principally of nonredeemable preferred stock
and common stock of companies that are privately held or
companies for which there has been very limited trading activity
or where less price transparency exists around the inputs to the
valuation.
Prices provided by independent pricing services and independent
non-binding broker quotations can vary widely even for the same
security.
The determination of estimated fair values by management in the
absence of quoted market prices is based on: (i) valuation
methodologies; (ii) securities we deem to be comparable;
and (iii) assumptions deemed appropriate
S-37
given the circumstances. The fair value estimates are made at a
specific point in time, based on available market information
and judgments about financial instruments, including estimates
of the timing and amounts of expected future cash flows and the
credit standing of the issuer or counterparty. Factors
considered in estimating fair value include: coupon rate,
maturity, estimated duration, call provisions, sinking fund
requirements, credit rating, industry sector of the issuer, and
quoted market prices of comparable securities. The use of
different methodologies and assumptions may have a material
effect on the estimated fair value amounts. During periods of
market disruption including periods of significantly rising or
high interest rates, rapidly widening credit spreads or
illiquidity, it may be difficult to value certain of our
securities, for example
sub-prime
mortgage-backed securities, mortgage-backed securities where the
underlying loans are Alt-A and CMBS, if trading becomes less
frequent
and/or
market data becomes less observable. In times of financial
market disruption, certain asset classes that were in active
markets with significant observable data may become illiquid. In
such cases, more securities may fall to Level 3 and thus
require more subjectivity and management judgment. As such,
valuations may include inputs and assumptions that are less
observable or require greater estimation, as well as valuation
methods which are more sophisticated or require greater
estimation thereby resulting in estimated fair values which may
be greater or less than the amount at which the investments may
be ultimately sold. Further, rapidly changing and unprecedented
credit and equity market conditions could materially impact the
valuation of securities as reported within our consolidated
financial statements and the
period-to-period
changes in estimated fair value could vary significantly.
Decreases in value may have a material adverse effect on our
results of operations or financial condition.
If Our Business Does Not Perform Well, We May Be Required
to Recognize an Impairment of Our Goodwill or Other Long-Lived
Assets or to Establish a Valuation Allowance Against the
Deferred Income Tax Asset, Which Could Adversely Affect Our
Results of Operations or Financial Condition
Goodwill represents the excess of the amounts we paid to acquire
subsidiaries and other businesses over the estimated fair value
of their net assets at the date of acquisition. As of
December 31, 2010, our goodwill was $11,781 million,
of which $6,959 million of goodwill was established in
connection with the acquisition of ALICO. We test goodwill at
least annually for impairment. Impairment testing is performed
based upon estimates of the estimated fair value of the
reporting unit to which the goodwill relates. The
reporting unit is the operating segment or a business one level
below that operating segment if discrete financial information
is prepared and regularly reviewed by management at that level.
The estimated fair value of the reporting unit is impacted by
the performance of the business. The performance of our
businesses may be adversely impacted by prolonged market
declines. If it is determined that the goodwill has been
impaired, we must write down the goodwill by the amount of the
impairment, with a corresponding charge to net income. Such
writedowns could have an adverse effect on our results of
operation or financial position. For example, our goodwill has
increased substantially as a result of the Acquisition. Market
factors, the failure of ALICO to perform well, or issues
relating to the integration of ALICO could result in the
reporting units containing parts of ALICO having fair values
lower than their respective carrying values, which would result
in a writedown of goodwill and, consequently, it could have a
material adverse effect on our results of operations.
Long-lived assets, including assets such as real estate, also
require impairment testing to determine whether changes in
circumstances indicate that MetLife will be unable to recover
the carrying amount of the asset group through future operations
of that asset group or market conditions that will impact the
estimated fair value of those assets. Such writedowns could have
a material adverse effect on our results of operations or
financial position.
Deferred income tax represents the tax effect of the differences
between the book and tax basis of assets and liabilities.
Deferred tax assets are assessed periodically by management to
determine if they are realizable. Factors in managements
determination include the performance of the business including
the ability to generate future taxable income. If based on
available information, it is more likely than not that the
deferred income tax asset will not be realized then a valuation
allowance must be established with a corresponding charge to net
income. Such charges could have a material adverse effect on our
results of operations or financial position.
S-38
If Our Business Does Not Perform Well or if Actual
Experience Versus Estimates Used in Valuing and Amortizing DAC,
Deferred Sales Inducements (DSI) and VOBA Vary
Significantly, We May Be Required to Accelerate the Amortization
and/or Impair the DAC, DSI and VOBA Which Could Adversely Affect
Our Results of Operations or Financial Condition
We incur significant costs in connection with acquiring new and
renewal business. Those costs that vary with and are primarily
related to the production of new and renewal business are
deferred and referred to as DAC. Bonus amounts credited to
certain policyholders, either immediately upon receiving a
deposit or as excess interest credits for a period of time, are
referred to as DSI. The recovery of DAC and DSI is dependent
upon the future profitability of the related business. The
amount of future profit or margin is dependent principally on
investment returns in excess of the amounts credited to
policyholders, mortality, morbidity, persistency, interest
crediting rates, dividends paid to policyholders, expenses to
administer the business, creditworthiness of reinsurance
counterparties and certain economic variables, such as
inflation. Of these factors, we anticipate that investment
returns are most likely to impact the rate of amortization of
such costs. The aforementioned factors enter into
managements estimates of gross profits or margins, which
generally are used to amortize such costs.
If the estimates of gross profits or margins were overstated,
then the amortization of such costs would be accelerated in the
period the actual experience is known and would result in a
charge to income. Significant or sustained equity market
declines could result in an acceleration of amortization of the
DAC and DSI related to variable annuity and variable universal
life contracts, resulting in a charge to income. Such
adjustments could have a material adverse effect on our results
of operations or financial condition.
VOBA is an intangible asset that represents the excess of book
value over the estimated fair value of acquired insurance,
annuity, and investment-type contracts in-force at the
acquisition date. The estimated fair value of the acquired
liabilities is based on actuarially determined projections, by
each block of business, of future policy and contract charges,
premiums, mortality and morbidity, separate account performance,
surrenders, operating expenses, investment returns,
nonperformance risk adjustment and other factors. Actual
experience on the purchased business may vary from these
projections. Revisions to estimates result in changes to the
amounts expensed in the reporting period in which the revisions
are made and could result in a charge to income. Also, as VOBA
is amortized similarly to DAC and DSI, an acceleration of the
amortization of VOBA would occur if the estimates of gross
profits or margins were overstated. Accordingly, the
amortization of such costs would be accelerated in the period in
which the actual experience is known and would result in a
charge to net income. Significant or sustained equity market
declines could result in an acceleration of amortization of the
VOBA related to variable annuity and variable universal life
contracts, resulting in a charge to income. Such adjustments
could have a material adverse effect on our results of
operations or financial condition.
Changes in Accounting Standards Issued by the Financial
Accounting Standards Board or Other
Standard-Setting
Bodies May Adversely Affect Our Financial Statements
Our financial statements are subject to the application of GAAP
(as defined below), which is periodically revised
and/or
expanded. Accordingly, from time to time we are required to
adopt new or revised accounting standards issued by recognized
authoritative bodies, including the Financial Accounting
Standards Board. Market conditions have prompted accounting
standard setters to expose new guidance which further interprets
or seeks to revise accounting pronouncements related to
financial instruments, structures or transactions, as well as to
issue new standards expanding disclosures. The impact of
accounting pronouncements that have been issued but not yet
implemented is disclosed in the 2010
Form 10-K
and in our quarterly reports on
Form 10-Q.
An assessment of proposed standards is not provided as such
proposals are subject to change through the exposure process
and, therefore, the effects on our financial statements cannot
be meaningfully assessed. It is possible that future accounting
standards we are required to adopt could change the current
accounting treatment that we apply to our consolidated financial
statements and that such changes could have a material adverse
effect on our financial condition and results of operations.
S-39
Changes in Our Discount Rate, Expected Rate of Return and
Expected Compensation Increase Assumptions for Our Pension and
Other Postretirement Benefit Plans May Result in Increased
Expenses and Reduce Our Profitability
We determine our pension and other postretirement benefit plan
costs based on our best estimates of future plan experience.
These assumptions are reviewed regularly and include discount
rates, expected rates of return on plan assets and expected
increases in compensation levels and expected medical inflation.
Changes in these assumptions may result in increased expenses
and reduce our profitability.
Guarantees Within Certain of Our Products that Protect
Policyholders Against Significant Downturns in Equity Markets
May Decrease Our Earnings, Increase the Volatility of Our
Results if Hedging or Risk Management Strategies Prove
Ineffective, Result in Higher Hedging Costs and Expose Us to
Increased Counterparty Risk
Certain of our variable annuity products include guaranteed
benefits. These include guaranteed death benefits, guaranteed
withdrawal benefits, lifetime withdrawal guarantees, guaranteed
minimum accumulation benefits, and guaranteed minimum income
benefits. Periods of significant and sustained downturns in
equity markets, increased equity volatility, or reduced interest
rates could result in an increase in the valuation of the future
policy benefit or policyholder account balance liabilities
associated with such products, resulting in a reduction to net
income. We use reinsurance in combination with derivative
instruments to mitigate the liability exposure and the
volatility of net income associated with these liabilities, and
while we believe that these and other actions have mitigated the
risks related to these benefits, we remain liable for the
guaranteed benefits in the event that reinsurers or derivative
counterparties are unable or unwilling to pay. In addition, we
are subject to the risk that hedging and other management
procedures prove ineffective or that unanticipated policyholder
behavior or mortality, combined with adverse market events,
produces economic losses beyond the scope of the risk management
techniques employed. These, individually or collectively, may
have a material adverse effect on net income, financial
condition or liquidity. We are also subject to the risk that the
cost of hedging these guaranteed minimum benefits increases as
implied volatilities increase
and/or
interest rates decrease, resulting in a reduction to net income.
The valuation of certain of the foregoing liabilities (carried
at fair value) includes an adjustment for nonperformance risk
that reflects the credit standing of the issuing entity. This
adjustment, which is not hedged, is based in part on publicly
available information regarding credit spreads related to
MetLife, Inc.s debt, including credit default swaps. In
periods of extreme market volatility, movements in these credit
spreads can have a significant impact on net income.
Guarantees Within Certain of Our Life and Annuity Products
May Increase Our Exposure to Foreign Exchange Risk, and Decrease
Our Earnings
Certain of our life and annuity products are exposed to foreign
exchange risk. Payments under these contracts may be required to
be made in different currencies, depending on the circumstances.
Therefore, payments may be required in a different currency than
the currency upon which the liability valuation is based. If the
currency upon which expected future payments are made
strengthens relative to the currency upon which the liability
valuation is based, the liability valuation may increase,
resulting in a reduction of net income.
We May Need to Fund Deficiencies in Our Closed Block;
Assets Allocated to the Closed Block Benefit Only the Holders of
Closed Block Policies
MLICs plan of reorganization, as amended (the
Plan of Reorganization), required that we
establish and operate an accounting mechanism, known as a closed
block, to ensure that the reasonable dividend expectations of
policyholders who own certain individual insurance policies of
MLIC are met. We allocated assets to the closed block in an
amount that will produce cash flows which, together with
anticipated revenue from the policies included in the closed
block, are reasonably expected to be sufficient to support
obligations and liabilities relating to these policies,
including, but not limited to, provisions for the payment of
claims and certain expenses and tax, and to provide for the
continuation of the policyholder dividend scales in effect for
1999, if the experience underlying such scales continues, and
for appropriate adjustments in such scales if the experience
changes. We cannot provide assurance that the closed block
assets, the cash flows generated by the closed block assets and
the anticipated revenue from the policies included in the closed
block will be sufficient to provide for the benefits guaranteed
under
S-40
these policies. If they are not sufficient, we must fund the
shortfall. Even if they are sufficient, we may choose, for
competitive reasons, to support policyholder dividend payments
with our general account funds.
The closed block assets, the cash flows generated by the closed
block assets and the anticipated revenue from the policies in
the closed block will benefit only the holders of those
policies. In addition, to the extent that these amounts are
greater than the amounts estimated at the time the closed block
was funded, dividends payable in respect of the policies
included in the closed block may be greater than they would be
in the absence of a closed block. Any excess earnings will be
available for distribution over time only to closed block
policyholders.
Litigation and Regulatory Investigations Are Increasingly
Common in Our Businesses and May Result in Significant Financial
Losses and/or Harm to Our Reputation
We face a significant risk of litigation and regulatory
investigations and actions in the ordinary course of operating
our businesses, including the risk of class action lawsuits. Our
pending legal and regulatory actions include proceedings
specific to us and others generally applicable to business
practices in the industries in which we operate. In connection
with our insurance operations, plaintiffs lawyers may
bring or are bringing class actions and individual suits
alleging, among other things, issues relating to sales or
underwriting practices, claims payments and procedures, product
design, disclosure, administration, denial or delay of benefits
and breaches of fiduciary or other duties to customers.
Plaintiffs in class action and other lawsuits against us may
seek very large or indeterminate amounts, including punitive and
treble damages, and the damages claimed and the amount of any
probable and estimable liability, if any, may remain unknown for
substantial periods of time.
Due to the vagaries of litigation, the outcome of a litigation
matter and the amount or range of potential loss at particular
points in time may normally be difficult to ascertain.
Uncertainties can include how fact finders will evaluate
documentary evidence and the credibility and effectiveness of
witness testimony, and how trial and appellate courts will apply
the law in the context of the pleadings or evidence presented,
whether by motion practice, or at trial or on appeal.
Disposition valuations are also subject to the uncertainty of
how opposing parties and their counsel will themselves view the
relevant evidence and applicable law.
On a quarterly and annual basis, we review relevant information
with respect to litigation and contingencies to be reflected in
our consolidated financial statements. The review includes
senior legal and financial personnel. Estimates of possible
losses or ranges of loss for particular matters cannot in the
ordinary course be made with a reasonable degree of certainty.
Liabilities are established when it is probable that a loss has
been incurred and the amount of the loss can be reasonably
estimated.
Liabilities have been established for a number of matters. It is
possible that some of the matters could require us to pay
damages or make other expenditures or establish accruals in
amounts that could not be estimated at December 31, 2010.
MLIC and its affiliates are currently defendants in numerous
lawsuits including class actions and individual suits, alleging
improper marketing or sales of individual life insurance
policies, annuities, mutual funds or other products.
In addition, MLIC is a defendant in a large number of lawsuits
seeking compensatory and punitive damages for personal injuries
allegedly caused by exposure to asbestos or asbestos-containing
products. These lawsuits principally have focused on allegations
with respect to certain research, publication and other
activities of one or more of MLICs employees during the
period from the 1920s through approximately the
1950s and have alleged that MLIC learned or should have
learned of certain health risks posed by asbestos and, among
other things, improperly publicized or failed to disclose those
health risks. Additional litigation relating to these matters
may be commenced in the future. The ability of MLIC to estimate
its ultimate asbestos exposure is subject to considerable
uncertainty, and the conditions impacting its liability can be
dynamic and subject to change. The availability of reliable data
is limited and it is difficult to predict with any certainty the
numerous variables that can affect liability estimates,
including the number of future claims, the cost to resolve
claims, the disease mix and severity of disease in pending and
future claims, the impact of the number of new claims filed in a
particular jurisdiction and variations in the law in the
jurisdictions in which claims are filed, the possible impact of
tort reform efforts, the willingness of courts to allow
plaintiffs to pursue claims against MLIC when exposure took
place after the dangers of asbestos exposure were well known,
and the impact of any possible future adverse verdicts and their
amounts. The number of
S-41
asbestos cases that may be brought or the aggregate amount of
any liability that MLIC may incur, and the total amount paid in
settlements in any given year are uncertain and may vary
significantly from year to year. Accordingly, it is reasonably
possible that our total exposure to asbestos claims may be
materially greater than the liability recorded by us in our
consolidated financial statements and that future charges to
income may be necessary. The potential future charges could be
material in the particular quarterly or annual periods in which
they are recorded.
We are also subject to various regulatory inquiries, such as
information requests, subpoenas and books and record
examinations, from state and federal regulators and other
authorities. A substantial legal liability or a significant
regulatory action against us could have a material adverse
effect on our business, financial condition and results of
operations. Moreover, even if we ultimately prevail in the
litigation, regulatory action or investigation, we could suffer
significant reputational harm, which could have a material
adverse effect on our business, financial condition and results
of operations, including our ability to attract new customers,
retain our current customers and recruit and retain employees.
Regulatory inquiries and litigation may cause volatility in the
price of stocks of companies in our industry.
The New York Attorney General announced on July 29, 2010
that his office had launched a major fraud investigation into
the life insurance industry for practices related to the use of
retained asset accounts as a settlement option for death
benefits and that subpoenas requesting comprehensive data
related to retained asset accounts have been served on MetLife
and other insurance carriers. We received the subpoena on
July 30, 2010. We also have received requests for documents
and information from U.S. congressional committees and
members as well as various state regulatory bodies, including
the New York Insurance Department. It is possible that other
state and federal regulators or legislative bodies may pursue
similar investigations or make related inquiries. We cannot
predict what effect any such investigations might have on our
earnings or the availability of our retained asset account known
as the Total Control Account (TCA), but we
believe that our financial statements taken as a whole would not
be materially affected. We believe that any allegations that
information about the TCA is not adequately disclosed or that
the accounts are fraudulent or violate state or federal laws are
without merit.
We cannot give assurance that current claims, litigation,
unasserted claims probable of assertion, investigations and
other proceedings against us will not have a material adverse
effect on our business, financial condition or results of
operations. It is also possible that related or unrelated
claims, litigation, unasserted claims probable of assertion,
investigations and proceedings may be commenced in the future,
and we could become subject to further investigations and have
lawsuits filed or enforcement actions initiated against us. In
addition, increased regulatory scrutiny and any resulting
investigations or proceedings could result in new legal actions
and precedents and industry-wide regulations that could
adversely affect our business, financial condition and results
of operations.
We May Not be Able to Protect Our Intellectual Property
and May be Subject to Infringement Claims
We rely on a combination of contractual rights with third
parties and copyright, trademark, patent and trade secret laws
to establish and protect our intellectual property. Although we
endeavor to protect our rights, third parties may infringe or
misappropriate our intellectual property. We may have to
litigate to enforce and protect our copyrights, trademarks,
patents, trade secrets and know-how or to determine their scope,
validity or enforceability. This would represent a diversion of
resources that may be significant and our efforts may not prove
successful. The inability to secure or protect our intellectual
property assets could have a material adverse effect on our
business and our ability to compete.
We may be subject to claims by third parties for
(i) patent, trademark or copyright infringement,
(ii) breach of copyright, trademark or license usage
rights, or (iii) misappropriation of trade secrets. Any
such claims and any resulting litigation could result in
significant expense and liability for damages. If we were found
to have infringed or misappropriated a third-party patent or
other intellectual property right, we could in some
circumstances be enjoined from providing certain products or
services to our customers or from utilizing and benefiting from
certain methods, processes, copyrights, trademarks, trade
secrets or licenses. Alternatively, we could be required to
enter into costly licensing arrangements with third parties or
implement a costly work around. Any of these scenarios could
have a material adverse effect on our business and results of
operations.
S-42
New and Impending Compensation and Corporate Governance
Regulations Could Hinder or Prevent Us From Attracting and
Retaining Management and Other Employees with the Talent and
Experience to Manage and Conduct Our Business Effectively
The compensation and corporate governance practices of financial
institutions have become and will continue to be subject to
increasing regulation and scrutiny. Dodd-Frank includes new
requirements that will affect our corporate governance and
compensation practices, including some that have resulted in (or
are likely to lead to) shareholders having the limited right to
use MetLife, Inc.s proxy statement to solicit proxies to
vote for their own candidates for director, impose additional
requirements for membership on Board committees, requirements
for additional shareholder votes on compensation matters,
requirements for policies to recover compensation previously
paid to certain executives under certain circumstances,
elimination of broker discretionary voting on compensation
matters, requirements for additional performance and
compensation disclosure, and other requirements. See
Various Aspects of Dodd-Frank Could Impact
Our Business Operations, Capital Requirements and Profitability
and Limit Our Growth. In addition, the Federal Reserve
Board, the FDIC and other U.S. bank regulators have
released guidelines on incentive compensation that may apply to
or impact MetLife, Inc. as a bank holding company. These
requirements and restrictions, and others Congress or regulators
may propose or implement, could hinder or prevent us from
attracting and retaining management and other employees with the
talent and experience to manage and conduct our business
effectively.
Although AIG has received assurances from the Troubled Asset
Relief Program Special Master for Executive Compensation that
neither we nor ALICO will be subject to compensation related
requirements and restrictions under programs established in
whole or in part under EESA, there can be no assurance that the
Acquisition will not lead to greater public or governmental
scrutiny, regulation, or restrictions on our compensation
practices as a result of the Acquisition and expansion into new
markets outside the United States, whether in connection with
AIGs having received U.S. government funding or as a
result of other factors.
Legislative and Regulatory Activity in Health Care and
Other Employee Benefits Could Increase the Costs or
Administrative Burdens of Providing Benefits to Our Employees or
Hinder or Prevent Us From Attracting and Retaining Employees, or
Affect our Profitability As a Provider of Life Insurance,
Annuities, and Non-Medical Health Insurance Benefit
Products
The Patient Protection and Affordable Care Act, signed into law
on March 23, 2010, and The Health Care and Education
Reconciliation Act of 2010, signed into law on March 30,
2010 (together, the Health Care Act), may
lead to fundamental changes in the way that employers, including
us, provide health care benefits, other benefits, and other
forms of compensation to their employees and former employees.
Among other changes, and subject to various effective dates, the
Health Care Act generally restricts certain limits on benefits,
mandates coverage for certain kinds of care, extends the
required coverage of dependent children through age 26,
eliminates pre-existing condition exclusions or limitations,
requires cost reporting and, in some cases, requires premium
rebates to participants under certain circumstances, limits
coverage waiting periods, establishes several penalties on
employers who fail to offer sufficient coverage to their
full-time employees, and requires employers under certain
circumstances to provide employees with vouchers to purchase
their own health care coverage. The Health Care Act also
provides for increased taxation of high cost
coverage, restricts the tax deductibility of certain
compensation paid by health insurers, reduces the tax
deductibility of retiree health care costs to the extent of any
retiree prescription drug benefit subsidy provided to the
employer by the federal government, increases Medicare taxes on
certain high earners, and establishes health insurance
exchanges for individual purchases of health
insurance.
The impact of the Health Care Act on us as an employer and on
the benefit plans we sponsor for employees or retirees and their
dependents, whether those benefits remain competitive or
effective in meeting their business objectives, and our costs to
provide such benefits and our tax liabilities in connection with
benefits or compensation, cannot be predicted. Furthermore, we
cannot predict the impact of choices that will be made by
various regulators, including the United States Treasury, the
IRS, the United States Department of Health and Human Services,
and state regulators, to promulgate regulations or guidance, or
to make determinations under or related to the Health Care Act.
Either the Health Care Act or any of these regulatory actions
could adversely affect our ability to attract, retain, and
motivate talented associates. They could also result in
increased or unpredictable costs to provide
S-43
employee benefits, and could harm our competitive position if we
are subject to fees, penalties, tax provisions or other
limitations in the Health Care Act and our competitors are not.
The Health Care Act also imposes requirements on us as a
provider of non-medical health insurance benefit products,
subject to various effective dates. It also imposes requirements
on the purchasers of certain of these products and has
implications for certain other MLIC products, such as annuities.
We cannot predict the impact of the Act or of regulations,
guidance or determinations made by various regulators, on the
various products that we offer. Either the Health Care Act or
any of these regulatory actions could adversely affect our
ability to offer certain of these products in the same manner as
we do today. They could also result in increased or
unpredictable costs to provide certain products, and could harm
our competitive position if the Health Care Act has a disparate
impact on our products compared to products offered by our
competitors.
The Preservation of Access to Care for Medicare Beneficiaries
and Pension Relief Act of 2010 also includes certain provisions
for defined benefit pension plan funding relief. These
provisions may impact the likelihood
and/or
timing of corporate plan sponsors terminating their plans
and/or
engaging in transactions to partially or fully transfer pension
obligations to an insurance company. As part of our Corporate
Benefit Funding segment, we offer general account and separate
account group annuity products that enable a plan sponsor to
transfer these risks, often in connection with the termination
of defined benefit pension plans. Consequently, this legislation
could indirectly affect the mix of our business, with fewer
closeouts and more non-guaranteed funding products, and
adversely impact our results of operations.
Changes in U.S. Federal and State Securities Laws and
Regulations, and State Insurance Regulations Regarding
Suitability of Annuity Product Sales, May Affect Our Operations
and Our Profitability
Federal and state securities laws and regulations apply to
insurance products that are also securities,
including variable annuity contracts and variable life insurance
policies. As a result, some of MetLife, Inc.s subsidiaries
and their activities in offering and selling variable insurance
contracts and policies are subject to extensive regulation under
these securities laws. These subsidiaries issue variable annuity
contracts and variable life insurance policies through separate
accounts that are registered with the SEC as investment
companies under the Investment Company Act. Each registered
separate account is generally divided into
sub-accounts,
each of which invests in an underlying mutual fund which is
itself a registered investment company under the Investment
Company Act. In addition, the variable annuity contracts and
variable life insurance policies issued by the separate accounts
are registered with the SEC under the Securities Act. Other
subsidiaries are registered with the SEC as broker-dealers under
the Exchange Act, and are members of and subject to regulation
by FINRA. Further, some of our subsidiaries are registered as
investment advisers with the SEC under the Investment Advisers
Act of 1940, and are also registered as investment advisers in
various states, as applicable.
Federal and state securities laws and regulations are primarily
intended to ensure the integrity of the financial markets and to
protect investors in the securities markets, as well as protect
investment advisory or brokerage clients. These laws and
regulations generally grant regulatory agencies broad rulemaking
and enforcement powers, including the power to limit or restrict
the conduct of business for failure to comply with the
securities laws and regulations. A number of changes have
recently been suggested to the laws and regulations that govern
the conduct of our variable insurance products business and our
distributors that could have a material adverse effect on our
financial condition and results of operations. For example,
Dodd-Frank authorizes the SEC to establish a standard of conduct
applicable to brokers and dealers when providing personalized
investment advice to retail and other customers. This standard
of conduct would be to act in the best interest of the customer
without regard to the financial or other interest of the broker
or dealer providing the advice. Further, proposals have been
made that the SEC establish a self-regulatory organization with
respect to registered investment advisers, which could increase
the level of regulatory oversight over such investment advisers.
In addition, state insurance regulators are becoming more active
in adopting and enforcing suitability standards with respect to
sales of annuities, both fixed and variable. In particular, the
NAIC has adopted a revised Suitability in Annuity Transactions
Model Regulation (SAT), that will, if enacted
by the states, place new responsibilities upon issuing insurance
companies with respect to the suitability of annuity sales,
including responsibilities for training agents. Several states
have already enacted laws based on the SAT.
S-44
We also may be subject to similar laws and regulations in the
foreign countries in which we offer products or conduct other
activities similar to those described above.
Changes in Tax Laws, Tax Regulations, or Interpretations
of Such Laws or Regulations Could Increase Our Corporate Taxes;
Changes in Tax Laws Could Make Some of Our Products Less
Attractive to Consumers
Changes in tax laws, Treasury and other regulations promulgated
thereunder, or interpretations of such laws or regulations could
increase our corporate taxes. The Obama Administration has
proposed corporate tax changes. Changes in corporate tax rates
could affect the value of deferred tax assets and deferred tax
liabilities. Furthermore, the value of deferred tax assets could
be impacted by future earnings levels.
Changes in tax laws could make some of our products less
attractive to consumers. A shift away from life insurance and
annuity contracts and other tax-deferred products would reduce
our income from sales of these products, as well as the assets
upon which we earn investment income. The Obama Administration
has proposed certain changes to individual income tax rates and
rules applicable to certain policies.
We cannot predict whether any tax legislation impacting
corporate taxes or insurance products will be enacted, what the
specific terms of any such legislation will be or whether, if at
all, any legislation would have a material adverse effect on our
financial condition and results of operations.
Changes to Regulations Under the Employee Retirement
Income Security Act of 1974 Could Adversely Affect Our
Distribution Model by Restricting Our Ability to Provide
Customers With Advice
The prohibited transaction rules of the U.S. Employment
Retirement Income Security Act of 1974, as amended
(ERISA) and the Internal Revenue Code
generally restrict the provision of investment advice to ERISA
plans and participants and Individual Retirement Accounts
(IRAs) if the investment recommendation
results in fees paid to the individual advisor, his or her firm
or their affiliates that vary according to the investment
recommendation chosen. In March 2010, the United States
Department of Labor (the DOL) issued proposed
regulations which provide limited relief from these investment
advice restrictions. If the proposed rules are issued in final
form and no additional relief is provided regarding these
investment advice restrictions, the ability of our affiliated
broker-dealers and their registered representatives to provide
investment advice to ERISA plans and participants, and with
respect to IRAs, would likely be significantly restricted. Also,
the fee and revenue arrangements of certain advisory programs
may be required to be revenue neutral, resulting in potential
lost revenues for these broker-dealers and their affiliates.
Other proposed regulatory initiatives under ERISA also may
negatively impact the current business model of our
broker-dealers. In particular, the DOL issued a proposed
regulation in October 2010 that would, if adopted as proposed,
significantly broaden the circumstances under which a person or
entity providing investment advice with respect to ERISA plans
or IRAs would be deemed a fiduciary under ERISA or the Internal
Revenue Code. If adopted, the proposed regulations may make it
easier for the DOL in enforcement actions, and for
plaintiffs attorneys in ERISA litigation, to attempt to
extend fiduciary status to advisors who would not be deemed
fiduciaries under current regulations.
In addition, the DOL has issued a number of regulations recently
that increase the level of disclosure that must be provided to
plan sponsors and participants, and may issue additional such
regulations in 2011. These ERISA disclosure requirements will
likely increase the regulatory and compliance burden upon
MetLife, resulting in increased costs.
We May Be Unable to Attract and Retain Sales
Representatives for Our Products
We must attract and retain productive sales representatives to
sell our insurance, annuities and investment products. Strong
competition exists among insurers for sales representatives with
demonstrated ability. In addition, there is competition for
representatives with other types of financial services firms,
such as independent broker-dealers.
We compete with other insurers for sales representatives
primarily on the basis of our financial position, support
services and compensation and product features. We continue to
undertake several initiatives to grow our career agency force
while continuing to enhance the efficiency and production of our
existing sales force. We cannot
S-45
provide assurance that these initiatives will succeed in
attracting and retaining new agents. Sales of individual
insurance, annuities and investment products and our results of
operations and financial condition could be materially adversely
affected if we are unsuccessful in attracting and retaining
agents.
MetLife, Inc.s Board of Directors May Control the
Outcome of Stockholder Votes on Many Matters Due to the Voting
Provisions of the MetLife Policyholder Trust
Under the Plan of Reorganization, we established the MetLife
Policyholder Trust (the Trust) to hold the
shares of MetLife, Inc. common stock allocated to eligible
policyholders not receiving cash or policy credits under the
Plan of Reorganization. As of February 18, 2011, the Trust
held 220,255,199 shares, or 22.3%, of the outstanding
shares of MetLife, Inc. common stock. Because of the number of
shares held in the Trust and the voting provisions of the Trust,
the Trust may affect the outcome of matters brought to a
stockholder vote.
Except on votes regarding certain fundamental corporate actions
described below, the trustee will vote all of the shares of
common stock held in the Trust in accordance with the
recommendations given by MetLife, Inc.s Board of Directors
to its stockholders or, if the Board gives no such
recommendations, as directed by the Board. As a result of the
voting provisions of the Trust, the Board of Directors may be
able to control votes on matters submitted to a vote of
stockholders, excluding those fundamental corporate actions, so
long as the Trust holds a substantial number of shares of common
stock.
If the vote relates to fundamental corporate actions specified
in the Trust, the trustee will solicit instructions from the
Trust beneficiaries and vote all shares held in the Trust in
proportion to the instructions it receives. These actions
include:
|
|
|
|
|
an election or removal of directors in which a stockholder has
properly nominated one or more candidates in opposition to a
nominee or nominees of MetLife, Inc.s Board of Directors
or a vote on a stockholders proposal to oppose a Board
nominee for director, remove a director for cause or fill a
vacancy caused by the removal of a director by stockholders,
subject to certain conditions;
|
|
|
|
a merger or consolidation, a sale, lease or exchange of all or
substantially all of the assets, or a recapitalization or
dissolution, of MetLife, Inc., in each case requiring a vote of
stockholders under applicable Delaware law;
|
|
|
|
any transaction that would result in an exchange or conversion
of shares of common stock held by the Trust for cash, securities
or other property; and
|
|
|
|
any proposal requiring MetLife, Inc.s Board of Directors
to amend or redeem the rights under MetLife, Inc.s
stockholder rights plan, other than a proposal with respect to
which we have received advice of nationally-recognized legal
counsel to the effect that the proposal is not a proper subject
for stockholder action under Delaware law. MetLife, Inc. does
not currently have a stockholder rights plan.
|
If a vote concerns any of these fundamental corporate actions,
the trustee will vote all of the shares of common stock held by
the Trust in proportion to the instructions it received, which
will give disproportionate weight to the instructions actually
given by Trust beneficiaries.
The Selling Stockholder has agreed to vote all shares of
MetLife, Inc. common stock acquired by it in connection with the
Acquisition in proportion to the votes cast by all other
stockholders of MetLife, Inc., including the Trust.
State Laws, Federal Laws, Our Certificate of Incorporation
and Our By-Laws May Delay, Deter or Prevent Takeovers and
Business Combinations that Stockholders Might Consider in Their
Best Interests
State laws and our certificate of incorporation and by-laws may
delay, deter or prevent a takeover attempt that stockholders
might consider in their best interests. For instance, they may
prevent stockholders from receiving the benefit from any premium
over the market price of MetLife, Inc.s common stock
offered by a bidder in a takeover context. Even in the absence
of a takeover attempt, the existence of these provisions may
adversely affect the prevailing market price of MetLife,
Inc.s common stock if they are viewed as discouraging
takeover attempts in the future.
S-46
Any person seeking to acquire a controlling interest in us would
face various regulatory obstacles which may delay, deter or
prevent a takeover attempt that stockholders of MetLife, Inc.
might consider in their best interests. First, the insurance
laws and regulations of the various states in which MetLife,
Inc.s insurance subsidiaries are organized may delay or
impede a business combination involving us. State insurance laws
prohibit an entity from acquiring control of an insurance
company without the prior approval of the domestic insurance
regulator. Under most states statutes, an entity is
presumed to have control of an insurance company if it owns,
directly or indirectly, 10% or more of the voting stock of that
insurance company or its parent company. We are also subject to
banking regulations, and may in the future become subject to
additional regulations. Dodd-Frank contains provisions that
could restrict or impede consolidation, mergers and acquisitions
by systemically significant firms
and/or large
bank holding companies. In addition, the Investment Company Act
would require approval by the contract owners of our variable
contracts in order to effectuate a change of control of any
affiliated investment adviser to a mutual fund underlying our
variable contracts. Finally, FINRA approval would be necessary
for a change of control of any FINRA registered broker-dealer
that is a direct or indirect subsidiary of MetLife, Inc.
In addition, Section 203 of the Delaware General
Corporation Law may affect the ability of an interested
stockholder to engage in certain business combinations,
including mergers, consolidations or acquisitions of additional
shares, for a period of three years following the time that the
stockholder becomes an interested stockholder. An
interested stockholder is defined to include persons
owning, directly or indirectly, 15% or more of the outstanding
voting stock of a corporation.
MetLife, Inc.s certificate of incorporation and by-laws
also contain provisions that may delay, deter or prevent a
takeover attempt that stockholders might consider in their best
interests. These provisions may adversely affect prevailing
market prices for MetLife, Inc.s common stock and include:
classification of MetLife, Inc.s Board of Directors into
three classes; a prohibition on the calling of special meetings
by stockholders; advance notice procedures for the nomination of
candidates to the Board of Directors and stockholder proposals
to be considered at stockholder meetings; and supermajority
voting requirements for the amendment of certain provisions of
the certificate of incorporation and by-laws.
The Continued Threat of Terrorism and Ongoing Military
Actions May Adversely Affect the Level of Claim Losses We Incur
and the Value of Our Investment Portfolio
The continued threat of terrorism, both within the United States
and abroad, ongoing military and other actions and heightened
security measures in response to these types of threats may
cause significant volatility in global financial markets and
result in loss of life, property damage, additional disruptions
to commerce and reduced economic activity. Some of the assets in
our investment portfolio may be adversely affected by declines
in the credit and equity markets and reduced economic activity
caused by the continued threat of terrorism. We cannot predict
whether, and the extent to which, companies in which we maintain
investments may suffer losses as a result of financial,
commercial or economic disruptions, or how any such disruptions
might affect the ability of those companies to pay interest or
principal on their securities or mortgage loans. The continued
threat of terrorism also could result in increased reinsurance
prices and reduced insurance coverage and potentially cause us
to retain more risk than we otherwise would retain if we were
able to obtain reinsurance at lower prices. Terrorist actions
also could disrupt our operations centers in the United States
or abroad. In addition, the occurrence of terrorist actions
could result in higher claims under our insurance policies than
anticipated. See Difficult Conditions
in the Global Capital Markets and the Economy Generally May
Materially Adversely Affect Our Business and Results of
Operations and These Conditions May Not Improve in the Near
Future.
The Occurrence of Events Unanticipated in Our Disaster
Recovery Systems and Management Continuity Planning Could Impair
Our Ability to Conduct Business Effectively
In the event of a disaster such as a natural catastrophe, an
epidemic, an industrial accident, a blackout, a computer virus,
a terrorist attack or war, unanticipated problems with our
disaster recovery systems could have a material adverse impact
on our ability to conduct business and on our results of
operations and financial position, particularly if those
problems affect our computer-based data processing,
transmission, storage and retrieval systems and destroy valuable
data. We depend heavily upon computer systems to provide
reliable service. Despite our implementation of a variety of
security measures, our computer systems could be subject to
physical and electronic break-ins, and similar disruptions from
unauthorized tampering. In addition, in the event that a
significant
S-47
number of our managers were unavailable in the event of a
disaster, our ability to effectively conduct business could be
severely compromised. These interruptions also may interfere
with our suppliers ability to provide goods and services
and our employees ability to perform their job
responsibilities.
Our Associates May Take Excessive Risks Which Could
Negatively Affect Our Financial Condition and Business
As an insurance enterprise, we are in the business of being paid
to accept certain risks. The associates who conduct our
business, including executive officers and other members of
management, sales managers, investment professionals, product
managers, sales agents, and other associates, do so in part by
making decisions and choices that involve exposing us to risk.
These include decisions such as setting underwriting guidelines
and standards, product design and pricing, determining what
assets to purchase for investment and when to sell them, which
business opportunities to pursue, and other decisions. Although
we endeavor, in the design and implementation of our
compensation programs and practices, to avoid giving our
associates incentives to take excessive risks, associates may
take such risks regardless of the structure of our compensation
programs and practices. Similarly, although we employ controls
and procedures designed to monitor associates business
decisions and prevent us from taking excessive risks, there can
be no assurance that these controls and procedures are or may be
effective. If our associates take excessive risks, the impact of
those risks could have a material adverse effect on our
financial condition or business operations.
Risks
Relating to the Offering of the Common Stock
MetLife, Inc.s Share Price Will Fluctuate
Although there has been some recent stabilization, stock markets
in general, and stock prices of financial services companies in
particular, including MetLife, Inc., have experienced
significant price and volume volatility since 2008. The market
price and volume of MetLife, Inc.s common stock may
continue to be subject to significant fluctuations due not only
to general stock market conditions but also to a change in
sentiment in the market regarding our operations, business
prospects, future funding, including in relation to the
Acquisition, or this offering. In addition to the risk factors
discussed above, the price and volume volatility of MetLife,
Inc.s common stock may be affected by:
|
|
|
|
|
the success or failure of our operating strategies and our
perceived prospects;
|
|
|
|
actual or anticipated fluctuations in our financial condition or
operating results;
|
|
|
|
variances in our operating results, for the first quarter of
2011 or for other periods, from the expectations of securities
analysts and investors;
|
|
|
|
the operating performance and securities price performance of
companies that investors consider to be comparable to
us; and
|
|
|
|
announcement of strategic developments, acquisitions and other
material events by us or our competitors.
|
There May Be Future Sales or Other Dilution of MetLife,
Inc.s Equity, Which May Adversely Affect the Market Price
of Its Common Stock
Except as may be required by the underwriters for this offering
of common stock, MetLife, Inc. is not restricted from issuing
additional common stock or preferred stock, including any
securities that are convertible into or exchangeable for, or
that represent the right to receive, common stock (including the
Series B Preferred Stock, to the extent not Repurchased and
cancelled, and the stock purchase contracts forming part of the
common equity units). The market price of MetLife, Inc.s
common stock could decline as a result of sales of a large
number of shares of its common stock or preferred stock or
similar securities in the market after this offering, or the
perception that such sales could occur. The issuance of
additional common stock will dilute the ownership interest of
existing common stockholders. See The
Issuance of Common Stock Pursuant to the Stock Purchase
Contracts Forming Part of the Common Equity Units Being Offered
By the Selling Stockholder in the Concurrent Offering and the
Issuance of the Common Stock Pursuant to the Conversion of the
Series B Preferred Stock, to the Extent that the Any of the
Shares of the Series B Preferred Stock are Not Repurchased
and Cancelled by MetLife, Inc., Will Have a Dilutive Impact on
MetLife, Inc.s Stockholders.
S-48
The Common Stock, Which is Subordinate to MetLife,
Inc.s Existing and Future Indebtedness and Preferred
Stock, Will Pay Dividends Only if and When Declared by MetLife,
Inc.s Board of Directors
Shares of the common stock are equity interests in MetLife, Inc.
and do not constitute indebtedness. As such, shares of the
common stock will rank junior to all indebtedness and other
non-equity claims on MetLife, Inc. with respect to assets
available to satisfy claims on MetLife, Inc., including in a
liquidation of MetLife, Inc. Additionally, holders of MetLife,
Inc.s common stock are subject to the prior dividend and
liquidation rights of any holders of MetLife, Inc.s
preferred stock then outstanding.
Dividends on the common stock are payable only if declared by
MetLife, Inc.s board of directors and are subject to
restrictions on payment of dividends out of lawfully available
funds. As a holding company for its insurance and financial
subsidiaries, the payment of dividends and other distributions
to MetLife, Inc. by its insurance subsidiaries is regulated by
insurance laws and regulations. See As
a Holding Company, MetLife, Inc. Depends on the Ability of Its
Subsidiaries to Transfer Funds to It to Meet Its Obligations and
Pay Dividends. Also, as a bank holding company regulated
by the Federal Reserve Board, MetLife, Inc. is subject to its
authority to restrict the payment of dividends to stockholders.
MetLife, Inc. has issued and outstanding indebtedness and
preferred stock under which it may defer interest or dividend
payments from time to time (although MetLife, Inc. has no
present intention to, and believes the likelihood is remote that
it will elect or be required to defer interest payments on these
instruments), but in that case, MetLife, Inc. would not be
permitted to declare or pay dividends on, make any distribution
with respect to, or redeem, purchase, acquire or make a
liquidation payment with respect to, any shares of its common
stock, during the deferral period.
The Issuance of Common Stock Pursuant to the Stock
Purchase Contracts Forming Part of the Common Equity Units Being
Offered By the Selling Stockholder in the Concurrent Offering
and the Issuance of the Common Stock Pursuant to the Conversion
of the Series B Preferred Stock, to the Extent that the Any
of the Shares of the Series B Preferred Stock are Not
Repurchased and Cancelled by MetLife, Inc., Will Have a Dilutive
Impact on MetLife, Inc.s Stockholders
The common equity units consist of (x) stock purchase
contracts obligating the holder to purchase a variable number of
shares of MetLife, Inc.s common stock on each of three
specified future settlement dates (approximately two, three and
four years after the closing of the Acquisition, subject to
deferral under certain circumstances) for a fixed amount per
stock purchase contract (an aggregate of $1.0 billion on
each settlement date) and (y) an interest in each of three
series of debt securities of MetLife, Inc. The aggregate amount
of MetLife, Inc.s common stock expected to be issued upon
settlement of the stock purchase contracts is expected to be
approximately 67,764,000 to 84,696,000 shares.
In addition, to the extent that MetLife, Inc. does not
Repurchase and cancel all of the shares of the Series B
Preferred Stock pursuant to the Coordination Agreement, MetLife,
Inc. will issue 10 shares of common stock for every share
of the 6,857,000 shares of the Series B Preferred
Stock that is not so Repurchased and cancelled.
As a result of the issuance of these securities, more shares of
common stock will be outstanding and each existing stockholder
will own a smaller percentage of our common stock then
outstanding.
Following This Offering and the Concurrent Offering, to
the Extent the Selling Stockholder Will Hold Any of MetLife,
Inc.s Equity Securities, the Selling Stockholder Will Be
Able to Sell Such Securities at Any Time From and After the Date
365 Days After the Closing of the Acquisition, Which Could Cause
MetLife, Inc.s Stock Price to Decrease
The Selling Stockholder agreed in the Investor Rights Agreement
entered into in connection with the Acquisition, not to transfer
any of MetLife, Inc.s securities received pursuant to the
terms of the Stock Purchase Agreement, at any time up to the
date 365 days after the closing of the Acquisition, without
the consent of MetLife, Inc. However, from and after such date,
the Selling Stockholder will be able to transfer up to half of
such equity securities, and from and after the first anniversary
of the closing of the Acquisition, the Selling Stockholder will
be able to transfer all of such securities, subject in each case
to certain limited volume and timing restrictions set forth in
the Investor Rights Agreement. Moreover, the Selling Stockholder
will agree to use commercially reasonable efforts to transfer,
and it will cause its affiliates to so transfer, all of MetLife,
Inc.s securities received in connection with the
Acquisition prior to the later of (i) the fifth anniversary
of the closing of the Acquisition, and (ii) the first
S-49
anniversary of the third stock purchase date under the stock
purchase contracts. Subject to certain conditions, we have
agreed to register the resale of MetLife, Inc.s equity and
other securities to be issued to the Selling Stockholder under
the Securities Act.
In connection with this offering of common stock, the concurrent
offering and the Repurchase of the Series B Preferred
Stock, MetLife, Inc. has entered into a limited waiver of the
Investor Rights Agreement with the Selling Stockholder and AIG
in order to permit the Selling Stockholder to offer and sell the
common stock and common equity units it received in the
Acquisition in this offering and the concurrent offering,
respectively, and to sell the Series B Preferred Stock to
MetLife, Inc. pursuant to the Coordination Agreement.
The sale or transfer of a substantial number of these securities
within a short period of time could cause MetLife, Inc.s
stock price to decrease, make it more difficult for us to raise
funds through future offerings of MetLife, Inc.s common
stock or acquire other businesses using MetLife, Inc.s
common stock as consideration.
S-50
SELECTED
HISTORICAL CONSOLIDATED FINANCIAL INFORMATION FOR
METLIFE
The following selected financial data has been derived from
MetLifes audited consolidated financial statements. The
statement of operations data for the years ended
December 31, 2010, 2009 and 2008, and the balance sheet
data at December 31, 2010 and 2009 have been derived from
MetLifes audited financial statements included in the 2010
Form 10-K.
The statement of operations data for the years ended
December 31, 2007 and 2006, and the balance sheet data at
December 31, 2008, 2007 and 2006 have been derived from
MetLifes audited financial statements not included herein.
This selected consolidated financial data should be read in
conjunction with and is qualified by reference to these
consolidated financial statements and the related notes and the
2010
Form 10-K.
The following consolidated statements of operations and
consolidated balance sheet data have been prepared in conformity
with accounting principles generally accepted in the United
States of America (GAAP).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In millions)
|
|
|
Statement of Operations Data (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums
|
|
$
|
27,394
|
|
|
$
|
26,460
|
|
|
$
|
25,914
|
|
|
$
|
22,970
|
|
|
$
|
22,052
|
|
Universal life and investment-type product policy fees
|
|
|
6,037
|
|
|
|
5,203
|
|
|
|
5,381
|
|
|
|
5,238
|
|
|
|
4,711
|
|
Net investment income
|
|
|
17,615
|
|
|
|
14,837
|
|
|
|
16,289
|
|
|
|
18,055
|
|
|
|
16,239
|
|
Other revenues
|
|
|
2,328
|
|
|
|
2,329
|
|
|
|
1,586
|
|
|
|
1,465
|
|
|
|
1,301
|
|
Net investment gains (losses)
|
|
|
(392
|
)
|
|
|
(2,906
|
)
|
|
|
(2,098
|
)
|
|
|
(318
|
)
|
|
|
(1,174
|
)
|
Net derivative gains (losses)
|
|
|
(265
|
)
|
|
|
(4,866
|
)
|
|
|
3,910
|
|
|
|
(260
|
)
|
|
|
(208
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
52,717
|
|
|
|
41,057
|
|
|
|
50,982
|
|
|
|
47,150
|
|
|
|
42,921
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Policyholder benefits and claims
|
|
|
29,545
|
|
|
|
28,336
|
|
|
|
27,437
|
|
|
|
23,783
|
|
|
|
22,869
|
|
Interest credited to policyholder account balances
|
|
|
4,925
|
|
|
|
4,849
|
|
|
|
4,788
|
|
|
|
5,461
|
|
|
|
4,899
|
|
Policyholder dividends
|
|
|
1,486
|
|
|
|
1,650
|
|
|
|
1,751
|
|
|
|
1,723
|
|
|
|
1,698
|
|
Other expenses
|
|
|
12,803
|
|
|
|
10,556
|
|
|
|
11,947
|
|
|
|
10,405
|
|
|
|
9,514
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
48,759
|
|
|
|
45,391
|
|
|
|
45,923
|
|
|
|
41,372
|
|
|
|
38,980
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations before provision for
income tax
|
|
|
3,958
|
|
|
|
(4,334
|
)
|
|
|
5,059
|
|
|
|
5,778
|
|
|
|
3,941
|
|
Provision for income tax expense (benefit)
|
|
|
1,181
|
|
|
|
(2,015
|
)
|
|
|
1,580
|
|
|
|
1,675
|
|
|
|
1,027
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations, net of income tax
|
|
|
2,777
|
|
|
|
(2,319
|
)
|
|
|
3,479
|
|
|
|
4,103
|
|
|
|
2,914
|
|
Income (loss) from discontinued operations, net of income tax
|
|
|
9
|
|
|
|
41
|
|
|
|
(201
|
)
|
|
|
362
|
|
|
|
3,526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
2,786
|
|
|
|
(2,278
|
)
|
|
|
3,278
|
|
|
|
4,465
|
|
|
|
6,440
|
|
Less: Net income (loss) attributable to noncontrolling interests
|
|
|
(4
|
)
|
|
|
(32
|
)
|
|
|
69
|
|
|
|
148
|
|
|
|
147
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to MetLife, Inc.
|
|
|
2,790
|
|
|
|
(2,246
|
)
|
|
|
3,209
|
|
|
|
4,317
|
|
|
|
6,293
|
|
Less: Preferred stock dividends
|
|
|
122
|
|
|
|
122
|
|
|
|
125
|
|
|
|
137
|
|
|
|
134
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) available to MetLife, Inc.s common
shareholders
|
|
$
|
2,668
|
|
|
$
|
(2,368
|
)
|
|
$
|
3,084
|
|
|
$
|
4,180
|
|
|
$
|
6,159
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-51
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In millions)
|
|
|
Balance Sheet Data (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General account assets (2)
|
|
$
|
547,569
|
|
|
$
|
390,273
|
|
|
$
|
380,839
|
|
|
$
|
399,007
|
|
|
$
|
383,758
|
|
Separate account assets
|
|
|
183,337
|
|
|
|
149,041
|
|
|
|
120,839
|
|
|
|
160,142
|
|
|
|
144,349
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
730,906
|
|
|
$
|
539,314
|
|
|
$
|
501,678
|
|
|
$
|
559,149
|
|
|
$
|
528,107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Policyholder liabilities and other policy-related balances (3)
|
|
$
|
401,905
|
|
|
$
|
283,759
|
|
|
$
|
282,261
|
|
|
$
|
261,442
|
|
|
$
|
252,099
|
|
Payables for collateral under securities loaned and other
transactions
|
|
|
27,272
|
|
|
|
24,196
|
|
|
|
31,059
|
|
|
|
44,136
|
|
|
|
45,846
|
|
Bank deposits
|
|
|
10,316
|
|
|
|
10,211
|
|
|
|
6,884
|
|
|
|
4,534
|
|
|
|
4,638
|
|
Short-term debt
|
|
|
306
|
|
|
|
912
|
|
|
|
2,659
|
|
|
|
667
|
|
|
|
1,449
|
|
Long-term debt (2)
|
|
|
27,586
|
|
|
|
13,220
|
|
|
|
9,667
|
|
|
|
9,100
|
|
|
|
8,822
|
|
Collateral financing arrangements
|
|
|
5,297
|
|
|
|
5,297
|
|
|
|
5,192
|
|
|
|
4,882
|
|
|
|
|
|
Junior subordinated debt securities
|
|
|
3,191
|
|
|
|
3,191
|
|
|
|
3,758
|
|
|
|
4,075
|
|
|
|
3,381
|
|
Other (2)
|
|
|
22,583
|
|
|
|
15,989
|
|
|
|
15,374
|
|
|
|
33,186
|
|
|
|
32,277
|
|
Separate account liabilities
|
|
|
183,337
|
|
|
|
149,041
|
|
|
|
120,839
|
|
|
|
160,142
|
|
|
|
144,349
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
681,793
|
|
|
|
505,816
|
|
|
|
477,693
|
|
|
|
522,164
|
|
|
|
492,861
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redeemable noncontrolling interests in partially owned
consolidated securities
|
|
|
117
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MetLife, Inc.s stockholders equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, at par value
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
Convertible preferred stock, at par value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, at par value
|
|
|
10
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
Additional paid-in capital
|
|
|
26,423
|
|
|
|
16,859
|
|
|
|
15,811
|
|
|
|
17,098
|
|
|
|
17,454
|
|
Retained earnings
|
|
|
21,363
|
|
|
|
19,501
|
|
|
|
22,403
|
|
|
|
19,884
|
|
|
|
16,574
|
|
Treasury stock, at cost
|
|
|
(172
|
)
|
|
|
(190
|
)
|
|
|
(236
|
)
|
|
|
(2,890
|
)
|
|
|
(1,357
|
)
|
Accumulated other comprehensive income (loss)
|
|
|
1,000
|
|
|
|
(3,058
|
)
|
|
|
(14,253
|
)
|
|
|
1,078
|
|
|
|
1,118
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total MetLife, Inc.s stockholders equity
|
|
|
48,625
|
|
|
|
33,121
|
|
|
|
23,734
|
|
|
|
35,179
|
|
|
|
33,798
|
|
Noncontrolling interests
|
|
|
371
|
|
|
|
377
|
|
|
|
251
|
|
|
|
1,806
|
|
|
|
1,448
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
48,996
|
|
|
|
33,498
|
|
|
|
23,985
|
|
|
|
36,985
|
|
|
|
35,246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and equity
|
|
$
|
730,906
|
|
|
$
|
539,314
|
|
|
$
|
501,678
|
|
|
$
|
559,149
|
|
|
$
|
528,107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
2010
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
|
(In millions, except per share data)
|
|
Other Data (1), (4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) available to MetLife, Inc.s common
shareholders
|
|
$
|
2,668
|
|
|
$
|
(2,368)
|
|
|
$
|
3,084
|
|
|
$
|
4,180
|
|
|
$
|
6,159
|
|
Return on MetLife, Inc.s common equity
|
|
|
6.9
|
%
|
|
|
(9.0)
|
%
|
|
|
11.2
|
%
|
|
|
12.9
|
%
|
|
|
20.9
|
%
|
Return on MetLife, Inc.s common equity, excluding
accumulated other comprehensive income (loss)
|
|
|
7.0
|
%
|
|
|
(6.8)
|
%
|
|
|
9.1
|
%
|
|
|
13.3
|
%
|
|
|
22.1
|
%
|
EPS Data (1), (5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (Loss) from Continuing Operations Available to MetLife,
Inc.s Common Shareholders Per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
3.01
|
|
|
$
|
(2.94)
|
|
|
$
|
4.60
|
|
|
$
|
5.32
|
|
|
$
|
3.64
|
|
Diluted
|
|
$
|
2.99
|
|
|
$
|
(2.94)
|
|
|
$
|
4.54
|
|
|
$
|
5.19
|
|
|
$
|
3.59
|
|
Income (Loss) from Discontinued Operations Per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.01
|
|
|
$
|
0.05
|
|
|
$
|
(0.41)
|
|
|
$
|
0.30
|
|
|
$
|
4.45
|
|
Diluted
|
|
$
|
0.01
|
|
|
$
|
0.05
|
|
|
$
|
(0.40)
|
|
|
$
|
0.29
|
|
|
$
|
4.40
|
|
Net Income (Loss) Available to MetLife, Inc.s Common
Shareholders Per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
3.02
|
|
|
$
|
(2.89)
|
|
|
$
|
4.19
|
|
|
$
|
5.62
|
|
|
$
|
8.09
|
|
Diluted
|
|
$
|
3.00
|
|
|
$
|
(2.89)
|
|
|
$
|
4.14
|
|
|
$
|
5.48
|
|
|
$
|
7.99
|
|
Cash Dividends Declared Per Common Share
|
|
$
|
0.74
|
|
|
$
|
0.74
|
|
|
$
|
0.74
|
|
|
$
|
0.74
|
|
|
$
|
0.59
|
|
|
|
|
(1) |
|
On November 1, 2010, MetLife, Inc. acquired ALICO. The
results of the Acquisition are reflected in the 2010 selected
financial data. |
|
(2) |
|
At December 31, 2010, general account assets, long-term
debt and other liabilities include amounts relating to variable
interest entities of $11,080 million, $6,902 million
and $93 million, respectively. |
|
(3) |
|
Policyholder liabilities and other policy-related balances
include future policy benefits, policyholder account balances,
other policy-related balances, policyholder dividends payable
and the policyholder dividend obligation. |
|
(4) |
|
Return on MetLife, Inc.s common equity is defined as net
income (loss) available to MetLife, Inc.s common
shareholders divided by MetLife, Inc.s average common
stockholders equity. |
|
(5) |
|
For the year ended December 31, 2009, shares related to the
assumed exercise or issuance of stock-based awards have been
excluded from the calculation of diluted earnings per common
share as these assumed shares are anti-dilutive. |
S-53
UNAUDITED
PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
On November 1, 2010, MetLife, Inc. acquired all of the
outstanding shares of capital stock of ALICO, pursuant to the
Stock Purchase Agreement, for a total purchase price of
approximately $16.4 billion, subject to adjustment, which
included cash of $7.2 billion and securities of MetLife,
Inc. valued at $9.2 billion.
The unaudited pro forma condensed combined statement of
operations and accompanying notes present the impact of the
Acquisition on MetLife, Inc.s results of operations under
the acquisition method of accounting. The unaudited pro forma
condensed combined statement of operations for the year ended
December 31, 2010 combines the historical consolidated
statement of operations of MetLife, Inc. for the year ended
December 31, 2010 (which includes ALICOs operations
for the month of November 2010) with the historical
combined statement of income of ALICO for the eleven months
ended October 31, 2010, giving effect to the Acquisition as
if it had been completed on January 1, 2010. The historical
financial information has been adjusted in the unaudited pro
forma condensed combined statement of operations to give effect
to pro forma events that are directly attributable to the
Acquisition and factually supportable, and are expected to have
a continuing impact on the combined results.
The unaudited pro forma condensed combined statement of
operations should be read in conjunction with the accompanying
notes and in conjunction with the audited historical
consolidated financial statements of MetLife, Inc. as of and for
the year ended December 31, 2010 and the related notes,
included in the 2010 Form 10-K.
The unaudited pro forma condensed combined statement of
operations is not intended to reflect the results of operations
that would have resulted had the Acquisition been effective
during the period presented or the results that may be obtained
by the combined company in the future. The unaudited pro forma
condensed combined statement of operations for the period
presented does not reflect future events that may occur after
the Acquisition, including, but not limited to, expense
efficiencies or revenue enhancements arising from the
Acquisition. It also does not give effect to certain one-time
charges that MetLife, Inc. expects to incur such as
restructuring and integration costs. Future results may vary
significantly from the results reflected in the unaudited pro
forma condensed combined statement of operations.
S-54
MetLife,
Inc.
Unaudited Pro Forma Condensed Combined
Statement of Operations For the Year Ended December 31,
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Historical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALICO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MetLife
|
|
|
Eleven Months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
Ended
|
|
|
Pro Forma
|
|
|
Reclassification
|
|
|
|
|
Pro Forma
|
|
|
|
2010
|
|
|
October 31, 2010
|
|
|
Adjustments
|
|
|
Adjustments
|
|
|
Notes
|
|
Combined
|
|
|
|
(In millions, except per share data)
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums
|
|
$
|
27,394
|
|
|
$
|
9,463
|
|
|
$
|
(160
|
)
|
|
$
|
(1,123
|
)
|
|
5(a); 6(a)
|
|
$
|
35,574
|
|
Universal life and investment-type product policy fees
|
|
|
6,037
|
|
|
|
|
|
|
|
(107
|
)
|
|
|
1,123
|
|
|
4(p); 5(a)
|
|
|
7,053
|
|
Net investment income
|
|
|
17,615
|
|
|
|
3,734
|
|
|
|
(857
|
)
|
|
|
|
|
|
4(a)
|
|
|
20,492
|
|
Other revenues
|
|
|
2,328
|
|
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,333
|
|
Net investment gains (losses)
|
|
|
(657
|
)
|
|
|
(98
|
)
|
|
|
(229
|
)
|
|
|
|
|
|
4(s); 4(t); 6(a); 6(b)
|
|
|
(984
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
52,717
|
|
|
|
13,104
|
|
|
|
(1,353
|
)
|
|
|
|
|
|
|
|
|
64,468
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Policyholder benefits and claims
|
|
|
29,545
|
|
|
|
7,596
|
|
|
|
(324
|
)
|
|
|
(2,135
|
)
|
|
4(q); 4(r); 4(v); 5(b); 6(a)
|
|
|
34,682
|
|
Interest credited to policyholder account balances
|
|
|
4,925
|
|
|
|
|
|
|
|
|
|
|
|
2,135
|
|
|
5(b)
|
|
|
7,060
|
|
Policyholder dividends
|
|
|
1,486
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,486
|
|
Other expenses
|
|
|
12,803
|
|
|
|
3,790
|
|
|
|
(1,186
|
)
|
|
|
|
|
|
4(b)
|
|
|
15,407
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
48,759
|
|
|
|
11,386
|
|
|
|
(1,510
|
)
|
|
|
|
|
|
|
|
|
58,635
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before provision for income tax
|
|
|
3,958
|
|
|
|
1,718
|
|
|
|
157
|
|
|
|
|
|
|
|
|
|
5,833
|
|
Provision for income tax expense
|
|
|
1,181
|
|
|
|
554
|
|
|
|
98
|
|
|
|
|
|
|
4(u)
|
|
|
1,833
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations, net of income tax
|
|
|
2,777
|
|
|
|
1,164
|
|
|
|
59
|
|
|
|
|
|
|
|
|
|
4,000
|
|
Less: Net income (loss) attributable to noncontrolling interests
|
|
|
(4
|
)
|
|
|
36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations, net of income tax,
attributable to shareholders
|
|
|
2,781
|
|
|
|
1,128
|
|
|
|
59
|
|
|
|
|
|
|
|
|
|
3,968
|
|
Less: Preferred stock dividends
|
|
|
122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations, net of income tax,
attributable to common shareholders
|
|
$
|
2,659
|
|
|
$
|
1,128
|
|
|
$
|
59
|
|
|
$
|
|
|
|
|
|
$
|
3,846
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per share from continuing operations, net of income tax,
attributable to common shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
3.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
$
|
2.99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
882
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,056
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
890
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,063
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to unaudited pro forma condensed combined
statement of operations
S-55
MetLife,
Inc.
Notes to
Unaudited Pro Forma Condensed Combined Statement of
Operations
|
|
1.
|
Description
of Transaction
|
Under the terms of the Stock Purchase Agreement, on
November 1, 2010, MetLife, Inc. (i) paid
$7.2 billion to the Selling Stockholder in cash, and
(ii) issued to the Selling Stockholder (a) 78,239,712
shares of MetLife, Inc.s common stock,
(b) 6,857,000 shares of the Series B Preferred
Stock and (c) 40,000,000 common equity units of MetLife,
Inc. with an aggregate stated amount at issuance of
$3.0 billion, initially consisting of (x) three stock
purchase contracts obligating the holder to purchase, on
specified future settlement dates, a variable number of shares
of MetLife, Inc.s common stock for a fixed price; and
(y) an interest in each of three series of debt securities
issued by MetLife, Inc.
The unaudited pro forma condensed combined statement of
operations is based on the historical financial statements of
MetLife, Inc. and ALICO and combines the condensed consolidated
statement of operations for the year ended December 31,
2010, for MetLife, Inc. (which includes ALICOs operations
for the month of November 2010) and the combined statement
of income for the eleven months ended October 31, 2010, for
ALICO. For ease of reference, all pro forma adjustments
reference MetLife, Inc.s December 31, 2010 year
end date and no adjustments were made to ALICOs reported
information for its different period-end date. Certain
adjustments and reclassifications have been recorded in the
unaudited pro forma condensed combined statement of operations
to conform to MetLife, Inc.s accounting policies and are
more fully described in Notes 4 and 5. The unaudited pro
forma condensed combined statement of operations gives effect to
the Acquisition as if it had occurred on January 1, 2010.
The unaudited pro forma condensed combined statement of
operations is presented in accordance with the requirements of
Article 11 of
Regulation S-X
published by the SEC. In accordance with Article 11 of
Regulation S-X,
discontinued operations and the related earnings per share data
have been excluded from the presentation of the unaudited pro
forma condensed combined statement of operations.
The unaudited pro forma condensed combined statement of
operations and accompanying notes present the impact of the
Acquisition on MetLife, Inc.s results of operations under
the acquisition method of accounting. The acquisition method of
accounting requires, among other things, that the consideration
transferred be measured at fair value at the acquisition date
and that assets acquired and liabilities assumed be recognized
at their fair values as of the acquisition date. Accordingly,
for purposes of determining the pro forma adjustments in the
condensed combined statement of operations, the assets acquired
and liabilities assumed were assumed to have been recorded as of
the acquisition date of January 1, 2010 at their respective
fair values.
The pro forma adjustments reflecting the acquisition are based
on certain estimates and assumptions. MetLife, Inc.s
management believes that the pro forma adjustments give
appropriate effect to those assumptions and are properly applied
in the unaudited pro forma condensed combined statement of
operations.
The unaudited pro forma condensed combined statement of
operations is not intended to reflect the results of operations
of the combined company that would have resulted had the
Acquisition been effective during the period presented or the
results that may be obtained by the combined company in the
future.
|
|
3.
|
Acquisition-Related
Costs
|
During the year ended December 31, 2010, MetLife, Inc.
incurred acquisition-related transaction costs, consisting
primarily of investment banking and legal fees, of
$106 million. This amount is reflected in MetLife,
Inc.s historical consolidated statement of operations for
the year ended December 31, 2010 and was included in other
expenses. A pro forma adjustment has been made to eliminate
these costs from the unaudited pro forma condensed combined
statement of operations for the year ended December 31,
2010 due to their non-recurring nature.
S-56
The following pro forma adjustments are included in the
unaudited pro forma condensed combined statement of operations:
(a) Adjustments to reflect the increase/(decrease) in net
investment income for the year ended December 31, 2010 as
follows:
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended
|
|
|
Note
|
|
|
|
December 31, 2010
|
|
|
Reference
|
|
|
|
(in millions)
|
|
|
Adjustment to income associated with commercial mortgage-backed
securities
|
|
$
|
6
|
|
|
|
4(c
|
)
|
Adjustment to amortization/accretion of fixed maturities
available-for-sale portfolio
|
|
|
(777
|
)
|
|
|
4(c
|
)
|
Elimination of interest income on investment in MetLife, Inc.
debt securities
|
|
|
(8
|
)
|
|
|
4(c
|
)
|
Adjustment to net investment income associated with reclass of
investment securities
|
|
|
(35
|
)
|
|
|
4(d
|
)
|
Adjustment to commercial mortgage loan income
|
|
|
45
|
|
|
|
4(e
|
)
|
Adjustment to income associated with policy loans
|
|
|
(43
|
)
|
|
|
4(f
|
)
|
Recognition of income on indemnification asset
|
|
|
2
|
|
|
|
4(g
|
)
|
Adjustment to depreciation expense on investment real estate
|
|
|
1
|
|
|
|
4(l
|
)
|
Elimination of net investment income associated with Peru joint
ventures
|
|
|
(48
|
)
|
|
|
6(a
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(857
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(b) Adjustments to reflect the (decrease)/increase in other
expenses for the year ended December 31, 2010 are as
follows:
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended
|
|
|
Note
|
|
|
|
December 31, 2010
|
|
|
Reference
|
|
|
|
(in millions)
|
|
|
Adjustment to remove acquisition-related transaction costs
incurred in 2010
|
|
$
|
(106
|
)
|
|
|
3
|
|
Elimination of interest expense on MetLife, Inc. debt securities
|
|
|
(8
|
)
|
|
|
4(c
|
)
|
Elimination of amortization on historical DAC
|
|
|
(1,808
|
)
|
|
|
4(h
|
)
|
Adjustment to DAC amortization related to new business
|
|
|
242
|
|
|
|
4(h
|
)
|
Amortization of VOBA, VODA and VOCRA
|
|
|
1,202
|
|
|
|
4(i
|
)
|
Amortization of negative VOBA
|
|
|
(806
|
)
|
|
|
4(j
|
)
|
Elimination of expense associated with historical deferred sales
inducements
|
|
|
(26
|
)
|
|
|
4(k
|
)
|
Adjustment to amortization of trademark assets
|
|
|
8
|
|
|
|
4(m
|
)
|
Adjustment to depreciation/amortization expense associated with
fixed assets and software capitalization
|
|
|
(13
|
)
|
|
|
4(n
|
)
|
Recognition of interest expense on debt securities issued in
connection with Acquisition
|
|
|
129
|
|
|
|
4(o
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(1,186
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c) An adjustment to decrease certain fixed maturity
securities relating to commercial mortgage-backed securities to
fair value based on MetLife, Inc.s valuation methodology
was assumed to have been made as of January 1, 2010. The
associated increase in net investment income is $6 million
for the year ended December 31, 2010 related primarily to
the net change in premium/discount of those securities. In
addition,
S-57
an adjustment to recognize the reduction of $777 million
for the year ended December 31, 2010 was recorded to
reflect the new cost basis and related amortization/accretion of
the acquired fixed maturities available-for-sale portfolio.
The elimination of ALICOs investment in MetLife,
Inc.s bonds resulted in the related elimination of
intercompany interest income/interest expense of $8 million
for the year ended December 31, 2010.
(d) An adjustment to reclassify trading securities to fixed
maturity securities
available-for-sale,
short term investments and cash in accordance with MetLife,
Inc.s intention not to hold the securities principally for
the purpose of selling in the near term resulted in a reduction
in net investment income of $35 million for the year ended
December 31, 2010.
(e) An adjustment to decrease mortgage loans to fair value
resulted in an increase in net investment income of
$45 million for the year ended December 31, 2010.
(f) An adjustment to increase policy loans to fair value
resulted in a reduction in net investment income of
$43 million for the year ended December 31, 2010,
related to the amortization of premium.
(g) An adjustment related to the change in value of
indemnification assets for established potential recoveries
related to the deterioration of fixed maturity securities
(including commercial mortgage-backed securities), mortgage
loans and certain investment funds resulted in an increase in
net investment income of $2 million for the year ended
December 31, 2010.
(h) An adjustment to eliminate ALICOs historical DAC
resulted in an amortization decrease of $1,808 million for
the year ended December 31, 2010. In addition, the
adjustment to increase other expenses for the DAC amortization
related to new business in the period presented in conformity
with MetLife, Inc.s accounting policy is $242 million
for the year ended December 31, 2010.
(i) Adjustments to establish VOBA, the value of
distribution agreements acquired (VODA) and
the value of customer relationships acquired
(VOCRA) arising from the Acquisition resulted
in an adjustment for the related amortization for VOBA, VODA and
VOCRA of $1,202 million for the year ended
December 31, 2010.
(j) For certain acquired blocks of business, the estimated
fair value of acquired liabilities exceeded the initial policy
reserves assumed at the acquisition date, resulting in a
negative VOBA which resulted in an adjustment for the related
amortization for negative VOBA of $806 million for the year
ended December 31, 2010.
(k) An adjustment to eliminate ALICOs deferred sales
inducement assets resulted in a reduction in amortization of
$26 million for the year ended December 31, 2010.
(l) An adjustment to increase investment real estate to
fair value resulted in an increase in net investment income of
$1 million for the year ended December 31, 2010.
(m) An adjustment to recognize the trademark values
acquired as an identifiable intangible asset arising from the
Acquisition resulted in an adjustment for trademark amortization
of $8 million for the year ended December 31, 2010.
(n) An adjustment to reduce fixed assets and capitalized
software to conform to MetLife, Inc.s capitalization
policy resulted in a reduction in depreciation expense of
$13 million for the year ended December 31, 2010.
(o) An adjustment to reflect the issuance of the debt
securities of MetLife, Inc. of $3.0 billion and the public
offering of senior notes issued in August, 2010 of
$3.0 billion in connection with the Acquisition was assumed
to have been made as of January 1, 2010 and the increase in
other expenses related to interest expense related to the debt
securities of MetLife, Inc. and the senior notes is
$129 million for the year ended December 31, 2010.
Interest expense on the debt securities of MetLife, Inc. was
based on an average annual contractual rate of 1.98%. Interest
expense on the public offering of senior debt was calculated
based on actual borrowing rates for the $3.0 billion in
aggregate principal amount of senior notes.
S-58
(p) An adjustment to eliminate ALICOs historical
unearned revenue is $107 million for the year ended
December 31, 2010.
(q) Adjustment to remove the effects of changes in embedded
derivatives on certain U.K. unit linked business contracts which
reduce earnings by $99 million for the year ended
December 31, 2010 since the related guarantees will not
impact MetLife, Inc.s future earnings based on the
provisions of the Stock Purchase Agreement.
(r) Adjustment to decrease policyholder benefits and claims
incurred by $107 million for the year ended
December 31, 2010 for the estimated effects of unlocking
actuarial assumptions used in determining future net benefit
premiums for certain traditional life insurance blocks of
business and to reverse the mark to market effects of the fair
value option used by ALICO for certain single premium variable
life products in Japan as MetLife, Inc. did not exercise such a
fair value election.
(s) Adjustment to reverse realized investment losses of
$83 million for the year ended December 31, 2010, to
conform to MetLife, Inc.s policy related to foreign
exchange.
(t) Adjustment to realize a net investment loss of
$9 million related to the release of unrealized
gains/losses to realized gains/losses on foreign currency
denominated fixed maturity securities for the year ended
December 31, 2010.
(u) The unaudited pro forma condensed combined statement of
operations pre-tax adjustments were tax effected at the
U.S. tax rate of 35%. For purposes of the unaudited pro
forma condensed statements of operations, it has been assumed
that earnings of foreign subsidiaries will not be permanently
reinvested. For the year ended December 31, 2010, the pro
forma pre-tax adjustments resulted in an increase to income tax
expense of $98 million.
(v) Adjustment to record an increase in indemnification
assets of $138 million associated with certain litigation
matters, which offsets the related litigation charge reflected
in ALICOs statement of income for the eleven months ended
October 31, 2010.
|
|
5.
|
Reclassification
Adjustments
|
The following reclassification adjustments have been made to
conform ALICOs accounting policies to those of MetLife,
Inc. which have been recorded in the unaudited pro forma
condensed combined statement of operations:
(a) Adjustment to reclassify universal life and
investment-type product policy fees of $1,123 million from
premiums for the year ended December 31, 2010.
(b) Adjustment to reclassify interest credited to
policyholder account balances of $2,135 million from
policyholder benefits and claims for the year ended
December 31, 2010.
|
|
6.
|
Pre
Closing Activities
|
(a) On October 27, 2010, ALICO sold its investments in
two joint ventures in Peru resulting in a gain of
$83 million which has been eliminated in the unaudited pro
forma condensed combined statement of operations. In addition,
the statement of operations items related to the Peru joint
ventures have been eliminated in the unaudited pro forma
condensed combined statement of operations for the year ended
December 31, 2010 and are presented below.
S-59
|
|
|
|
|
|
|
Eleven Months
|
|
|
|
Ended
|
|
|
|
October 31, 2010
|
|
|
|
(In millions)
|
|
|
Revenues
|
|
|
|
|
Premiums
|
|
$
|
160
|
|
Net investment income
|
|
|
48
|
|
Net investment gains
|
|
|
5
|
|
Expenses
|
|
|
|
|
Policyholder benefits and claims
|
|
|
178
|
|
Net income attributable to noncontrolling interests
|
|
|
22
|
|
(b) Prior to the closing of the Acquisition, AIG was
required to complete certain transactions that affect ALICO, as
required by the Stock Purchase Agreement. As a result, the
following adjustments to eliminate gains were made in the
unaudited pro forma condensed combined statement of operations
for the year ended December 31, 2010:
(i) a gain of $29 million for the year ended
December 31, 2010 associated with an intercompany
settlement of a foreign currency derivative between ALICO and
AIG;
(ii) a gain of $78 million for the year ended
December 31, 2010, associated with the intercompany
settlement of swap positions between ALICO and AIG Financial
Products; and
(iii) a gain of $108 million for the year ended
December 31, 2010, associated with the sale of AIG common
stock to AIG.
|
|
7.
|
Pro Forma
Earnings Per Share
|
The pro forma basic and diluted earnings per share amounts
presented in the unaudited pro forma condensed combined
statement of operations are based upon the estimated weighted
average number of common shares outstanding, as adjusted for the
following items:
(i) the public offering of 86,250,000 shares of
MetLife, Inc. common stock issued on August 6, 2010, in
connection with financing the cash portion of the transaction;
(ii) the issuance of 78,239,712 shares of MetLife,
Inc. common stock to the Selling Stockholder; and
(iii) conversion of the Series B Preferred Stock into
68,570,000 shares of MetLife, Inc. common stock.
|
|
|
|
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
|
(In millions)
|
|
|
Basic
|
|
|
|
|
Weighted average common shares outstanding, as reported (1)
|
|
|
823
|
|
Common shares issued in connection with the Acquisition (2)
|
|
|
164
|
|
Common shares upon conversion of Series B Preferred Stock
(3)
|
|
|
69
|
|
|
|
|
|
|
Weighted average common shares outstanding, pro forma
|
|
|
1,056
|
|
|
|
|
|
|
Diluted
|
|
|
|
|
Weighted average common shares outstanding, as reported (1)
|
|
|
830
|
|
Common shares issued in connection with the Acquisition (2)
|
|
|
164
|
|
Common shares upon conversion of Series B Preferred Stock
(3)
|
|
|
69
|
|
|
|
|
|
|
Weighted average common shares outstanding, pro forma
|
|
|
1,063
|
|
|
|
|
|
|
S-60
|
|
|
(1) |
|
Weighted average common shares, as reported for both basic and
diluted, are adjusted to remove the incremental common shares
associated with common stock issued on August 6, 2010, as
well as the incremental common shares associated with the common
stock and the Series B Preferred Stock issued to the
Selling Stockholder on November 1, 2010 in connection with
the Acquisition. The shares associated with common stock are
included in the total Common shares issued in connection
with the Acquisition and assumed to be outstanding for the
entire 2010 year. The shares associated with the
Series B Preferred Stock are included in the total
Common shares upon conversion of Series B Preferred
Stock and are assumed to be outstanding for the entire
2010 year. |
|
(2) |
|
Includes shares issued on August 6, 2010 as well as shares
of MetLife, Inc. common stock issued to the Selling Stockholder
on November 1, 2010. |
|
(3) |
|
For purposes of the earnings per share calculation, the
Series B Preferred Stock is treated on an as-converted
basis for both basic and diluted weighted average shares. |
S-61
USE OF
PROCEEDS
MetLife, Inc. estimates that its net proceeds of this offering
will be $2,950,824,237.50. Pursuant to the Coordination
Agreement, MetLife, Inc. intends to use all of its net proceeds
from this offering to fund the Repurchase, for a purchase price
equal to such net proceeds. Each share of Series B
Preferred Stock is convertible into ten shares of common stock
(subject to anti-dilution adjustments), subject to a favorable
vote of MetLife, Inc.s common shareholders. To the extent
MetLife, Inc. sells fewer than 68,570,000 shares of common
stock in this offering, it will use all of the net proceeds that
it receives in this offering to repurchase a proportionate
number of shares of the Series B Preferred Stock (on an
as-converted basis) from the Selling Stockholder, for a purchase
price equal to such net proceeds. Upon receipt, any shares of
the Series B Preferred Stock will be cancelled by MetLife,
Inc.
MetLife, Inc. will not receive any proceeds from the sale of
common stock by the Selling Stockholder.
S-62
CAPITALIZATION
The following table sets forth our consolidated capitalization
at December 31, 2010, on an actual basis and as adjusted to
give effect to this offering of the common stock and the
Repurchase of the Series B Preferred Stock. This
information should be read in conjunction with our consolidated
financial statements at December 31, 2010, including the
notes thereto, and other financial information pertaining to us
incorporated herein by reference as well as the unaudited pro
forma financial information included in Unaudited Pro
Forma Condensed Combined Statement of Operations.
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2010
|
|
|
|
|
|
|
As Adjusted for
|
|
|
|
|
|
|
this Offering of
|
|
|
|
|
|
|
Common Stock and
|
|
|
|
Actual
|
|
|
the Repurchase(1)(2)
|
|
|
|
(In millions)
|
|
|
Short-term debt
|
|
$
|
306
|
|
|
$
|
306
|
|
Long-term debt(3)
|
|
|
27,586
|
|
|
|
27,586
|
|
Collateral financing arrangements
|
|
|
5,297
|
|
|
|
5,297
|
|
Junior subordinated debt securities
|
|
|
3,191
|
|
|
|
3,191
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
36,380
|
|
|
|
36,380
|
|
|
|
|
|
|
|
|
|
|
MetLife, Inc.s Stockholders Equity:
|
|
|
|
|
|
|
|
|
Preferred stock, at par value
|
|
|
1
|
|
|
|
1
|
|
Convertible preferred stock, at par value
|
|
|
|
|
|
|
|
|
Common stock, at par value
|
|
|
10
|
|
|
|
11
|
|
Additional paid-in capital
|
|
|
26,423
|
|
|
|
26,567
|
|
Retained earnings
|
|
|
21,363
|
|
|
|
21,218
|
|
Treasury stock, at cost
|
|
|
(172
|
)
|
|
|
(172
|
)
|
Accumulated other comprehensive income (loss)
|
|
|
1,000
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
|
|
Total MetLife, Inc.s stockholders equity
|
|
|
48,625
|
|
|
|
48,625
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
85,005
|
|
|
$
|
85,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Reflects the issuance of 68,570,000 shares of common stock
at a price per share of $43.25 for total consideration of
$2,966 million less transaction costs of approximately
$16 million for net proceeds from the offering of
$2,950 million. Also reflects the repurchase and
elimination of 6,857,000 shares of the Series B
Preferred Stock resulting from the Repurchase. |
|
(2) |
|
There is no adjustment in this column to reflect the Selling
Stockholders concurrent offering of 40,000,000 of common
equity units. |
|
(3) |
|
Includes $6,902 million of long-term debt relating to
variable interest entities. |
S-63
COMMON
STOCK PRICE RANGE AND DIVIDENDS
MetLife, Inc.s common stock is listed on the New York
Stock Exchange. Trading, as reported on the New York Stock
Exchange, and dividend information follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Price Range
|
|
Cash Dividend
|
|
|
High
|
|
Low
|
|
Per Share
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
First Quarter (through March 2, 2011)
|
|
$
|
48.63
|
|
|
$
|
43.41
|
|
|
$
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
44.92
|
|
|
$
|
37.74
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
42.73
|
|
|
$
|
36.49
|
|
|
|
|
|
Second Quarter
|
|
$
|
47.10
|
|
|
$
|
37.76
|
|
|
|
|
|
First Quarter
|
|
$
|
43.34
|
|
|
$
|
33.64
|
|
|
|
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
38.35
|
|
|
$
|
33.22
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
40.83
|
|
|
$
|
26.90
|
|
|
|
|
|
Second Quarter
|
|
$
|
35.50
|
|
|
$
|
23.43
|
|
|
|
|
|
First Quarter
|
|
$
|
35.97
|
|
|
$
|
12.10
|
|
|
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
48.15
|
|
|
$
|
16.48
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
63.00
|
|
|
$
|
43.75
|
|
|
|
|
|
Second Quarter
|
|
$
|
62.88
|
|
|
$
|
52.77
|
|
|
|
|
|
First Quarter
|
|
$
|
61.52
|
|
|
$
|
54.62
|
|
|
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
70.87
|
|
|
$
|
60.46
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
69.92
|
|
|
$
|
59.62
|
|
|
|
|
|
Second Quarter
|
|
$
|
69.04
|
|
|
$
|
63.29
|
|
|
|
|
|
First Quarter
|
|
$
|
65.92
|
|
|
$
|
59.10
|
|
|
|
|
|
The reported last sale price for our common stock on the New
York Stock Exchange on March 2, 2011 was $43.41 per
share. As of February 18, 2011, there were
986,585,463 shares of common stock outstanding. As of
February 18, 2011, our outstanding shares of common stock
were held by 90,250 stockholders of record.
S-64
SELLING
STOCKHOLDER
The Selling Stockholder, a subsidiary of AIG, proposes to offer
and sell up to 78,239,712 shares of MetLife, Inc. common
stock, representing 7.9% of MetLife, Inc.s outstanding
common stock as of February 28, 2011. Following completion
of this offering, the Selling Stockholder will own no shares of
common stock.
The Selling Stockholder received the 78,239,712 shares of
common stock offered by this prospectus supplement pursuant to
the Acquisition. Total consideration for the Acquisition also
included $7.2 billion of cash, 6,857,000 shares of
Series B Preferred Stock (convertible into
68,570,000 shares of MetLife, Inc.s common stock
(subject to anti-dilution adjustments) upon a favorable vote of
MetLife, Inc.s common shareholders) and 40,000,000 common
equity units with an aggregate stated value of $3.0 billion.
For a discussion of certain relationships between MetLife, Inc.,
AIG and the Selling Stockholder see Corporate
Governance Related Party Transactions in
MetLife, Inc.s
Form 10-K/A
filed on March 1, 2011, which is incorporated by reference
herein.
S-65
COORDINATION
AGREEMENT
On March 1, 2011, MetLife, Inc. entered into the
Coordination Agreement with the Selling Stockholder and AIG,
pursuant to which MetLife, Inc. agreed to repurchase from the
Selling Stockholder the number of shares of Series B
Preferred Stock equal to the lesser of
(i) 6,857,000 shares of Series B Preferred Stock
and (ii) the actual number of shares of MetLife,
Inc.s common stock, up to 68,570,000 shares, actually
sold and delivered by MetLife, Inc. in this offering of common
stock, divided by ten. The Series B Preferred Stock was
previously issued by MetLife, Inc. to the Selling Stockholder at
the closing of the Acquisition in accordance with the Stock
Purchase Agreement. The aggregate consideration to be paid for
the Repurchase will equal MetLife, Inc.s net proceeds from
the offering by MetLife, Inc. of up to 68,570,000 shares of
its common stock.
The 6,857,000 shares of Series B Preferred Stock are
convertible into 68,570,000 shares of MetLife, Inc.s
common stock, subject to a favorable vote of MetLife,
Inc.s stockholders at its 2011 annual meeting. Pursuant to
the terms of the Stock Purchase Agreement, MetLife, Inc. is
obligated to pay a $300 million compensatory payment to the
Selling Stockholder in the event that MetLife, Inc.s
stockholders do not approve the conversion of the Series B
Preferred Stock. Pursuant to the Coordination Agreement, the
$300 million compensatory payment will be reduced in
proportion to the number of shares of Series B Preferred
Stock repurchased by MetLife.
The consummation of the Repurchase, which is expected to occur
concurrently with, or immediately following, the closing of this
offering of common stock, is subject to the satisfaction of
customary closing conditions, including the receipt of any
required governmental approvals and third party contractual
consents. Additionally, the consummation of the Repurchase is
subject to the successful consummation of the offering by
MetLife, Inc. of up to 68,570,000 shares of its common
stock as contemplated by this prospectus supplement and the
receipt of a letter from the United States Department of the
Treasury, the Selling Stockholder and AIA Aurora LLC,
confirming, among other things, the release of all encumbrances
on the shares of Series B Preferred Stock to be repurchased
in the Repurchase.
In addition to customary termination provisions, MetLife, Inc.
may, prior to the execution of the underwriting agreement for
this offering of common stock, terminate the Coordination
Agreement in the event that MetLife, Inc.s board of
directors (or a committee thereof), determines that the offering
of up to 68,570,000 shares of its common stock cannot be
completed on terms acceptable to MetLife, Inc. in its sole
discretion. Similarly, AIG may, prior to the execution of the
underwriting agreement for this offering of common stock,
terminate the Coordination Agreement in the event that
AIGs board of directors (or a committee thereof),
determines that this offering of common stock or the concurrent
offering cannot be completed on terms acceptable to AIG in its
sole discretion. Additionally, either AIG or MetLife, Inc. may
terminate the Coordination Agreement between the pricing of this
offering of common stock and the consummation of this offering,
in the event that the underwriting agreement for this offering
of common stock is terminated in accordance with its terms.
The Coordination Agreement amends the Stock Purchase Agreement
with respect to certain indemnification-related obligations of
AIG and the Selling Stockholder. As of the date of this
prospectus supplement, 40,000,000 common equity units of
MetLife, Inc. to be offered in the concurrent offering are
currently held in an indemnification collateral account in order
to secure the Selling Stockholders indemnification
obligations to MetLife, Inc. pursuant to the Stock Purchase
Agreement. Pursuant to the Coordination Agreement, in the event
that the net proceeds from the concurrent offering equal at
least $3.0 billion, then $3.0 billion (which is the
aggregate stated amount of the common equity units) will be
placed in the indemnification collateral account and any
proceeds above such amount will be distributed to the Selling
Stockholder. In such case, any unsold equity units will be
released from the indemnification collateral account to the
Selling Stockholder. In the event that less than all of the
common equity units are sold in the concurrent offering, and the
concurrent offering generates net proceeds of less than
$3.0 billion, an amount equal to the aggregate stated
amount of the common equity units sold in the concurrent
offering will be deposited in the indemnification collateral
account, and any net proceeds from the concurrent offering above
such aggregate stated amount will be distributed to the Selling
Stockholder, with the unsold common equity units remaining in
the indemnification collateral account. If the Selling
Stockholder sells all of the common equity units in the
concurrent offering but the net proceeds from the offering are
less than $3.0 billion, the entire net proceeds from the
concurrent offering will be deposited in the indemnification
collateral account. In that case, the amount that the Selling
Stockholder is entitled to withdraw from the indemnification
collateral account on certain scheduled release dates pursuant
to the terms of the Stock Purchase Agreement will be reduced by
the amount by which the net proceeds from the concurrent
offering are less than $3.0 billion.
S-66
The Coordination Agreement also provides, among other things,
(i) for mechanics that govern the release from the
indemnification collateral account of such common equity units
sold in the concurrent offering and the allocation of the net
proceeds from the concurrent offering to the indemnification
collateral account and the Selling Stockholder, (ii) that
the Selling Stockholder will only be permitted to substitute
cash for any collateral held in the indemnification collateral
account, (iii) that the Selling Stockholder will not be
permitted to make indemnification payments under the Stock
Purchase Agreement utilizing MetLife, Inc.s common stock
or any shares of Series B Preferred Stock, (iv) that
indemnification payments to be made by the Selling Stockholder
by utilizing the collateral held in the indemnification
collateral account will be satisfied first by delivery of cash
held in such account and, to the extent such cash collateral is
insufficient, by delivery of equity units held in such account,
(v) that common equity units will first be released from
the indemnification collateral account on the scheduled release
dates as provided in the Stock Purchase Agreement, followed by
any cash held in such account and (vi) that a portion of
the net proceeds from the concurrent offering and, to the extent
such proceeds are insufficient, a sufficient amount of the net
proceeds from the offering by the Selling Stockholder of up to
78,239,712 shares of MetLife, Inc.s common stock, will be
delivered to MetLife, Inc. in connection with the payment of
certain tax liabilities in connection with the Acquisition
pursuant to the terms of the Coordination Agreement.
The Coordination Agreement provides for, among other things, the
release of the Selling Stockholder from the transfer
restrictions under the Investor Rights Agreement solely to the
extent necessary to permit this offering of common stock and the
concurrent offering to proceed. These restrictions include the
lock-up,
which prevents the Selling Stockholder from transferring any of
MetLife, Inc.s securities it received in the Acquisition
before the end of July 2011, and limitations on the amount of
MetLife, Inc. securities held by the Selling Stockholder that
can be sold in any one offering or in any period of
180 days. In the event that the Selling Stockholder is
unable to dispose of all of MetLife, Inc.s common stock
and common equity units that it holds in this offering and the
concurrent offering, respectively, any unsold securities will
remain subject to the
lock-up
until November 1, 2011, and any unsold shares of common
stock or common equity units that are not sold in this offering
or the concurrent offering, respectively, and any shares of
Series B Preferred Stock not repurchased in the Repurchase
will remain subject in all respects to the terms, conditions and
restrictions of the Investor Rights Agreement.
The representations and warranties in the Coordination Agreement
are the product of negotiations among the parties thereto and
are for the sole benefit of the parties thereto. Any
inaccuracies in such representations and warranties are subject
to waiver by the parties thereto in accordance with the
Coordination Agreement without notice or liability to any other
person. In some instances, the representations and warranties in
the Coordination Agreement may represent an allocation among the
parties thereto of risks associated with particular matters
regardless of the knowledge of any of the parties thereto.
Consequently, persons other than the parties to the Coordination
Agreement may not rely upon the representations and warranties
in the Coordination Agreement as characterizations of actual
facts or circumstances as of the date of the Coordination
Agreement or as of any other date.
Pursuant to the terms of the Coordination Agreement, the parties
have agreed to enter into an Amended and Restated
Indemnification Collateral Account Security and Control
Agreement with Deutsche Bank Trust Company Americas, as
securities intermediary, pledge collateral agent and stock
purchase contract agent (the Amended Indemnification
Control Agreement). The Amended Indemnification
Control Agreement makes conforming changes to the
Indemnification Collateral Account Security and Control
Agreement, dated as of November 1, 2010, by and among
MetLife, Inc., the Selling Stockholder, Deutsche Bank
Trust Company Americas, as securities intermediary, pledge
collateral agent and stock purchase contract agent, and AIG, as
necessary to reflect the agreements and understandings in the
Coordination Agreement described above.
S-67
CERTAIN
MATERIAL U.S. FEDERAL INCOME TAX
CONSIDERATIONS FOR
NON-U.S.
HOLDERS
The following is a general discussion of certain material
U.S. federal income tax consequences resulting from the
purchase, ownership and disposition of MetLife, Inc.s
common stock by a
non-U.S. holder
(as defined below) that acquires MetLife, Inc.s common
stock pursuant to this offering. The following discussion is
based on provisions of the Code, applicable U.S. Treasury
regulations promulgated thereunder and administrative and
judicial interpretations, all as in effect on the date of this
prospectus supplement, and all of which are subject to change,
possibly on a retroactive basis. This discussion is limited to
non-U.S. holders
who hold MetLife, Inc.s common stock as a capital
asset within the meaning of Section 1221 of the Code.
This discussion is only addressed to
non-U.S. holders
and does not consider and does not address tax considerations
applicable to holders in light of their particular circumstances
or to holders that may be subject to special tax rules,
including, without limitation, financial institutions (including
banks), insurance companies, retirement plans, mutual funds,
hybrid entities, certain former citizens or former long-term
residents of the United States, dealers in securities or
currencies, holders who acquire their common stock pursuant to
the exercise of employee stock options or as compensation,
persons subject to the
mark-to-market
rules of the Code, foreign governments, international
organizations, controlled foreign corporations, passive foreign
investment companies, persons that will hold our stock as a part
of a hedging transaction, synthetic security,
straddle, conversion transaction, or
other integrated transaction for U.S. federal income tax
purposes, entities treated as partnerships for U.S. federal
income tax purposes, and tax-exempt organizations. This
discussion does not consider any U.S. federal gift or
estate tax consequences, or U.S. state or local or
non-U.S. tax
consequences resulting from the purchase, ownership or
disposition of MetLife, Inc.s common stock.
If a partnership (including any entity treated as a partnership
for U.S. federal income tax purposes) is a holder of
MetLife, Inc.s common stock, the tax treatment of a
partner in the partnership generally will depend upon the status
of the partner and the activities of the partnership. Holders
that are partnerships, and partners in such partnerships, should
consult their tax advisors about the tax consequences resulting
from the purchase, ownership and disposition of MetLife,
Inc.s common stock.
As used in this discussion, the term
non-U.S. holder
means a holder that is a beneficial owner of MetLife,
Inc.s common stock that is not, for U.S. federal
income tax purposes:
|
|
|
|
|
an individual citizen or resident of the United States;
|
|
|
|
a corporation (or other entity treated as a corporation for
U.S. federal income tax purposes) created or organized in
or under the laws of the United States, any state thereof or the
District of Columbia;
|
|
|
|
an estate the income of which is subject to U.S. federal
income tax regardless of its source; or
|
|
|
|
a trust, if (1) a court within the United States is able to
exercise primary supervision over the administration of the
trust and one or more United States persons have authority to
control all substantial decisions of the trust or (2) it
has a valid election in effect under applicable
U.S. Treasury regulations to be treated as a domestic trust.
|
Prospective investors are urged to consult their own tax
advisors regarding the U.S. federal, state, local, and
non-U.S. income
and other tax considerations with respect to purchasing, owning
and disposing of shares of MetLife, Inc.s common stock.
Distributions
on MetLife, Inc.s Common Stock
Distributions paid on MetLife, Inc.s common stock will
constitute dividends for U.S. federal income tax purposes
to the extent paid from our current or accumulated earnings and
profits, as determined under U.S. federal income tax
principles.
With respect to distributions that are treated as dividends for
U.S. federal income tax purposes, we will have to withhold
U.S. federal income tax at a rate of 30% (or such lower
rate under an applicable income tax treaty), from the gross
amount of the dividends paid to a
non-U.S. holder,
unless such dividends are effectively connected with such
holders conduct of a trade or business in the United
States (and, if an income tax treaty applies, are attributable
S-68
to a permanent establishment maintained by the
non-U.S. holder
in the United States). Under applicable U.S. Treasury
regulations,
non-U.S. holders
are required to satisfy certain certification and other
requirements (e.g., as set forth on IRS
Form W-8
BEN (or suitable substitute form)) in order to claim a reduced
rate of withholding on dividend payments pursuant to an
applicable income tax treaty. A
non-U.S. holder
that is eligible for a reduced rate of withholding of
U.S. federal income tax under an income tax treaty may
obtain a refund or credit of any excess amounts withheld by
timely filing an appropriate claim for refund with the IRS.
Non-U.S. holders
should consult their tax advisors regarding their entitlement to
benefits under a relevant income tax treaty.
Dividends that are effectively connected with a
non-U.S. holders
conduct of a trade or business in the United States (and, if an
income tax treaty applies, are attributable to a permanent
establishment maintained by the
non-U.S. holder
in the United States) are taxed on a net income basis at the
regular graduated U.S. federal income tax rates in the same
manner as if the
non-U.S. holder
were a resident of the United States. In such cases, we will not
have to withhold U.S. federal income tax if the
non-U.S. holder
complies with applicable certification and other requirements
(e.g., as set forth on IRS
Form W-8ECI
(or suitable substitute form)). In addition, a branch
profits tax may be imposed at a 30% rate, or a lower rate
under an applicable income tax treaty, if the
non-U.S. holder
is a foreign corporation that has earnings and profits
(attributable to dividends or otherwise) that are effectively
connected with such holders conduct of a trade or business
in the United States.
To the extent distributions exceed our current and accumulated
earnings and profits, such distributions will constitute a
return of capital to
non-U.S. holders
of MetLife, Inc.s common stock, and will first reduce the
non-U.S. holders
adjusted tax basis in such stock, but not below zero. The
amounts of any such distribution in excess of such adjusted tax
basis will be treated as gain from the sale of stock which
generally should not be subject to U.S. federal income tax
(except as described below). See discussion below under
Gain on Disposition of Common Stock for
a more detailed discussion regarding the U.S. federal
income tax consequences to a
non-U.S. holder
with respect to gain on the sale of MetLife, Inc.s common
stock.
Gain on
Disposition of Common Stock
Subject to the discussion below under
Information Reporting and Backup Withholding
Tax and Newly Enacted Legislation,
a
non-U.S. holder
generally will not be subject to U.S. federal income tax or
any withholding thereof with respect to any gain realized on a
sale or other disposition of MetLife, Inc.s common stock
(including, as a result of receiving distributions that are not
treated as dividends on such stock in excess of such
holders adjusted tax basis in such stock) unless one of
the following applies:
|
|
|
|
|
the gain is effectively connected with the
non-U.S. holders
conduct of a trade or business in the United States (and, if an
income tax treaty applies, is attributable to a permanent
establishment maintained by the
non-U.S. holder
in the United States); in which case, the
non-U.S. holder
will generally be taxed on its net gain derived from the
disposition at the regular graduated rates and in the same
manner as if the
non-U.S. holder
were a resident of the United States and, if the
non-U.S. holder
is a foreign corporation, the branch profits tax
described above may also apply;
|
|
|
|
the
non-U.S. holder
is an individual who is present in the United States for
183 days or more in the taxable year of the disposition and
meets certain other requirements; in which case, the
non-U.S. holder
will be subject to a 30% tax on the gain derived from the
disposition, although such gain may be offset by
U.S. source capital losses recognized during the same
taxable year; or
|
|
|
|
MetLife, Inc.s common stock constitutes a United
States real property interest (USRPI)
by reason of our status as a United States real property
holding corporation (USRPHC) for
U.S. federal income tax purposes at any time during the
shorter of the
5-year
period ending on the date the
non-U.S. holder
disposes of MetLife, Inc.s common stock or the period such
holder held MetLife, Inc.s common stock.
|
We believe that we are not currently and do not anticipate
becoming a USRPHC. Moreover, even if we are, or become, a
USRPHC,
non-U.S. holders
would not be subject to U.S. federal income tax (including
withholding thereof) if our stock is regularly traded on
an established securities market within the meaning of
Section 897(c)(3) of the Code, unless such a holder owned
(directly or indirectly) more than 5% of MetLife, Inc.s
common stock during the applicable period (in which case, such
holder would be subject to U.S. federal
S-69
income tax with respect to the net gain recognized on the sale
of MetLife, Inc.s common stock at regular graduated rates
and related reporting and filing requirements). We believe that
MetLife, Inc.s common stock should be treated as
regularly traded on an established securities
market. If MetLife, Inc.s common stock does not meet
this requirement and we are, or become, a USRPHC,
non-U.S. holders
(regardless of the percentage of MetLife, Inc.s common
stock owned by such holders) would be subject to
U.S. federal income tax (including withholding thereof at
the rate of 10% on the gross proceeds paid to such holder) and
related reporting and filing requirements with respect to the
sale of MetLife, Inc.s common stock.
Non-U.S. holders
who own or may own (in each case, directly or indirectly) more
than 5% of MetLife, Inc.s common stock should consult
their tax advisors with respect to the tax consequences of a
disposition of MetLife, Inc.s common stock.
Information
Reporting and Backup Withholding Tax
Annual reports to the IRS and to each
non-U.S. holder
will be made reporting the amount of distributions paid to such
holder and the tax withheld from those distributions, if any.
These reporting requirements apply regardless of whether
withholding was reduced or eliminated by an applicable income
tax treaty. Copies of the information returns reporting those
distributions and withholding may also be made available under
the provisions of an applicable income tax treaty or agreement
to the tax authorities in the country in which the
non-U.S. holder
is a resident.
Under some circumstances, U.S. Treasury regulations require
backup withholding and additional information reporting on
reportable payments on common stock. The gross amount of
dividends paid to a
non-U.S. holder
that fails to certify its
non-U.S. holder
status in accordance with applicable U.S. Treasury
regulations generally will be reduced by backup withholding at
the applicable rate (currently 28%), unless the 30% rate of
withholding described above applies.
The payment of the proceeds of the sale or other disposition of
common stock by a
non-U.S. holder
to or through the U.S. office of any broker, U.S. or
foreign, generally will be reported to the IRS and reduced by
backup withholding, unless the
non-U.S. holder
either certifies under penalties of perjury that it is a
non-U.S. holder
and that certain other conditions are met, or otherwise
establishes an exemption. The payment of the proceeds from the
disposition of common stock by a
non-U.S. holder
to or through a
non-U.S. office
of a
non-U.S. broker
generally will not be reduced by backup withholding or reported
to the IRS. However, the payment of proceeds from the
disposition of common stock to or through a
non-U.S. office
of a broker that is a United States person or has certain
enumerated connections with the United States will be reported
to the IRS unless the broker has documentary evidence in its
files that the holder is a
non-U.S. holder
and certain other conditions are met, or the
non-U.S. holder
otherwise establishes an exemption.
Backup withholding is not an additional tax. Any amounts
withheld under the backup withholding rules from a payment to a
non-U.S. holder
can be refunded or credited against the
non-U.S. holders
U.S. federal income tax liability, if any; provided,
that the required information is furnished to the IRS in a
timely manner. These backup withholding and information
reporting rules are complex and
non-U.S. holders
are urged to consult their own tax advisors regarding the
application of these rules to them.
Newly
Enacted Legislation
Legislation was enacted on March 18, 2010 that generally
imposes a withholding tax of 30% on dividends paid with respect
to stock of U.S. issuers and the gross proceeds of a
disposition of such stock paid to a foreign financial
institution (other than with respect to dividends or gross
proceeds that are effectively connected with the conduct of a
trade or business in the United States), unless such institution
enters into an agreement with the U.S. government to
collect and provide to the U.S. tax authorities substantial
information regarding U.S. account holders of such
institution (which would include certain account holders that
are foreign entities with U.S. owners). For this purpose, a
foreign financial institution includes, among others, a
non-U.S. entity
that (i) is a bank, (ii) holds, as a substantial
portion of its business, financial assets for the account for
others or (iii) is engaged primarily in the business of
investing, reinvesting or trading in securities, partnership
interests, commodities or any interest in securities,
partnership interests or commodities. The legislation also
generally imposes a withholding tax of 30% on dividends from
such stock and the gross proceeds of a disposition of such stock
paid to a non-financial foreign entity
S-70
(other than with respect to dividends or gross proceeds that are
effectively connected with the conduct of a trade or business in
the United States), unless such entity provides the withholding
agent with a certification that it does not have any substantial
U.S. owners or a certification identifying the direct and
indirect substantial U.S. owners of the entity. These
reporting requirements generally will not apply to any payment
beneficially owned by (i) a non-financial foreign entity
that is a corporation the stock of which is regularly traded on
an established securities market, (ii) certain corporations
that are affiliated with an entity described in clause (i), or
(iii) certain other specified types of entities. Under
certain circumstances (for example, if the recipient is a
resident in a country having a tax treaty with the United
States), a holder of such stock might be eligible for refunds or
credits of such taxes. The newly enacted withholding and
reporting requirements generally will apply to payments made on
or after January 1, 2013. The legislation also imposes new
U.S. return disclosure obligations (and related penalties
for failure to disclose) on individuals required to file
U.S. federal income tax returns that hold certain specified
foreign financial assets (which include financial accounts in
foreign financial institutions). Potential investors are urged
to consult with their own tax advisors regarding the possible
implications of this recently enacted legislation on their
investment in MetLife, Inc.s common stock.
The foregoing discussion of U.S. federal income tax
considerations is for general information purposes only and is
not tax or legal advice. Accordingly, you should consult your
own tax advisor as to the particular tax consequences to you of
purchasing, owning and disposing of MetLife, Inc.s common
stock, including the applicability and effect of any
U.S. federal, state, local or
non-U.S. tax
laws, and of any changes or proposed changes in applicable
law.
S-71
UNDERWRITING
Goldman, Sachs & Co., Citigroup Global Markets Inc.
and Credit Suisse Securities (USA) LLC are acting as
representatives of the underwriters named below. Subject to the
terms and conditions set forth in an underwriting agreement
among MetLife, Inc., AIG, the Selling Stockholder and the
underwriters, MetLife, Inc. and the Selling Stockholder have
agreed to sell to each of the underwriters named below, and each
of the underwriters has severally agreed to purchase, the
respective number of shares of common stock set forth in the
following table:
|
|
|
|
|
|
|
Number of
|
|
Underwriter
|
|
Shares
|
|
|
Goldman, Sachs & Co.
|
|
|
36,408,810
|
|
Citigroup Global Markets Inc.
|
|
|
14,680,973
|
|
Credit Suisse Securities (USA) LLC
|
|
|
11,010,730
|
|
Barclays Capital Inc.
|
|
|
8,808,583
|
|
Deutsche Bank Securities Inc.
|
|
|
8,808,583
|
|
J.P. Morgan Securities LLC
|
|
|
8,808,583
|
|
Merrill Lynch, Pierce, Fenner & Smith Incorporated
|
|
|
8,808,583
|
|
Morgan Stanley & Co. Incorporated
|
|
|
8,808,583
|
|
UBS Securities LLC
|
|
|
8,808,583
|
|
Wells Fargo Securities, LLC
|
|
|
8,808,583
|
|
BNP Paribas Securities Corp.
|
|
|
1,194,443
|
|
HSBC Securities (USA) Inc.
|
|
|
1,194,443
|
|
Mizuho Securities USA Inc.
|
|
|
1,194,443
|
|
Nomura Securities North America, LLC
|
|
|
1,194,443
|
|
Piper Jaffray & Co.
|
|
|
1,194,443
|
|
PNC Capital Markets LLC
|
|
|
1,194,443
|
|
RBC Capital Markets, LLC
|
|
|
1,194,443
|
|
RBS Securities Inc.
|
|
|
1,194,443
|
|
Scotia Capital (USA) Inc.
|
|
|
1,194,443
|
|
SG Americas Securities, LLC
|
|
|
1,194,443
|
|
SMBC Nikko Capitals Markets Limited
|
|
|
1,194,443
|
|
Cabrera Capital Markets, LLC
|
|
|
852,295
|
|
CastleOak Securities, L.P.
|
|
|
852,295
|
|
Guzman & Company
|
|
|
852,295
|
|
Lebenthal & Co., LLC
|
|
|
852,295
|
|
Loop Capital Markets LLC
|
|
|
852,295
|
|
MFR Securities, Inc.
|
|
|
852,295
|
|
M.R. Beal & Company
|
|
|
852,295
|
|
Muriel Siebert & Co., Inc.
|
|
|
852,295
|
|
Samuel A. Ramirez & Company, Inc.
|
|
|
852,295
|
|
The Williams Capital Group, L.P.
|
|
|
852,295
|
|
Toussaint Capital Partners, LLC
|
|
|
852,295
|
|
Blaylock Robert Van, LLC
|
|
|
535,000
|
|
|
|
|
|
|
Total
|
|
|
146,809,712
|
|
|
|
|
|
|
Subject to the terms and conditions set forth in the
underwriting agreement, the underwriters have agreed, severally
and not jointly, to purchase all of the shares sold under the
underwriting agreement if any of these shares are purchased. If
an underwriter defaults, the underwriting agreement provides
that the purchase commitments of the non-defaulting underwriters
may be increased or the underwriting agreement may be terminated.
S-72
MetLife, Inc., AIG and the Selling Stockholder have agreed to
indemnify the several underwriters against certain liabilities,
including liabilities under the Securities Act, or to contribute
to payments the underwriters may be required to make in respect
of those liabilities.
The underwriters are offering the shares of common stock,
subject to prior sale, when, as and if issued to and accepted by
them, subject to the conditions contained in the underwriting
agreement, such as the receipt by the underwriters of
officers certificates and legal opinions. It is a
condition to the closing of the MetLife, Inc. offering of common
stock pursuant to this prospectus supplement that all of the
closing conditions of the Repurchase transaction (except the
condition that the offering of the shares of common stock by
MetLife, Inc. pursuant to this prospectus supplement has been
consummated) under the Coordination Agreement will need to be
satisfied or waived. It is a condition to the closing of the
Selling Stockholder offering of common stock that the
Coordination Agreement is in full force and effect. The
underwriters reserve the right to withdraw, cancel or modify
offers to the public and to reject orders in whole or in part.
If fewer than 146,809,712 shares of the common stock can be
sold in this offering, the number of shares that can be sold
will be allocated first, to the shares of common stock that
MetLife, Inc. proposes to sell, and second, to the shares of
common stock that the Selling Stockholder proposes to sell.
Commissions
and Discounts
The representatives have advised MetLife, Inc. and the Selling
Stockholder that the underwriters propose initially to offer the
shares to the public at the public offering price set forth on
the cover page of this prospectus supplement and to dealers at
that price less a concession not in excess of $0.129750 per
share. After the initial offering, the public offering price,
concession or any other term of the offering may be changed.
The following table shows the public offering price,
underwriting discounts and commissions and proceeds before
expenses.
|
|
|
|
|
|
|
|
|
|
|
Per Share
|
|
Total
|
|
Public offering price
|
|
$
|
43.25000
|
|
|
$
|
6,349,520,044.00
|
|
Underwriting discounts and commissions
|
|
$
|
0.21625
|
|
|
$
|
31,747,600.22
|
|
Proceeds, before expenses, to MetLife, Inc.
|
|
$
|
43.03375
|
|
|
$
|
2,950,824,237.50
|
|
Proceeds, before expenses, to the Selling Stockholder
|
|
$
|
43.03375
|
|
|
$
|
3,366,948,206.28
|
|
The expenses of the offering, not including the underwriting
discounts and commissions, to MetLife, Inc. are estimated at
$1 million.
No Sales
of Similar Securities
MetLife, Inc., its executive officers and directors, the Selling
Stockholder and AIG have each agreed not to sell or transfer any
common stock or securities convertible into, exchangeable for or
exercisable for common stock, for 60 days after the date of
this prospectus supplement without first obtaining the written
consent of Goldman, Sachs & Co. Specifically, MetLife,
Inc., its executive officers and directors, the Selling
Stockholder and AIG have agreed, with certain limited exceptions
(including securities issued by MetLife, Inc. under its benefit
plans and securities held by affiliates of AIG and the Selling
Stockholder in connection with ordinary course (i) proprietary
and third party fund and asset management activities, (ii)
brokerage and securities trading activities and
(iii) financial services and insurance activities), not to
directly or indirectly:
|
|
|
|
|
offer, sell, issue, contract to sell, pledge or otherwise
dispose of any shares of the common stock or securities
convertible into or exchangeable or exercisable for any shares
of the common stock;
|
|
|
|
enter into a transaction that would have the same effect as
described above;
|
|
|
|
enter into any swap, hedge or other arrangement that transfers,
in whole or in part, any of the economic consequences of
ownership of the common stock;
|
S-73
|
|
|
|
|
in the case of MetLife, Inc., the Selling Stockholder and AIG,
establish or increase a put equivalent position or liquidate or
decrease a call equivalent position in the common stock;
|
|
|
|
in the case of our executive officers and directors, demand that
we file a registration statement related to the common stock;
|
|
|
|
in the case of MetLife, Inc., file a registration statement
related to the common stock; or
|
|
|
|
in the case of MetLife, Inc., publicly disclose the intention to
take any of the foregoing actions;
|
in each case, without the prior written consent of Goldman,
Sachs & Co.
New York
Stock Exchange Listing
The shares of common stock are listed on the New York Stock
Exchange under the symbol MET.
Price
Stabilization, Short Positions
Until the distribution of the shares is completed, SEC rules may
limit underwriters and selling group members from bidding for
and purchasing the common stock. However, the representatives
may engage in transactions that stabilize the price of the
common stock, such as bids or purchases to peg, fix or maintain
that price.
In connection with the offering, the underwriters may purchase
and sell the common stock in the open market. These transactions
may include short sales, stabilizing transactions, purchases on
the open market to cover positions created by short sales and
stabilizing transactions. Short sales involve the sale by the
underwriters of a greater number of shares than they are
required to purchase in the offering. The underwriters will need
to close out any short sale by purchasing shares in the open
market. The underwriters are likely to create a short position
if they are concerned that there may be downward pressure on the
price of common stock in the open market after pricing that
could adversely affect investors who purchase in the offering.
Stabilizing transactions consist of various bids for or
purchases of shares of common stock made by the underwriters in
the open market prior to the completion of the offering. The
underwriters may also impose a penalty bid. This occurs when a
particular underwriter repays to the underwriters a portion of
the underwriting discount received by it because the
representatives have repurchased shares sold by or for the
account of such underwriter in stabilizing or short covering
transactions.
Similar to other purchase transactions, the underwriters
purchases to cover the syndicate short sales may have the effect
of raising or maintaining the market price of the common stock
or preventing or retarding a decline in the market price of the
common stock. As a result, the price of the common stock may be
higher than the price that might otherwise exist in the open
market. The underwriters may conduct these transactions on the
New York Stock Exchange, in the
over-the-counter
market or otherwise.
Neither MetLife, Inc. nor any of the underwriters makes any
representation or prediction as to the direction or magnitude of
any effect that the transactions described above may have on the
price of the common stock. In addition, neither MetLife, Inc.
nor any of the underwriters makes any representation that the
representatives will engage in these transactions or that these
transactions, once commenced, will not be discontinued without
notice.
Electronic
Offer, Sale and Distribution of Shares
In connection with the offering, certain of the underwriters or
securities dealers may distribute prospectuses by electronic
means, such as
e-mail. In
addition, one or more of the underwriters may facilitate
Internet distribution for this offering to certain of its
Internet subscription customers. One or more of the underwriters
may allocate a limited number of shares for sale to its online
brokerage customers. An electronic prospectus is available on
the Internet web site maintained by one or more of the
underwriters. Other than the prospectus in electronic format,
the information on such underwriters web site is neither
part of this prospectus supplement nor of the accompanying
prospectus.
Other
Relationships
In the ordinary course of their respective businesses, the
underwriters and their affiliates have engaged, and may in the
future engage, in commercial, investment or retail banking
transactions with us and our affiliates for which they have in
the past received, and may in the future receive, customary fees.
S-74
In the ordinary course of their various business activities, the
underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial
instruments (including bank loans) for their own account and for
the accounts of their customers and such investment and
securities activities may involve securities
and/or
instruments of MetLife, Inc. The underwriters and their
respective affiliates may also make investment recommendations
and/or
publish or express independent research views in respect of such
securities or instruments and may at any time hold, or recommend
to clients that they acquire, long
and/or short
positions in such securities and instruments.
Nomura Securities North America, LLC, a U.S. broker dealer,
will offer and sell shares of the common stock to investors
through Nomura Securities International, Inc., an affiliated
U.S. broker dealer.
Each underwriter has represented and agreed with MetLife, Inc.
as set forth below with respect to the following jurisdictions:
Notice to
Prospective Investors in the EEA
In relation to each Member State of the European Economic Area
which has implemented the Prospectus Directive (each, a Relevant
Member State), with effect from and including the date on which
the Prospectus Directive is implemented in that Relevant Member
State, it has not made and will not make an offer of common
stock which is the subject of the offering contemplated by this
prospectus supplement to the public in that Relevant Member
State other than:
(a) to any legal entity which is a qualified investor as
defined in the Prospectus Directive;
(b) to fewer than 100 or, if the Relevant Member State has
implemented the relevant provision of the 2010 PD Amending
Directive, 150, natural or legal persons (other than qualified
investors as defined in the Prospectus Directive), as permitted
under the Prospectus Directive, subject to obtaining the prior
consent of the representatives for any such offer; or
(c) in any other circumstances falling within
Article 3(2) of the Prospectus Directive,
provided that no such offer of common stock shall require
MetLife, Inc. or any representative to publish a prospectus
pursuant to Article 3 of the Prospectus Directive or
supplement a prospectus pursuant to Article 16 of the
Prospectus Directive.
For the purposes of this provision, the expression an
offer to the public in relation to any common stock
in any Relevant Member State means the communication in any form
and by any means of sufficient information on the terms of the
offer and any common stock to be offered so as to enable an
investor to decide to purchase or subscribe the common stock, as
the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State, the
expression Prospectus Directive means Directive
2003/71/EC (and amendments thereto, including the 2010 PD
Amending Directive, to the extent implemented in the Relevant
Member State) and includes any relevant implementing measure in
each Relevant Member State and the expression 2010 PD
Amending Directive means Directive 2010/73/EU.
Notice to
Prospective Investors in the United Kingdom
(a) It has only communicated or caused to be communicated
and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity
(within the meaning of Section 21 of the Financial Services
and Market Act 2000, or FSMA) received by it in connection with
the issue or sale of the common stock in circumstances in which
Section 21(1) of the FSMA does not apply to MetLife, Inc.
or any representative; and
(b) It has complied and will comply with all applicable
provisions of the FSMA with respect to anything done by it in
relation to the common stock in, from or otherwise involving the
United Kingdom.
Notice to
Prospective Investors in Switzerland
This prospectus supplement (and the accompanying prospectus), as
well as any other material relating to the common stock which is
the subject of the offering contemplated by this prospectus
supplement (and the accompanying prospectus), do not constitute
an issue prospectus pursuant to Article 652a or
Article 1156 of the Swiss Code of Obligations. The common
stock will not be listed on the SIX Swiss Exchange and,
therefore, the documents relating to the common stock,
including, but not limited to, this prospectus supplement (and
the accompanying prospectus) may not comply with the disclosure
standards of the listing rules (including any additional listing
rules or prospectus
S-75
schemes) of the SIX Swiss Exchange. The common stock is being
offered in Switzerland by way of a private placement,
i.e., to a small number of selected investors
only, without any public offer and only to investors who do not
purchase the common stock with the intention to distribute it to
the public. The investors will be individually approached by the
issuer from time to time. This prospectus supplement (and the
accompanying prospectus) as well as any other material relating
to the common stock, is personal and confidential and does not
constitute an offer to any other person. This prospectus
supplement (and the accompanying prospectus) may only be used by
those investors to whom it has been handed out in connection
with the offering described herein and may neither directly nor
indirectly be distributed or made available to other persons
without express consent of the issuer. It may not be used in
connection with any other offer and shall in particular not be
copied
and/or
distributed to the public in (or from) Switzerland.
Notice to
Prospective Investors in the Dubai International Financial
Centre
This prospectus supplement (and the accompanying prospectus)
relates to an exempt offer in accordance with the Offered
Securities Rules of the Dubai Financial Services Authority. This
prospectus supplement (and the accompanying prospectus) is
intended for distribution only to persons of a type specified in
those rules. It must not be delivered to, or relied on by, any
other person. The Dubai Financial Services Authority has no
responsibility for reviewing or verifying any documents in
connection with exempt offers. The Dubai Financial Services
Authority has not approved this prospectus supplement (and the
accompanying prospectus) nor taken steps to verify the
information set out in it, and has no responsibility for it. The
common stock which is the subject of the offering contemplated
by this prospectus supplement may be illiquid
and/or
subject to restrictions on their resale. Prospective purchasers
of the common stock offered should conduct their own due
diligence on the common stock. If you do not understand the
contents of this prospectus supplement (and the accompanying
prospectus) you should consult an authorized financial adviser.
Notice to
Prospective Investors in Australia
This prospectus supplement (and the accompanying prospectus) is
not a formal disclosure document and has not been, nor will be,
lodged with the Australian Securities and Investments
Commission. This prospectus supplement (and the accompanying
prospectus) does not purport to contain all information that
investors or their professional advisers would expect to find in
a prospectus or other disclosure document (as defined in the
Corporations Act 2001 (Australia)) for the purposes of
Part 6D.2 of the Corporations Act 2001 (Australia) or in a
product disclosure statement for the purposes of Part 7.9
of the Corporations Act 2001 (Australia), in either case, in
relation to the common stock.
The common stock is not being offered in Australia to
retail clients as defined in sections 761G and
761GA of the Corporations Act 2001 (Australia). This offering is
being made in Australia solely to wholesale clients
for the purposes of section 761G of the Corporations Act
2001 (Australia) and, as such, no prospectus, product disclosure
statement or other disclosure document in relation to the common
stock has been, or will be, prepared.
This prospectus supplement (and the accompanying prospectus)
does not constitute an offer in Australia other than to
wholesale clients. By submitting an application for the common
stock, you represent and warrant to us that you are a wholesale
client for the purposes of section 761G of the Corporations
Act 2001 (Australia). If any recipient of this prospectus
supplement (and the accompanying prospectus) is not a wholesale
client, no offer of, or invitation to apply for, the common
stock shall be deemed to be made to such recipient and no
applications for the common stock will be accepted from such
recipient. Any offer to a recipient in Australia, and any
agreement arising from acceptance of such offer, is personal and
may only be accepted by the recipient. In addition, by applying
the common stock you undertake to us that, for a period of
12 months from the date of issue of the common stock, you
will not transfer any interest in the common stock to any person
in Australia other than to a wholesale client.
Notice to
Prospective Investors in Hong Kong
The common stock may not be offered or sold by means of any
document other than (i) in circumstances which do not
constitute an offer to the public within the meaning of the
Companies Ordinance (Cap. 32, Laws of Hong Kong), or
(ii) to professional investors within the
meaning of the Securities and Futures Ordinance (Cap. 571, Laws
of Hong Kong) and any rules made thereunder, or (iii) in
other circumstances which do not result in this prospectus
supplement (and the accompanying prospectus) being a
prospectus within the meaning of the Companies
Ordinance
S-76
(Cap. 32, Laws of Hong Kong), and no advertisement, invitation
or document relating to the common stock may be issued or may be
in the possession of any person for the purpose of issue (in
each case, whether in Hong Kong or elsewhere), which is directed
at, or the contents of which are likely to be accessed or read
by, the public in Hong Kong (except if permitted to do so under
the laws of Hong Kong) other than with respect to the common
stock which is or is intended to be disposed of only to persons
outside Hong Kong or only to professional investors
within the meaning of the Securities and Futures Ordinance (Cap.
571, Laws of Hong Kong) and any rules made thereunder.
Notice to
Prospective Investors in Japan
The common stock has not been and will not be registered under
the Financial Instruments and Exchange Law of Japan (the
Financial Instruments and Exchange Law) and
each underwriter has agreed that it will not offer or sell any
common stock, directly or indirectly, in Japan or to, or for the
benefit of, any resident of Japan (which term as used herein
means any person resident in Japan, including any corporation or
other entity organized under the laws of Japan), or to others
for re-offering or resale, directly or indirectly, in Japan or
to a resident of Japan, except pursuant to an exemption from the
registration requirements of, and otherwise in compliance with,
the Financial Instruments and Exchange Law and any other
applicable laws, regulations and ministerial guidelines of Japan.
Notice to
Prospective Investors in Singapore
Neither this prospectus supplement nor the accompanying
prospectus has been registered as a prospectus with the Monetary
Authority of Singapore. Accordingly, this prospectus supplement,
the accompanying prospectus or any other document or material in
connection with the offer or sale, or invitation for
subscription or purchase, of the common stock may not be
circulated or distributed, nor may the common stock be offered
or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to
persons in Singapore other than (i) to an institutional
investor under Section 274 of the Securities and Futures
Act, Chapter 289 of Singapore (the SFA),
(ii) to a relevant person, or any person pursuant to
Section 275(1A), and in accordance with the conditions,
specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA.
Where the common stock is subscribed or purchased under
Section 275 by a relevant person which is: (a) a
corporation (which is not an accredited investor) the sole
business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of
whom is an accredited investor; or (b) a trust (where the
trustee is not an accredited investor) whose sole purpose is to
hold investments and each beneficiary is an accredited investor,
common stock, debentures and units of common stock and
debentures of that corporation or the beneficiaries rights
and interest in that trust shall not be transferable for
6 months after that corporation or that trust has acquired
the common stock under Section 275 except: (1) to an
institutional investor under Section 274 of the SFA or to a
relevant person, or any person pursuant to Section 275(1A),
and in accordance with the conditions, specified in
Section 275 of the SFA; (2) where no consideration is
given for the transfer; or (3) by operation of law.
S-77
LEGAL
OPINIONS
Certain legal matters will be passed upon for MetLife, Inc. by
Matthew Ricciardi, Chief Counsel Public Company and
Corporate Law, of MetLife Group, Inc., an affiliate of MetLife,
Inc. The validity of the common stock offered hereby will be
passed upon by Dewey & LeBoeuf LLP, New York, New
York, which has also acted as special tax counsel for MetLife,
Inc. Certain legal matters will be passed upon for the Selling
Stockholder by Sullivan & Cromwell LLP, New York, New
York. Mr. Ricciardi is paid a salary by an affiliate of
MetLife, Inc., is a participant in various employee benefit
plans offered by MetLife, Inc. and its affiliates to employees
generally, is paid equity-based compensation in accordance with
MetLifes compensation programs and owns MetLife, Inc.
common stock. Dewey & LeBoeuf LLP has, from time to
time, represented, currently represents, and may continue to
represent, some or all of the underwriters in connection with
various legal matters. Dewey & LeBoeuf LLP maintains
various group and other insurance policies with MLIC.
Debevoise & Plimpton LLP, New York, New York is acting
as counsel to the underwriters. Debevoise & Plimpton
LLP has in the past provided, and continues to provide, legal
services to MetLife, Inc. and certain of its affiliates, and to
AIG and certain of its affiliates. Debevoise &
Plimpton LLP maintains various group insurance policies with
MLIC.
EXPERTS
The consolidated financial statements and financial statement
schedules, incorporated by reference in this prospectus
supplement from the 2010
Form 10-K,
and the effectiveness of MetLifes internal control over
financial reporting for the year ended December 31, 2010,
have been audited by Deloitte & Touche LLP, an
independent registered public accounting firm, as stated in
their reports (which (1) express an unqualified opinion on
the consolidated financial statements and financial statement
schedules and includes an explanatory paragraph regarding
changes in MetLifes method of accounting for the
recognition and presentation of
other-than-temporary
impairment losses for certain investments as required by
accounting guidance adopted on April 1, 2009, and its
method of accounting for certain assets and liabilities to a
fair value measurement approach as required by accounting
guidance adopted on January 1, 2008, and (2) express
an unqualified opinion on MetLifes effectiveness of
internal control over financial reporting), which are
incorporated herein by reference. Such consolidated financial
statements and financial statement schedules have been so
incorporated in reliance upon the reports of such firm given
upon their authority as experts in accounting and auditing.
The audited historical combined financial statements of American
Life, ALICO Services, Inc. and DelAm and subsidiaries
(collectively, the Company) included as
Exhibit 99.1 to MetLife, Inc.s Current Report on
Form 8-K
dated August 2, 2010 and incorporated by reference in this
prospectus supplement have been so incorporated in reliance on
the report (which contains an explanatory paragraph related to
the Companys change in method of accounting for
other-than-temporary
impairments of fixed maturity securities as of March 1,
2009) of PricewaterhouseCoopers LLP, an independent
registered public accounting firm, given on the authority of
said firm as experts in auditing and accounting.
S-78
PROSPECTUS
METLIFE,
INC.
DEBT SECURITIES, PREFERRED STOCK,
DEPOSITARY SHARES,
COMMON STOCK, WARRANTS, PURCHASE CONTRACTS AND UNITS
METLIFE
CAPITAL TRUST V
METLIFE CAPITAL TRUST VI
METLIFE CAPITAL TRUST VII
METLIFE CAPITAL TRUST VIII
METLIFE CAPITAL TRUST IX
TRUST PREFERRED
SECURITIES
Fully and Unconditionally Guaranteed by MetLife, Inc.,
As Described in this Prospectus and the Accompanying Prospectus
Supplement
MetLife, Inc., or any of the trusts named above, may offer these
securities, or any combination thereof, from time to time in
amounts, at prices and on other terms to be determined at the
time of the offering. MetLife, Inc., or any of the trusts named
above, will provide the specific terms of these securities in
supplements to this prospectus. You should read this prospectus
and the accompanying prospectus supplement carefully before you
make your investment decision.
THIS PROSPECTUS MAY NOT BE USED TO SELL SECURITIES UNLESS
ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.
MetLife, Inc., or any of the trusts named above, may offer
securities through underwriting syndicates managed or co-managed
by one or more underwriters, through agents, or directly to
purchasers. The prospectus supplement for each offering of
securities will describe in detail the plan of distribution for
that offering. For general information about the distribution of
securities offered, please see Plan of Distribution
in this prospectus.
MetLife, Inc.s common stock is listed on the New York
Stock Exchange under the trading symbol MET. Unless
otherwise stated in this prospectus or an accompanying
prospectus supplement, none of these securities will be listed
on a securities exchange, other than MetLife, Inc.s common
stock.
MetLife, Inc., or any of the trusts named above, or any of their
respective affiliates may use this prospectus and the applicable
prospectus supplement in a remarketing or other resale
transaction involving the securities after their initial sale.
These transactions may be executed at negotiated prices that are
related to market prices at the time of purchase or sale, or at
other prices, as determined from time to time.
Investing in our securities or the securities of the trusts
involves risk. See Risk Factors on page 1 of
this prospectus.
None of the Securities and Exchange Commission, any state
securities commission, the New York Superintendent of Insurance
or any other regulatory body has approved or disapproved of
these securities or determined if this prospectus or the
accompanying prospectus supplement is truthful or complete. They
have not made, nor will they make, any determination as to
whether anyone should buy these securities. Any representation
to the contrary is a criminal offense.
The date of this prospectus is November 30, 2010
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
15
|
|
|
|
|
21
|
|
|
|
|
23
|
|
|
|
|
24
|
|
|
|
|
25
|
|
|
|
|
25
|
|
|
|
|
28
|
|
|
|
|
30
|
|
|
|
|
32
|
|
|
|
|
32
|
|
i
ABOUT
THIS PROSPECTUS
Unless otherwise stated or the context otherwise requires,
references in this prospectus to MetLife,
we, our, or us refer to
MetLife, Inc., and its direct and indirect subsidiaries, while
references to MetLife, Inc. refer only to MetLife,
Inc. on an unconsolidated basis. References in this prospectus
to the trusts refer to MetLife Capital Trust V,
MetLife Capital Trust VI, MetLife Capital Trust VII,
MetLife Capital Trust VIII and MetLife Capital
Trust IX.
This prospectus is part of a registration statement that
MetLife, Inc. and the trusts filed with the U.S. Securities
and Exchange Commission (the SEC) using a
shelf registration process. Under this shelf
process, MetLife, Inc. may, from time to time, sell any
combination of debt securities, preferred stock, depositary
shares, common stock, warrants, purchase contracts and units and
the trusts may, from time to time, sell trust preferred
securities guaranteed by MetLife, Inc., as described in this
prospectus, in one or more offerings in one or more foreign
currencies, foreign currency units or composite currencies. This
prospectus provides you with a general description of the
securities MetLife, Inc. and the trusts may offer. Each time
that securities are sold, a prospectus supplement that will
contain specific information about the terms of that offering
will be provided. The prospectus supplement may also add, update
or change information contained in this prospectus. You should
read both this prospectus and any prospectus supplement together
with additional information described under the heading
Where You Can Find More Information.
You should rely on the information contained or incorporated by
reference in this prospectus. Neither MetLife, Inc. nor the
trusts have authorized anyone to provide you with different
information. If anyone provides you with different or
inconsistent information, you should not rely on it. Neither
MetLife, Inc. nor the trusts are making an offer to sell these
securities in any jurisdiction where the offer or sale is not
permitted.
You should assume that the information in this prospectus is
accurate as of the date of the prospectus. Our business,
financial condition, results of operations and prospects may
have changed since that date.
RISK
FACTORS
Investing in MetLife, Inc. securities or the securities of the
trusts involve risks. We urge you to carefully consider the risk
factors described in our filings with the SEC that are
incorporated by reference in this prospectus and, if applicable,
in any prospectus supplement, pricing supplement or free writing
prospectus used in connection with an offering of our
securities, as well as the information relating to us identified
herein in Note Regarding Forward-Looking Statements,
before making an investment decision.
NOTE REGARDING
FORWARD-LOOKING STATEMENTS
This prospectus and the accompanying prospectus supplement may
contain or incorporate by reference information that includes or
is based upon forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements give expectations or forecasts of
future events. These statements can be identified by the fact
that they do not relate strictly to historical or current facts.
They use words such as anticipate,
estimate, expect, project,
intend, plan, believe and
other words and terms of similar meaning in connection with a
discussion of future operating or financial performance. In
particular, these include statements relating to future actions,
prospective services or products, future performance or results
of current and anticipated services or products, sales efforts,
expenses, the outcome of contingencies such as legal
proceedings, trends in operations and financial results.
Any or all forward-looking statements may turn out to be wrong.
They can be affected by inaccurate assumptions or by known or
unknown risks and uncertainties. Many such factors will be
important in determining MetLifes actual future results.
These statements are based on current expectations and the
current economic environment. They involve a number of risks and
uncertainties that are difficult to predict. These statements
are not guarantees of future performance. Actual results could
differ materially from those expressed or implied in the
forward-looking statements. Risks, uncertainties, and other
factors that might cause such differences include the risks,
uncertainties and other factors identified in MetLife,
Inc.s filings with the U.S. Securities and Exchange
1
Commission (the SEC). These factors include:
(1) the imposition of onerous conditions following the
acquisition of American Life Insurance Company
(ALICO), a subsidiary of ALICO Holdings LLC
(ALICO Holdings) and Delaware American Life
Insurance Company (DelAm) (collectively, the
Acquisition); (2) difficulties in integrating
the business acquired in the Acquisition (the Alico
Business); (3) uncertainty with respect to the
outcome of the closing agreement entered into between ALICO and
the United States Internal Revenue Service in connection with
the Acquisition; (4) uncertainty with respect to the making
of elections under Section 338 of the U.S. Internal
Revenue Code of 1986, as amended, and any benefits therefrom;
(5) an inability to manage the growth of the Alico
Business; (6) a writedown of the goodwill established in
connection with the Acquisition; (7) exchange rate
fluctuations; (8) an inability to predict the financial
impact of the Acquisition on MetLifes business and
financial results; (9) events relating to American
International Group, Inc. (AIG) that could adversely
affect the Alico Business or MetLife; (10) the dilutive
impact on MetLife, Inc.s stockholders resulting from the
issuance of equity securities to ALICO Holdings in connection
with the Acquisition; (11) a decrease in MetLife,
Inc.s stock price as a result of ALICO Holdings
ability to sell its equity securities; (12) the conditional
payment obligation of approximately $300 million to ALICO
Holdings if the conversion of the Series B Contingent
Convertible Junior Participating Non-Cumulative Perpetual
Preferred Stock (Series B Preferred Stock)
issued to ALICO Holdings in connection with the Acquisition into
MetLife, Inc.s common stock is not approved;
(13) change of control provisions in the Alico
Business agreements; (14) effects of guarantees
within certain of the Alico Business variable life and
annuity products; (15) regulatory action in the financial
services industry affecting the combined business;
(16) financial instability in Europe and possible
writedowns of sovereign debt of European nations;
(17) difficult conditions in the global capital markets;
(18) increased volatility and disruption of the capital and
credit markets, which may affect MetLifes ability to seek
financing or access its credit facilities; (19) uncertainty
about the effectiveness of the U.S. governments
programs to stabilize the financial system, the imposition of
fees relating thereto, or the promulgation of additional
regulations; (20) impact of comprehensive financial
services regulation reform on MetLife; (21) exposure to
financial and capital market risk; (22) changes in general
economic conditions, including the performance of financial
markets and interest rates, which may affect MetLifes
ability to raise capital, generate fee income and market-related
revenue and finance statutory reserve requirements and may
require MetLife to pledge collateral or make payments related to
declines in value of specified assets; (23) potential
liquidity and other risks resulting from MetLifes
participation in a securities lending program and other trans
actions; (24) investment losses and defaults, and changes
to investment valuations; (25) impairments of goodwill and
realized losses or market value impairments to illiquid assets;
(26) defaults on MetLifes mortgage loans;
(27) the impairment of other financial institutions;
(28) MetLifes ability to address unforeseen
liabilities, asset impairments, or rating actions arising from
any future acquisitions or dispositions, and to successfully
integrate acquired businesses with minimal disruption;
(29) economic, political, currency and other risks relating
to MetLifes international operations; (30) MetLife,
Inc.s primary reliance, as a holding company, on dividends
from its subsidiaries to meet debt payment obligations and the
applicable regulatory restrictions on the ability of the
subsidiaries to pay such dividends; (31) downgrades in
MetLife, Inc.s and its affiliates claims paying
ability, financial strength or credit ratings;
(32) ineffectiveness of risk management policies and
procedures; (33) availability and effectiveness of
reinsurance or indemnification arrangements, as well as default
or failure of counterparties to perform; (34) discrepancies
between actual claims experience and assumptions used in setting
prices for MetLifes products and establishing the
liabilities for MetLifes obligations for future policy
benefits and claims; (35) catastrophe losses;
(36) heightened competition, including with respect to
pricing, entry of new competitors, consolidation of
distributors, the development of new products by new and
existing competitors, distribution of amounts available under
U.S. government programs, and for personnel;
(37) unanticipated changes in industry trends;
(38) changes in accounting standards, practices
and/or
policies; (39) changes in assumptions related to deferred
policy acquisition costs (DAC), deferred sales
inducements (DSI), value of business acquired
(VOBA) or goodwill; (40) increased expenses
relating to pension and postretirement benefit plans, as well as
health care and other employee benefits; (41) exposure to
losses related to variable annuity guarantee benefits, including
from significant and sustained downturns or extreme volatility
in equity markets, reduced interest rates, unanticipated
policyholder behavior, mortality or longevity, and the
adjustment for nonperformance risk; (42) deterioration in
the experience of the closed block established in
connection with the reorganization of Metropolitan Life
Insurance Company; (43) adverse results or other
consequences from litigation, arbitration or regulatory
investigations; (44) discrepancies between actual
experience and assumptions used in establishing liabilities
related to other contingencies or obligations;
(45) regulatory, legislative or tax changes relating to
MetLifes insurance,
2
banking, international, or other operations that may affect the
cost of, or demand for, MetLifes products or services,
impair its ability to attract and retain talented and
experienced management and other employees, or increase the cost
or administrative burdens of providing benefits to employees;
(46) the effects of business disruption or economic
contraction due to terrorism, other hostilities, or natural
catastrophes; (47) the effectiveness of MetLifes
programs and practices in avoiding giving its associates
incentives to take excessive risks; (48) other risks and
uncertainties described from time to time in MetLife,
Inc.s filings with the SEC; and (49) any of the
foregoing factors as they relate to the Alico Business and its
operations.
MetLife, Inc. does not undertake any obligation to publicly
correct or update any forward-looking statement if MetLife, Inc.
later becomes aware that such statement is not likely to be
achieved. Please consult any further disclosures MetLife, Inc.
makes on related subjects in reports to the SEC.
NOTE REGARDING
RELIANCE ON STATEMENTS IN OUR CONTRACTS
In reviewing the agreements included as exhibits to any of the
documents incorporated by reference into this prospectus and the
accompanying prospectus supplements, please remember that they
are included to provide you with information regarding their
terms and are not intended to provide any other factual or
disclosure information about MetLife, Inc., its subsidiaries or
the other parties to the agreements. The agreements contain
representations and warranties by each of the parties to the
applicable agreement. These representations and warranties have
been made solely for the benefit of the other parties to the
applicable agreement and:
|
|
|
|
|
should not in all instances be treated as categorical statements
of fact, but rather as a way of allocating the risk to one of
the parties if those statements prove to be inaccurate;
|
|
|
|
have been qualified by disclosures that were made to the other
party in connection with the negotiation of the applicable
agreement, which disclosures are not necessarily reflected in
the agreement;
|
|
|
|
may apply standards of materiality in a way that is different
from what may be viewed as material to investors; and
|
|
|
|
were made only as of the date of the applicable agreement or
such other date or dates as may be specified in the agreement
and are subject to more recent developments.
|
Accordingly, these representations and warranties may not
describe the actual state of affairs as of the date they were
made or at any other time. Additional information about MetLife,
Inc. and its subsidiaries may be found elsewhere in this
prospectus and the accompanying prospectus supplement, as well
as MetLife, Inc.s other public filings, which are
available without charge through the SEC website at www.sec.gov.
WHERE YOU
CAN FIND MORE INFORMATION
MetLife, Inc. files reports, proxy statements and other
information with the SEC. These reports, proxy statements and
other information, including the registration statement of which
this prospectus is a part, can be read and copied at the
SECs public reference room at 100 F Street,
N.E., Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330
for further information on the operation of the public reference
room. The SEC maintains an internet site at www.sec.gov that
contains reports, proxy and information statements and other
information regarding companies that file electronically with
the SEC, including MetLife, Inc. MetLife, Inc.s common
stock is listed and traded on the New York Stock Exchange under
the symbol MET. These reports, proxy statements and
other information can also be read at the offices of the New
York Stock Exchange, 11 Wall Street, New York, New York
10005.
The SEC allows incorporation by reference into this
prospectus of information that MetLife, Inc. files with the SEC.
This permits MetLife, Inc. to disclose important information to
you by referencing these filed documents. Any information
referenced this way is considered part of this prospectus, and
any information filed with the SEC subsequent to the date of
this prospectus will automatically be deemed to update and
supersede this information. Information furnished under
Item 2.02 and Item 7.01 of MetLife, Inc.s
Current Reports on
Form 8-K
is not
3
incorporated by reference in this registration statement and
prospectus. MetLife, Inc. incorporates by reference the
following documents which have been filed with the SEC:
|
|
|
|
|
Annual Report on
Form 10-K
and
Form 10-K/A
for the year ended December 31, 2009;
|
|
|
|
Quarterly Reports on
Form 10-Q
and
Form 10-Q/A
for the quarter ended March 31, 2010 and Quarterly Reports
on
Form 10-Q
for the quarters ended June 30, 2010 and September 30,
2010;
|
|
|
|
Registration Statement on
Form 8-A,
dated March 31, 2000, relating to registration of shares of
MetLife, Inc.s common stock;
|
|
|
|
Definitive Proxy Statement filed on March 23, 2010
(Proxy Statement); and
|
|
|
|
Current Reports on
Form 8-K
filed January 29, 2010, February 22, 2010,
March 5, 2010, March 11, 2010, April 13, 2010,
May 3, 2010, May 7, 2010, May 17, 2010,
August 2, 2010, August 5, 2010, August 6, 2010,
August 16, 2010, October 18, 2010, October 28,
2010, October 29, 2010, November 2, 2010,
November 15, 2010 and November 30, 2010.
|
MetLife, Inc. incorporates by reference the documents listed
above and any future filings made with the SEC in accordance
with Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934 until MetLife, Inc. and the trusts file a
post-effective amendment which indicates the termination of the
offering of the securities made by this prospectus. Any reports
filed by us with the SEC after the date of this prospectus and
before the date that the offering of the securities by means of
this prospectus is terminated will automatically update and,
where applicable, supersede any information contained in this
prospectus or incorporated by reference in this prospectus.
MetLife, Inc. will provide without charge upon written or oral
request, a copy of any or all of the documents which are
incorporated by reference into this prospectus, other than
exhibits to those documents, unless those exhibits are
specifically incorporated by reference into those documents.
Requests should be directed to Investor Relations, MetLife,
Inc., 1095 Avenue of the Americas, New York, New York 10036, by
electronic mail (metir@metlife.com) or by telephone
(212-578-2211).
You may also obtain some of the documents incorporated by
reference into this document at MetLifes website,
www.metlife.com. You should be aware that all other information
contained on MetLifes website is not a part of this
document.
METLIFE,
INC.
We are a leading provider of insurance, employee benefits and
financial services with operations throughout the United States
and the Latin America, Asia Pacific and Europe, Middle East and
India regions. Through our subsidiaries and affiliates, we offer
life insurance, annuities, auto and homeowners insurance, retail
banking and other financial services to individuals, as well as
group insurance and retirement & savings products and
services to corporations and other institutions.
As a holding company, the primary source of MetLife, Inc.s
liquidity is dividends it receives from its insurance
subsidiaries. MetLife, Inc.s insurance subsidiaries are
subject to regulatory restrictions on the payment of dividends
imposed by the regulators of their respective domiciles. The
dividend limitation for U.S. insurance subsidiaries is
based on the surplus to policyholders as of the immediately
preceding calendar year and statutory net gain from operations
of the immediately preceding calendar year. Statutory accounting
practices, as prescribed by insurance regulators of various
states in which we conduct business, differ in certain respects
from accounting principles used in financial statements prepared
in conformity with GAAP. The significant differences relate to
the treatment of DAC, certain deferred income tax, required
investment reserves, reserve calculation assumptions, goodwill
and surplus notes.
MetLife, Inc. is incorporated under the laws of the State of
Delaware. MetLife, Inc.s principal executive offices are
located at 200 Park Avenue, New York, New York
10166-0188,
and its telephone number is
212-578-2211.
4
THE
TRUSTS
MetLife Capital Trust V, MetLife Capital Trust VI,
MetLife Capital Trust VII, MetLife Capital Trust VIII
and MetLife Capital Trust IX are statutory trusts formed on
October 31, 2007 under Delaware law pursuant to
declarations of trust between the trustees named therein and
MetLife, Inc. and the filing of certificates of trust with the
Secretary of State of the State of Delaware. MetLife, Inc., as
sponsor of the trusts, and the trustees named in the
declarations of trust will amend and restate the declarations of
trust in their entirety substantially in the forms which are
incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part, as of or prior
to the date the trusts issue any trust preferred securities. The
declarations of trust will be qualified as indentures under the
Trust Indenture Act of 1939, as amended (the
Trust Indenture Act).
The trusts exist for the exclusive purposes of:
|
|
|
|
|
issuing preferred securities offered by this prospectus and
common securities to MetLife, Inc.;
|
|
|
|
investing the gross proceeds of the preferred securities and
common securities in related series of debt securities, which
may be senior or subordinated, issued by MetLife, Inc.; and
|
|
|
|
engaging in only those other activities which are necessary,
appropriate, convenient or incidental to the purposes set forth
above.
|
The payment of periodic cash distributions on the trust
preferred securities and payments on liquidation and redemption
with respect to the trust preferred securities, in each case to
the extent the trusts have funds legally and immediately
available, will be guaranteed by MetLife, Inc. to the extent set
forth under Description of Guarantees.
MetLife, Inc. will own, directly or indirectly, all of the
common securities of the trusts. The common securities will
represent an aggregate liquidation amount equal to at least 3%
of each trusts total capitalization. The preferred
securities of each trust will represent the remaining 97% of
each trusts total capitalization. The common securities
will have terms substantially identical to, and will rank equal
in priority of payment with, the preferred securities. However,
if MetLife, Inc. defaults on the related series of debt
securities, then cash distributions and liquidation, redemption
and other amounts payable on the common securities will be
subordinate to the trust preferred securities in priority of
payment.
The trusts each have a term of approximately 55 years, but
may dissolve earlier as provided in their respective
declarations of trust. The trusts activities will be
conducted by the trustees appointed by MetLife, Inc., as the
direct or indirect holder of all of the common securities. The
holder of the common securities of each trust will be entitled
to appoint, remove or replace any of, or increase or reduce the
number of, the trustees of the trust. However, the number of
trustees shall be at least three, at least one of which shall be
an administrative trustee. The duties and obligations of the
trustees will be governed by the declaration of trust for each
trust. A majority of the trustees of each trust will be persons
who are employees or officers of or affiliated with MetLife,
Inc. One trustee of each trust will be a financial institution
which will be unaffiliated with MetLife, Inc. and which will act
as property trustee and as indenture trustee for purposes of the
Trust Indenture Act, pursuant to the terms set forth in a
prospectus supplement. In addition, unless the property trustee
maintains a principal place of business in the State of
Delaware, and otherwise meets the requirements of applicable
law, one trustee of each trust will have its principal place of
business or reside in the State of Delaware.
The property trustee will hold title to the debt securities for
the benefit of the holders of the trust securities and the
property trustee will have the power to exercise all rights,
powers and privileges under the indenture as the holder of the
debt securities. In addition, the property trustee will maintain
exclusive control of a segregated non-interest bearing bank
account to hold all payments made in respect of the debt
securities for the benefit of the holders of the trust
securities. The property trustee will make payments of
distributions and payments on liquidation, redemption and
otherwise to the holders of the trust securities out of funds
from this property account.
The rights of the holders of the trust preferred securities,
including economic rights, rights to information and voting
rights, are provided in the declarations of trust of MetLife
Capital Trust V, MetLife Capital Trust VI, MetLife
Capital Trust VII, MetLife Capital Trust VIII and
MetLife Capital Trust IX, including any amendments thereto,
the trust preferred securities, the Delaware Statutory
Trust Act and the Trust Indenture Act.
5
MetLife, Inc. will pay all fees and expenses related to the
trusts and the offering of trust preferred securities. The
principal offices of each trust is: The Bank of New York
(Delaware), 100 White Clay Center, Route 273, Newark, Delaware
19711, Attention: Corporate Trust Administration. The
telephone number of each trust is:
302-283-8905.
Please read the prospectus supplement relating to the trust
preferred securities for further information concerning the
trusts and the trust preferred securities.
USE OF
PROCEEDS
We may use the proceeds of securities sold or re-sold under this
registration statement for, among other things, general
corporate purposes. The prospectus supplement for each offering
of securities will specify the intended use of the proceeds of
that offering. Unless otherwise indicated in an accompanying
prospectus supplement, the trusts will use all of the proceeds
they receive from the sale of trust preferred securities to
purchase debt securities issued by MetLife, Inc.
RATIO OF
EARNINGS TO FIXED CHARGES
The following table sets forth MetLifes historical ratio
of earnings to fixed charges for the periods indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine
|
|
|
|
|
|
|
|
|
|
|
|
|
Months Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
For the Years Ended December 31,
|
|
|
2010
|
|
2009
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
2005
|
|
|
(In millions)
|
|
Ratio of Earnings to Fixed Charges(1),(2)
|
|
|
1.75
|
|
|
|
|
|
|
|
|
|
|
|
1.92
|
|
|
|
1.74
|
|
|
|
1.60
|
|
|
|
1.87
|
|
|
|
|
(1) |
|
For purposes of this computation, earnings are defined as income
before provision for income tax and discontinued operations and
excluding undistributed income and losses from equity method
investments, non-controlling interest and fixed charges,
excluding capitalized interest. Fixed charges are the sum of
interest and debt issue costs, interest credited to bank
deposits, interest credited to policyholder account balances, an
estimated interest component of rent expense and preferred stock
dividends. Interest costs of $312 million related to
variable interest entities are included in this computation for
the nine months ended September 30, 2010. |
|
(2) |
|
Earnings were insufficient to cover fixed charges at a 1:1 ratio
by $3,069 million and $2,860 million for the nine
months ended September 30, 2009 and the year ended
December 31, 2009, respectively, primarily due to increased
net derivatives losses on freestanding derivatives. |
DESCRIPTION
OF SECURITIES
This prospectus contains summary descriptions of the debt
securities, preferred stock, depositary shares, common stock,
warrants, purchase contracts and units that MetLife, Inc. may
sell from time to time, and the trust preferred securities
guaranteed by MetLife, Inc. that the trusts may sell from time
to time. These summary descriptions are not meant to be complete
descriptions of each security. However, this prospectus and the
accompanying prospectus supplement contain the material terms of
the securities being offered.
DESCRIPTION
OF DEBT SECURITIES
As used in this prospectus, debt securities means the
debentures, notes, bonds and other evidences of indebtedness
that MetLife, Inc. may issue from time to time. The debt
securities will either be senior debt securities or subordinated
debt securities. Unless the applicable prospectus supplement
states otherwise, senior debt securities will be issued under
the Senior Indenture dated as of November 9, 2001 between
MetLife, Inc, and Bank One Trust Company, N.A. (predecessor
to The Bank of New York Mellon Trust Company, N.A.) (the
Senior Indenture) and subordinated debt securities
will be issued under the Subordinated Indenture dated as of
June 21, 2005 between MetLife, Inc. and J.P. Morgan
Trust Company, National Association (predecessor to The
Bank of
6
New York Mellon Trust Company, N.A.) (the
Subordinated Indenture). This prospectus sometimes
refers to the Senior Indenture and the Subordinated Indenture
collectively as the Indentures.
The Senior Indenture and the Subordinated Indenture are
incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part. The statements
and descriptions in this prospectus or in any prospectus
supplement regarding provisions of the Indentures and debt
securities are summaries thereof, do not purport to be complete
and are subject to, and are qualified in their entirety by
reference to, all of the provisions of the Indentures and the
debt securities, including the definitions therein of certain
terms.
General
The debt securities will be direct unsecured obligations of
MetLife, Inc. The senior debt securities will rank equally with
all of MetLife, Inc.s other senior and unsubordinated
debt. The subordinated debt securities will be subordinate and
junior in right of payment to all of MetLife, Inc.s
present and future senior indebtedness.
Because MetLife, Inc. is principally a holding company, its
right to participate in any distribution of assets of any
subsidiary, including Metropolitan Life Insurance Company, upon
the subsidiarys liquidation or reorganization or
otherwise, is subject to the prior claims of creditors of the
subsidiary, except to the extent MetLife, Inc. may be recognized
as a creditor of that subsidiary. Accordingly, MetLife,
Inc.s obligations under the debt securities will be
effectively subordinated to all existing and future indebtedness
and liabilities of its subsidiaries, including liabilities under
contracts of insurance and annuities written by MetLife,
Inc.s insurance subsidiaries, and holders of debt
securities should look only to MetLife, Inc.s assets for
payment thereunder.
The Indentures do not limit the aggregate principal amount of
debt securities that MetLife, Inc. may issue and provide that
MetLife, Inc. may issue debt securities from time to time in one
or more series, in each case with the same or various
maturities, at par or at a discount. MetLife, Inc. may issue
additional debt securities of a particular series without the
consent of the holders of the debt securities of such series
outstanding at the time of the issuance. Any such additional
debt securities, together with all other outstanding debt
securities of that series, will constitute a single series of
debt securities under the applicable Indenture. The Indentures
also do not limit our ability to incur other debt.
Each prospectus supplement will describe the terms relating to
the specific series of debt securities being offered. These
terms will include some or all of the following:
|
|
|
|
|
the title of debt securities and whether they are subordinated
debt securities or senior debt securities;
|
|
|
|
any limit on the aggregate principal amount of the debt
securities;
|
|
|
|
the price or prices at which MetLife, Inc. will sell the debt
securities;
|
|
|
|
the maturity date or dates of the debt securities;
|
|
|
|
the rate or rates of interest, if any, which may be fixed or
variable, per annum at which the debt securities will bear
interest, or the method of determining such rate or rates, if
any;
|
|
|
|
the date or dates from which any interest will accrue, the dates
on which interest will be payable, or the method by which such
date or dates will be determined;
|
|
|
|
the right, if any, to extend the interest payment periods and
the duration of any such deferral period, including the maximum
consecutive period during which interest payment periods may be
extended;
|
|
|
|
whether the amount of payments of principal of (and premium, if
any) or interest on the debt securities may be determined with
reference to any index, formula or other method, such as one or
more currencies, commodities, equity indices or other indices,
and the manner of determining the amount of such payments;
|
|
|
|
the dates on which MetLife, Inc. will pay interest on the debt
securities and the regular record date for determining who is
entitled to the interest payable on any interest payment date;
|
|
|
|
the place or places where the principal of (and premium, if any)
and interest on the debt securities will be payable;
|
7
|
|
|
|
|
if MetLife, Inc. possesses the option to do so, the periods
within which and the prices at which MetLife, Inc. may redeem
the debt securities, in whole or in part, pursuant to optional
redemption provisions, and the other terms and conditions of any
such provisions;
|
|
|
|
MetLife, Inc.s obligation, if any, to redeem, repay or
purchase debt securities by making periodic payments to a
sinking fund or through an analogous provision or at the option
of holders of the debt securities, and the period or periods
within which and the price or prices at which MetLife, Inc. will
redeem, repay or purchase the debt securities, in whole or in
part, pursuant to such obligation, and the other terms and
conditions of such obligation;
|
|
|
|
the denominations in which the debt securities will be issued,
if other than denominations of $1,000 and integral multiples of
$1,000;
|
|
|
|
the portion, or methods of determining the portion, of the
principal amount of the debt securities which MetLife, Inc. must
pay upon the acceleration of the maturity of the debt securities
in connection with an Event of Default (as described below), if
other than the full principal amount;
|
|
|
|
the currency, currencies or currency unit in which MetLife, Inc.
will pay the principal of (and premium, if any) or interest, if
any, on the debt securities, if not United States dollars and
the manner of determining the equivalent thereof in United
States dollars;
|
|
|
|
provisions, if any, granting special rights to holders of the
debt securities upon the occurrence of specified events;
|
|
|
|
any deletions from, modifications of or additions to the Events
of Default or MetLife, Inc.s covenants with respect to the
applicable series of debt securities, and whether or not such
Events of Default or covenants are consistent with those
contained in the applicable Indenture;
|
|
|
|
the application, if any, of the terms of the Indenture relating
to defeasance and covenant defeasance (which terms are described
below) to the debt securities;
|
|
|
|
whether the subordination provisions summarized below or
different subordination provisions will apply to the debt
securities;
|
|
|
|
the terms, if any, upon which the holders may or are required to
convert or exchange such debt securities into or for MetLife,
Inc.s common stock or other securities or property or into
securities of a third party, including conversion price (which
may be adjusted), the method of calculating the conversion
price, or the conversion period;
|
|
|
|
whether any of the debt securities will be issued in global or
certificated form and, if so, the terms and conditions upon
which global debt securities may be exchanged for certificated
debt securities;
|
|
|
|
any change in the right of the trustee or the requisite holders
of debt securities to declare the principal amount thereof due
and payable because of an Event of Default;
|
|
|
|
the depositary for global or certificated debt securities;
|
|
|
|
if applicable, a discussion of the U.S. federal income tax
considerations applicable to specific debt securities;
|
|
|
|
any trustees, authenticating or paying agents, transfer agents
or registrars or other agents with respect to the debt
securities; and
|
|
|
|
any other terms of the debt securities not inconsistent with the
provisions of the Indentures, as amended or supplemented.
|
Unless otherwise specified in the applicable prospectus
supplement, the debt securities will not be listed on any
securities exchange.
Unless otherwise specified in the applicable prospectus
supplement, the debt securities will be issued in fully
registered form without coupons.
8
Debt securities may be sold at a substantial discount below
their stated principal amount, bearing no interest or interest
at a rate which at the time of issuance is below market rates.
The applicable prospectus supplement will describe the federal
income tax consequences and special considerations applicable to
any such debt securities. The debt securities may also be issued
as indexed securities or securities denominated in foreign
currencies or currency units, as described in more detail in the
prospectus supplement relating to any of the particular debt
securities. The prospectus supplement relating to specific debt
securities will also describe any special considerations and
certain additional tax considerations applicable to such debt
securities.
Subordination
The prospectus supplement relating to any offering of
subordinated debt securities will describe the specific
subordination provisions. However, unless otherwise noted in the
prospectus supplement, subordinated debt securities will be
subordinate and junior in right of payment to all of MetLife,
Inc.s Senior Indebtedness (as described below).
Under the Subordinated Indenture, Senior
Indebtedness means all amounts due on obligations in
connection with any of the following, whether outstanding at the
date of execution of the Subordinated Indenture or thereafter
incurred or created:
|
|
|
|
|
the principal of (and premium, if any) and interest in respect
of indebtedness of MetLife, Inc. for borrowed money and
indebtedness evidenced by securities, debentures, bonds or other
similar instruments issued by MetLife, Inc.;
|
|
|
|
all capital lease obligations of MetLife, Inc.;
|
|
|
|
all obligations of MetLife, Inc. issued or assumed as the
deferred purchase price of property, all conditional sale
obligations of MetLife, Inc. and all obligations of MetLife,
Inc. under any title retention agreement (but excluding trade
accounts payable in the ordinary course of business);
|
|
|
|
all obligations of MetLife, Inc. for the reimbursement on any
letter of credit, bankers acceptance, security purchase
facility or similar credit transaction;
|
|
|
|
all obligations of MetLife, Inc. in respect of interest rate
swap, cap or other agreements, interest rate future or options
contracts, currency swap agreements, currency future or option
contracts and other similar agreements;
|
|
|
|
all obligations of the types referred to above of other persons
for the payment of which MetLife, Inc. is responsible or liable
as obligor, guarantor or otherwise; and
|
|
|
|
all obligations of the types referred to above of other persons
secured by any lien on any property or asset of MetLife, Inc.
whether or not such obligation is assumed by MetLife, Inc.
|
Senior Indebtedness does not include:
|
|
|
|
|
indebtedness or monetary obligations to trade creditors created
or assumed by MetLife, Inc. in the ordinary course of business
in connection with the obtaining of materials or services;
|
|
|
|
indebtedness that is, by its terms, subordinated to, or ranks
equal with, the subordinated debt securities; and
|
|
|
|
any indebtedness of MetLife, Inc. to its affiliates (including
all debt securities and guarantees in respect of those debt
securities issued to any trust, partnership or other entity
affiliated with MetLife, Inc. that is a financing vehicle of
MetLife, Inc. in connection with the issuance by such financing
entity of preferred securities or other securities guaranteed by
MetLife, Inc.) unless otherwise expressly provided in the terms
of any such indebtedness.
|
At September 30, 2010 and December 31, 2009, Senior
Indebtedness aggregated approximately $13,419 billion and
$10,458 billion, respectively. The amount of Senior
Indebtedness which MetLife, Inc. may issue is subject to
limitations imposed by its board of directors.
9
Senior Indebtedness shall continue to be Senior Indebtedness and
be entitled to the benefits of the subordination provisions
irrespective of any amendment, modification or waiver of any
term of such Senior Indebtedness.
Unless otherwise noted in the accompanying prospectus
supplement, if MetLife, Inc. defaults in the payment of any
principal of (or premium, if any) or interest on any Senior
Indebtedness when it becomes due and payable, whether at
maturity or at a date fixed for prepayment or by declaration or
otherwise, then, unless and until such default is cured or
waived or ceases to exist, MetLife, Inc. will make no direct or
indirect payment (in cash, property, securities, by set-off or
otherwise) in respect of the principal of or interest on the
subordinated debt securities or in respect of any redemption,
retirement, purchase or other requisition of any of the
subordinated debt securities.
In the event of the acceleration of the maturity of any
subordinated debt securities, the holders of all senior debt
securities outstanding at the time of such acceleration will
first be entitled to receive payment in full of all amounts due
on the senior debt securities before the holders of the
subordinated debt securities will be entitled to receive any
payment of principal (and premium, if any) or interest on the
subordinated debt securities.
If any of the following events occurs, MetLife, Inc. will pay in
full all Senior Indebtedness before it makes any payment or
distribution under the subordinated debt securities, whether in
cash, securities or other property, to any holder of
subordinated debt securities:
|
|
|
|
|
any dissolution or
winding-up
or liquidation or reorganization of MetLife, Inc., whether
voluntary or involuntary or in bankruptcy, insolvency or
receivership;
|
|
|
|
any general assignment by MetLife, Inc. for the benefit of
creditors; or
|
|
|
|
any other marshaling of MetLife, Inc.s assets or
liabilities.
|
In such event, any payment or distribution under the
subordinated debt securities, whether in cash, securities or
other property, which would otherwise (but for the subordination
provisions) be payable or deliverable in respect of the
subordinated debt securities, will be paid or delivered directly
to the holders of Senior Indebtedness in accordance with the
priorities then existing among such holders until all Senior
Indebtedness has been paid in full. If any payment or
distribution under the subordinated debt securities is received
by the trustee of any subordinated debt securities in
contravention of any of the terms of the Subordinated Indenture
and before all the Senior Indebtedness has been paid in full,
such payment or distribution or security will be received in
trust for the benefit of, and paid over or delivered and
transferred to, the holders of the Senior Indebtedness at the
time outstanding in accordance with the priorities then existing
among such holders for application to the payment of all Senior
Indebtedness remaining unpaid to the extent necessary to pay all
such Senior Indebtedness in full.
The Subordinated Indenture does not limit the issuance of
additional Senior Indebtedness.
If debt securities are issued to a trust in connection with the
issuance of trust preferred securities, such debt securities may
thereafter be distributed pro rata to the holders of such trust
securities in connection with the dissolution of such trust upon
the occurrence of certain events described in the applicable
prospectus supplement.
Restrictive
Covenants
Unless an accompanying prospectus supplement states otherwise,
the following restrictive covenants shall apply to each series
of senior debt securities:
Limitation on Liens. So long as any senior
debt securities are outstanding, neither MetLife, Inc. nor any
of its subsidiaries will create, assume, incur or guarantee any
debt which is secured by any mortgage, pledge, lien, security
interest or other encumbrance on any capital stock of:
|
|
|
|
|
Metropolitan Life Insurance Company;
|
|
|
|
any successor to substantially all of the business of
Metropolitan Life Insurance Company which is also a subsidiary
of MetLife, Inc.; or
|
|
|
|
any corporation (other than MetLife, Inc.) having direct or
indirect control of Metropolitan Life Insurance Company or any
such successor.
|
10
However, this restriction will not apply if the debt securities
then outstanding are secured at least equally and ratably with
the otherwise prohibited secured debt so long as it is
outstanding.
Limitations on Dispositions of Stock of Certain
Subsidiaries. So long as any senior debt
securities are outstanding and subject to the provisions of the
Senior Indenture regarding mergers, consolidations and sales of
assets, neither MetLife, Inc. nor any of its subsidiaries will
sell or otherwise dispose of any shares of capital stock (other
than preferred stock having no voting rights of any kind) of:
|
|
|
|
|
Metropolitan Life Insurance Company;
|
|
|
|
any successor to substantially all of the business of
Metropolitan Life Insurance Company which is also a subsidiary
of MetLife, Inc.; or
|
|
|
|
any corporation (other than MetLife, Inc.) having direct or
indirect control of Metropolitan Life Insurance Company or any
such successor;
|
except for, in each case:
|
|
|
|
|
a sale or other disposition of any of such stock to a
wholly-owned subsidiary of MetLife, Inc. or of such
subsidiary; or
|
|
|
|
a sale or other disposition of all of such stock for at least
fair value (as determined by MetLife, Inc.s board of
directors acting in good faith); or a sale or other disposition
required to comply with an order of a court or regulatory
authority of competent jurisdiction, other than an order issued
at MetLife, Inc.s request or the request of any of
MetLife, Inc.s subsidiaries.
|
Consolidation,
Merger, Sale of Assets and Other Transactions
(i) MetLife, Inc. may not merge with or into or consolidate
with another corporation or sell, assign, transfer, lease or
convey all or substantially all of its properties and assets to,
any other corporation other than a direct or indirect
wholly-owned subsidiary of MetLife, Inc., and (ii) no
corporation may merge with or into or consolidate with MetLife,
Inc. or, except for any direct or indirect wholly-owned
subsidiary of MetLife, Inc., sell, assign, transfer, lease or
convey all or substantially all of its properties and assets to
MetLife, Inc., unless:
|
|
|
|
|
MetLife, Inc. is the surviving corporation or the corporation
formed by or surviving such merger or consolidation or to which
such sale, assignment, transfer, lease or conveyance has been
made, if other than MetLife, Inc., has expressly assumed by
supplemental indenture all the obligations of MetLife, Inc.
under the debt securities, the Indentures, and any guarantees of
preferred securities or common securities issued by the trusts;
|
|
|
|
immediately after giving effect to such transaction, no default
or Event of Default has occurred and is continuing;
|
|
|
|
if at the time any preferred securities of the trusts are
outstanding, such transaction is not prohibited under the
applicable declaration of trust and the applicable preferred
securities guarantee of each trust; and
|
|
|
|
MetLife, Inc. delivers to the trustee an officers
certificate and an opinion of counsel, each stating that the
supplemental indenture complies with the applicable Indenture.
|
Events of
Default, Notice and Waiver
Unless an accompanying prospectus supplement states otherwise,
the following shall constitute Events of Default
under the Indentures with respect to each series of debt
securities:
|
|
|
|
|
MetLife, Inc.s failure to pay any interest on any debt
security of such series when due and payable, continued for
30 days;
|
|
|
|
MetLife, Inc.s failure to pay principal (or premium, if
any) on any debt security of such series when due, regardless of
whether such payment became due because of maturity, redemption,
acceleration or otherwise, or is required by any sinking fund
established with respect to such series;
|
11
|
|
|
|
|
MetLife, Inc.s failure to observe or perform any other of
its covenants or agreements with respect to such series for
90 days after MetLife, Inc. receives notice of such failure;
|
|
|
|
certain defaults with respect to MetLife, Inc.s debt which
result in a principal amount in excess of $100,000,000 becoming
or being declared due and payable prior to the date on which it
would otherwise have become due and payable (other than the debt
securities or non-recourse debt);
|
|
|
|
certain events of bankruptcy, insolvency or reorganization of
MetLife, Inc.; and
|
|
|
|
certain events of dissolution or
winding-up
of the trusts in the event that debt securities are issued to
the trusts or a trustee of the trusts in connection with the
issuance of securities by the trusts.
|
If an Event of Default with respect to any debt securities of
any series outstanding under either of the Indentures shall
occur and be continuing, the trustee under such Indenture or the
holders of at least 25% in aggregate principal amount of the
debt securities of that series outstanding may declare, by
notice as provided in the applicable Indenture, the principal
amount (or such lesser amount as may be provided for in the debt
securities of that series) of all the debt securities of that
series outstanding to be due and payable immediately; provided
that, in the case of an Event of Default involving certain
events in bankruptcy, insolvency or reorganization, acceleration
is automatic; and, provided further, that after such
acceleration, but before a judgment or decree based on
acceleration, the holders of a majority in aggregate principal
amount of the outstanding debt securities of that series may,
under certain circumstances, rescind and annul such acceleration
if all Events of Default, other than the nonpayment of
accelerated principal, have been cured or waived. Upon the
acceleration of the maturity of original issue discount
securities, an amount less than the principal amount thereof
will become due and payable. Reference is made to the prospectus
supplement relating to any original issue discount securities
for the particular provisions relating to acceleration of
maturity thereof.
Any past default under either Indenture with respect to debt
securities of any series, and any Event of Default arising
therefrom, may be waived by the holders of a majority in
principal amount of all debt securities of such series
outstanding under such Indenture, except in the case of
(i) default in the payment of the principal of (or premium,
if any) or interest on any debt securities of such series, or
(ii) default in respect of a covenant or provision which
may not be amended or modified without the consent of the holder
of each outstanding debt security of such series affected.
The trustee is required, within 90 days after the
occurrence of a default (which is known to the trustee and is
continuing), with respect to the debt securities of any series
(without regard to any grace period or notice requirements), to
give to the holders of the debt securities of such series notice
of such default; provided, however, that, except in the case of
a default in the payment of the principal of (and premium, if
any) or interest, or in the payment of any sinking fund
installment, on any debt securities of such series, the trustee
shall be protected in withholding such notice if it in good
faith determines that the withholding of such notice is in the
interests of the holders of the debt securities of such series.
The trustee, subject to its duties during default to act with
the required standard of care, may require indemnification by
the holders of the debt securities of any series with respect to
which a default has occurred before proceeding to exercise any
right or power under the Indentures at the request of the
holders of the debt securities of such series. Subject to such
right of indemnification and to certain other limitations, the
holders of a majority in aggregate principal amount of the
outstanding debt securities of any series under either Indenture
may direct the time, method and place of conducting any
proceeding for any remedy available to the trustee, or
exercising any trust or power conferred on the trustee with
respect to the debt securities of such series.
No holder of a debt security of any series may institute any
action against MetLife, Inc. under either of the Indentures
(except actions for payment of overdue principal of (and
premium, if any) or interest on such debt security or for the
conversion or exchange of such debt security in accordance with
its terms) unless (i) the holder has given to the trustee
written notice of an Event of Default and of the continuance
thereof with respect to the debt securities of such series
specifying an Event of Default, as required under the applicable
Indenture, (ii) the holders of at least 25% in aggregate
principal amount of the debt securities of that series then
outstanding under such Indenture shall have requested the
trustee to institute such action and offered to the trustee
reasonable indemnity
12
against the costs, expenses and liabilities to be incurred in
compliance with such request, and (iii) the trustee shall
not have instituted such action within 60 days of such
request.
MetLife, Inc. is required to furnish annually to the trustee
statements as to MetLife, Inc.s compliance with all
conditions and covenants under each Indenture.
Discharge,
Defeasance and Covenant Defeasance
If indicated in the applicable prospectus supplement, MetLife,
Inc. may discharge or defease its obligations under each
Indenture as set forth below.
MetLife, Inc. may discharge certain obligations to holders of
any series of debt securities issued under either the Senior
Indenture or the Subordinated Indenture which have not already
been delivered to the trustee for cancellation and which have
either become due and payable or are by their terms due and
payable within one year (or scheduled for redemption within one
year) by irrevocably depositing with the trustee cash or, in the
case of debt securities payable only in U.S. dollars,
U.S. government obligations (as defined in either
Indenture), as trust funds in an amount certified to be
sufficient to pay when due, whether at maturity, upon redemption
or otherwise, the principal of (and premium, if any) and
interest on such debt securities.
If indicated in the applicable prospectus supplement, MetLife,
Inc. may elect either (i) to defease and be discharged from
any and all obligations with respect to the debt securities of
or within any series (except as otherwise provided in the
relevant Indenture) (defeasance) or (ii) to be
released from its obligations with respect to certain covenants
applicable to the debt securities of or within any series
(covenant defeasance), upon the deposit with the
relevant Indenture trustee, in trust for such purpose, of money
and/or
government obligations which, through the payment of principal
and interest in accordance with their terms, will provide money
in an amount sufficient, without reinvestment, to pay the
principal of (and premium, if any) or interest on such debt
securities to maturity or redemption, as the case may be, and
any mandatory sinking fund or analogous payments thereon. As a
condition to defeasance or covenant defeasance, MetLife, Inc.
must deliver to the trustee an opinion of counsel to the effect
that the holders of such debt securities will not recognize
income, gain or loss for federal income tax purposes as a result
of such defeasance or covenant defeasance and will be subject to
federal income tax on the same amounts and in the same manner
and at the same times as would have been the case if such
defeasance or covenant defeasance had not occurred. Such opinion
of counsel, in the case of defeasance under clause (i)
above, must refer to and be based upon a ruling of the Internal
Revenue Service or a change in applicable federal income tax law
occurring after the date of the relevant Indenture. In addition,
in the case of either defeasance or covenant defeasance,
MetLife, Inc. shall have delivered to the trustee (i) an
officers certificate to the effect that the relevant debt
securities exchange(s) have informed it that neither such debt
securities nor any other debt securities of the same series, if
then listed on any securities exchange, will be delisted as a
result of such deposit, and (ii) an officers
certificate and an opinion of counsel, each stating that all
conditions precedent with respect to such defeasance or covenant
defeasance have been complied with.
MetLife, Inc. may exercise its defeasance option with respect to
such debt securities notwithstanding its prior exercise of its
covenant defeasance option.
Modification
and Waiver
Under the Indentures, MetLife, Inc. and the applicable trustee
may supplement the Indentures for certain purposes which would
not materially adversely affect the interests or rights of the
holders of debt securities of a series without the consent of
those holders. MetLife, Inc. and the applicable trustee may also
modify the Indentures or any supplemental indenture in a manner
that affects the interests or rights of the holders of debt
securities with the consent of the holders of at least a
majority in aggregate principal amount of the outstanding debt
securities of each affected series issued under the Indenture.
However, the Indentures require the consent of each holder of
debt securities that would be affected by any modification which
would:
|
|
|
|
|
extend the fixed maturity of any debt securities of any series,
or reduce the principal amount thereof, or reduce the rate or
extend the time of payment of interest thereon, or reduce any
premium payable upon the redemption thereof;
|
13
|
|
|
|
|
reduce the amount of principal of an original issue discount
debt security or any other debt security payable upon
acceleration of the maturity thereof;
|
|
|
|
change the currency in which any debt security or any premium or
interest is payable;
|
|
|
|
impair the right to enforce any payment on or with respect to
any debt security;
|
|
|
|
adversely change the right to convert or exchange, including
decreasing the conversion rate or increasing the conversion
price of, any debt security (if applicable);
|
|
|
|
reduce the percentage in principal amount of outstanding debt
securities of any series, the consent of whose holders is
required for modification or amendment of the Indentures or for
waiver of compliance with certain provisions of the Indentures
or for waiver of certain defaults;
|
|
|
|
reduce the requirements contained in the Indentures for quorum
or voting; or
|
|
|
|
modify any of the above provisions.
|
If debt securities are held by a trust or a trustee of a trust,
a supplemental indenture that affects the interests or rights of
the holders of debt securities will not be effective until the
holders of not less than a majority in liquidation preference of
the preferred securities and common securities of the applicable
trust, collectively, have consented to the supplemental
indenture; provided, further, that if the consent of the holder
of each outstanding debt security is required, the supplemental
indenture will not be effective until each holder of the
preferred securities and the common securities of the applicable
trust has consented to the supplemental indenture.
The Indentures permit the holders of at least a majority in
aggregate principal amount of the outstanding debt securities of
any series issued under the Indenture which is affected by the
modification or amendment to waive MetLife, Inc.s
compliance with certain covenants contained in the Indentures.
Payment
and Paying Agents
Unless otherwise indicated in the applicable prospectus
supplement, payment of interest on a debt security on any
interest payment date will be made to the person in whose name a
debt security is registered at the close of business on the
record date for the interest.
Unless otherwise indicated in the applicable prospectus
supplement, principal, interest and premium on the debt
securities of a particular series will be payable at the office
of such paying agent or paying agents as MetLife, Inc. may
designate for such purpose from time to time. Notwithstanding
the foregoing, at MetLife, Inc.s option, payment of any
interest may be made by check mailed to the address of the
person entitled thereto as such address appears in the security
register.
Unless otherwise indicated in the applicable prospectus
supplement, a paying agent designated by MetLife, Inc. and
located in the Borough of Manhattan, The City of New York, will
act as paying agent for payments with respect to debt securities
of each series. All paying agents initially designated by
MetLife, Inc. for the debt securities of a particular series
will be named in the applicable prospectus supplement. MetLife,
Inc. may at any time designate additional paying agents or
rescind the designation of any paying agent or approve a change
in the office through which any paying agent acts, except that
MetLife, Inc. will be required to maintain a paying agent in
each place of payment for the debt securities of a particular
series.
All moneys paid by MetLife, Inc. to a paying agent for the
payment of the principal, interest or premium on any debt
security which remain unclaimed at the end of two years after
such principal, interest or premium has become due and payable
will be repaid to MetLife, Inc. upon request, and the holder of
such debt security thereafter may look only to MetLife, Inc. for
payment thereof.
Denominations,
Registrations and Transfer
Unless an accompanying prospectus supplement states otherwise,
debt securities will be represented by one or more global
certificates registered in the name of a nominee for The
Depository Trust Company (DTC). In such
14
case, each holders beneficial interest in the global
securities will be shown on the records of DTC and transfers of
beneficial interests will only be effected through DTCs
records.
A holder of debt securities may only exchange a beneficial
interest in a global security for certificated securities
registered in the holders name if:
|
|
|
|
|
DTC notifies MetLife, Inc. that it is unwilling or unable to
continue serving as the depositary for the relevant global
securities or DTC ceases to maintain certain qualifications
under the Securities Exchange Act of 1934 and no successor
depositary has been appointed for 90 days; or
|
|
|
|
MetLife, Inc. determines, in its sole discretion and subject to
the procedures of DTC, that the global security shall be
exchangeable.
|
If debt securities are issued in certificated form, they will
only be issued in the minimum denomination specified in the
accompanying prospectus supplement and integral multiples of
such denomination. Transfers and exchanges of such debt
securities will only be permitted in such minimum denomination.
Transfers of debt securities in certificated form may be
registered at the trustees corporate office or at the
offices of any paying agent or trustee appointed by MetLife,
Inc. under the Indentures. Exchanges of debt securities for an
equal aggregate principal amount of debt securities in different
denominations may also be made at such locations.
Governing
Law
The Indentures and debt securities will be governed by, and
construed in accordance with, the internal laws of the State of
New York, without regard to its principles of conflicts of laws.
Relationship
with the Trustees
The trustee under the Indentures is The Bank of New York Mellon
Trust Company, N.A. (in the case of the Senior Indenture,
as successor to Bank One Trust Company, N.A., and in the
case of the Subordinated Indenture, as successor to
J.P. Morgan Trust Company, National Association).
MetLife, Inc. and its subsidiaries maintain ordinary banking and
trust relationships with a number of banks and trust companies,
including the trustee under the Indentures.
Conversion
or Exchange Rights
The prospectus supplement will describe the terms, if any, on
which a series of debt securities may be convertible into or
exchangeable for securities described in this prospectus. These
terms will include provisions as to whether conversion or
exchange is mandatory, at the option of the holder or at
MetLife, Inc.s option. These provisions may allow or
require the number of shares of MetLife, Inc.s common
stock or other securities to be received by the holders of such
series of debt securities to be adjusted.
DESCRIPTION
OF CAPITAL STOCK
MetLife, Inc.s authorized capital stock consists of:
|
|
|
|
|
200,000,000 shares of preferred stock, par value $0.01 per
share, of which 90,857,000 shares were issued and
outstanding as of November 23, 2010:
|
|
|
|
|
|
27,600,000 shares of Floating Rate Non-Cumulative Preferred
Stock, Series A (the Series A Preferred
Stock), of which 24,000,000 shares were issued and
outstanding as of November 23, 2010;
|
|
|
|
69,000,000 shares of 6.500% Non-Cumulative Preferred Stock,
Series B (the Series B Preferred Stock) of
which 60,000,000 shares were issued and outstanding as of
November 23, 2010;
|
|
|
|
6,857,000 shares of Series B Contingent Convertible Junior
Participating
Non-Cumulative
Perpetual Preferred Stock (the Series B Contingent
Convertible Preferred Stock), of which 6,857,000 shares
were issued and outstanding as of November 23, 2010; and
|
|
|
|
10,000,000 shares of Series A Junior Participating
Preferred Stock, par value $0.01 per share, of which no shares
were issued or outstanding as of the date of this
prospectus; and
|
15
|
|
|
|
|
3,000,000,000 shares of common stock, par value $0.01 per
share, of which 985,254,724 shares were outstanding as of
November 1, 2010. The 6,857,000 shares of Series B
Contingent Convertible Preferred Stock will be convertible into
68,570,000 shares of MetLife, Inc.s common stock upon a
favorable vote of MetLife, Inc.s stockholders. The
remaining shares of authorized and unissued common stock will be
available for future issuance without additional stockholder
approval.
|
Common
Stock
Dividends. The holders of common stock, after
any preferences of holders of any preferred stock, are entitled
to receive dividends as determined by the board of directors.
The issuance of dividends will depend upon, among other factors
deemed relevant by MetLife, Inc.s board of directors,
MetLifes financial condition, results of operations, cash
requirements, future prospects and regulatory restrictions on
the payment of dividends by Metropolitan Life Insurance Company
and MetLife, Inc.s other subsidiaries. There is no
requirement or assurance that MetLife, Inc. will declare and pay
any dividends. In addition, (i) the certificates of
designation for the Series A Preferred Stock, the
Series B Preferred Stock and Series B Contingent
Convertible Preferred Stock, (ii) MetLife, Inc.s
6.40%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2066,
(iii) MetLife, Inc.s 10.75%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2069, (iv) MetLife,
Inc.s 6.817% Senior Debt Securities, Series A,
due 2018, (v) MetLife, Inc.s 7.717% Senior Debt
Securities, Series B, due 2019 (vi) upon an exchange
of the 7.875%
Fixed-to-Floating
Rate Exchangeable Surplus Trust Securities of MetLife
Capital Trust IV, the related 7.875%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2067 of MetLife, Inc.
and (vii) upon exchange of the 9.250%
Fixed-to-Floating
Rate Exchangeable Surplus Trust Securities of MetLife
Capital Trust X, the related 9.250%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2068 of MetLife, Inc.,
all prohibit the declaration or payment of dividends or
distributions on common stock under certain circumstances. Under
the certificates of designation for the Series A Preferred
Stock, the Series B Preferred Stock and Series B Contingent
Convertible Preferred Stock, if dividends on such securities are
not paid, no dividends may be paid on the common stock.
Similarly, under the 6.40%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2066, under certain
circumstances, if interest is not paid in full on such
securities, whether because of an optional deferral or a trigger
event, subject to certain exceptions, then no dividends may be
paid on the common stock.
Voting Rights. The holders of common stock are
entitled to one vote per share on all matters on which the
holders of common stock are entitled to vote and do not have any
cumulative voting rights.
Liquidation and Dissolution. In the event of
MetLife, Inc.s liquidation, dissolution or
winding-up,
the holders of common stock are entitled to share equally and
ratably in MetLife, Inc.s assets, if any, remaining after
the payment of all of MetLife, Inc.s liabilities and the
liquidation preference of any outstanding class or series of
preferred stock.
Other Rights. The holders of common stock have
no preemptive, conversion, redemption or sinking fund rights.
The holders of shares of MetLife, Inc.s common stock are
not required to make additional capital contributions.
Transfer Agent and Registrar. The transfer
agent and registrar for MetLife, Inc.s common stock is
Mellon Investor Services LLC, successor to ChaseMellon
Shareholder Services, L.L.C.
Preferred
Stock
General. MetLife, Inc.s board of
directors has the authority to issue preferred stock in one or
more series and to fix the title and number of shares
constituting any such series and the designations, powers,
preferences, limitations and relative rights including offering
price, any dividend rights (including whether dividends will be
cumulative or non-cumulative), dividend rate, voting rights,
terms of any redemption, any redemption price or prices,
conversion or exchange rights and any liquidation preferences of
the shares constituting any series, without any further vote or
action by stockholders. The specific terms of the preferred
stock will be described in the prospectus supplement.
16
MetLife, Inc. has authorized 10,000,000 shares of
Series A Junior Participating Preferred Stock for issuance
in connection with a stockholder rights plan. The stockholder
rights plan expired at the close of business on April 4,
2010 and was not renewed.
Voting Rights. The Delaware General
Corporation Law provides that the holders of preferred stock
will have the right to vote separately as a class on any
proposal involving fundamental changes in the rights of holders
of such preferred stock. The prospectus supplement will describe
the voting rights, if any, of the preferred stock.
Conversion or Exchange. The prospectus
supplement will describe the terms, if any, on which the
preferred stock may be convertible into or exchangeable for
securities described in this prospectus. These terms will
include provisions as to whether conversion or exchange is
mandatory, at the option of the holder or at MetLife,
Inc.s option. These provisions may set forth the
conversion price, the method of determining the conversion price
and the conversion period and may allow or require the number of
shares of MetLife, Inc.s common stock or other securities
to be received by the holders of preferred stock to be adjusted.
Redemption. The prospectus supplement will
describe the obligation, if any, to redeem the preferred stock
in whole or in part at the times and at the redemption prices
set forth in the applicable prospectus supplement.
Unless otherwise indicated in the applicable prospectus
supplement, MetLife, Inc. may not purchase or redeem any of the
outstanding shares or any series of preferred stock unless full
cumulative dividends, if any, have been paid or declared and set
apart for payment upon all outstanding shares of any series of
preferred stock for all past dividend periods, and unless all of
MetLife, Inc.s matured obligations with respect to all
sinking funds, retirement funds or purchase funds for all series
of preferred stock then outstanding have been met.
Certain
Provisions in MetLife, Inc.s Certificate of Incorporation
and By-Laws and in Delaware and New York Law
A number of provisions of MetLife, Inc.s certificate of
incorporation and by-laws deal with matters of corporate
governance and rights of stockholders. The following discussion
is a general summary of selected provisions of MetLife,
Inc.s certificate of incorporation and by-laws and
regulatory provisions that might be deemed to have a potential
anti-takeover effect. These provisions may have the
effect of discouraging a future takeover attempt which is not
approved by MetLife, Inc.s board of directors but which
individual stockholders may deem to be in their best interests
or in which stockholders may receive a substantial premium for
their shares over then current market prices. As a result,
stockholders who might desire to participate in such a
transaction may not have an opportunity to do so. Such
provisions will also render the removal of the incumbent board
of directors or management more difficult. Some provisions of
the Delaware General Corporation Law and the New York Insurance
Law may also have an anti-takeover effect. The following
description of selected provisions of MetLife, Inc.s
certificate of incorporation and by-laws and selected provisions
of the Delaware General Corporation Law and the New York
Insurance Law is necessarily general and reference should be
made in each case to MetLife, Inc.s certificate of
incorporation and by-laws, which are incorporated by reference
as exhibits to the registration statement of which this
prospectus forms a part, and to the provisions of those laws.
Classified
Board of Directors and Removal of Directors
Pursuant to MetLife, Inc.s certificate of incorporation,
the directors are divided into three classes, as nearly equal in
number as possible, with each class having a term of three
years. The classes serve staggered terms, such that the term of
one class of directors expires each year. Any effort to obtain
control of MetLife, Inc.s board of directors by causing
the election of a majority of the board may require more time
than would be required without a staggered election structure.
MetLife, Inc.s certificate of incorporation also provides
that, subject to the rights of the holders of any class of
preferred stock, directors may be removed only for cause at a
meeting of stockholders by a vote of a majority of the shares
then entitled to vote. This provision may have the effect of
slowing or impeding a change in membership of MetLife,
Inc.s board of directors that would effect a change of
control. As disclosed in our Proxy Statement, we expect to seek
shareholder approval at our 2011 Annual Meeting to amend
MetLife, Inc.s certificate of incorporation in order to
declassify MetLife, Inc.s board of directors and provide
for the annual election of all directors. Declassifying MetLife,
Inc.s board of directors would be phased in over a
three-year period such that directors may serve the full terms
to which they have been elected before the change to annual
elections. If
17
classification of MetLife, Inc.s board of directors is
approved at the 2011 Annual Meeting, then beginning with
MetLife, Inc.s 2014 Annual Meeting, all directors will be
elected for terms that would end at the following years
Annual Meeting.
Exercise
of Duties by Board of Directors
MetLife, Inc.s certificate of incorporation provides that
while the MetLife Policyholder Trust (as described below) is in
existence, each MetLife, Inc. director is required, in
exercising his or her duties as a director, to take the
interests of the trust beneficiaries into account as if they
were holders of the shares of common stock held in the trust,
except to the extent that any such director determines, based on
advice of counsel, that to do so would violate his or her duties
as a director under Delaware law.
Restriction
on Maximum Number of Directors and Filling of Vacancies on
MetLife, Inc.s Board of Directors
Pursuant to MetLife, Inc.s by-laws and subject to the
rights of the holders of any class of preferred stock, the
number of directors may be fixed and increased or decreased from
time to time by resolution of the board of directors, but the
board of directors will at no time consist of fewer than three
directors. Subject to the rights of the holders of any class of
preferred stock, stockholders can only remove a director for
cause by a vote of a majority of the shares entitled to vote, in
which case the vacancy caused by such removal may be filled at
such meeting by the stockholders entitled to vote for the
election of the director so removed. Any vacancy on the board of
directors, including a vacancy resulting from an increase in the
number of directors or resulting from a removal for cause where
the stockholders have not filled the vacancy, subject to the
rights of the holders of any class of preferred stock, may be
filled by a majority of the directors then in office, although
less than a quorum. If the vacancy is not so filled it will be
filled by the stockholders at the next annual meeting of
stockholders. The stockholders are not permitted to fill
vacancies between annual meetings, except where the vacancy
resulted from a removal for cause. These provisions give
incumbent directors significant authority that may have the
effect of limiting the ability of stockholders to effect a
change in management.
Advance
Notice Requirements for Nomination of Directors and Presentation
of New Business at Meetings of Stockholders; Action by Written
Consent
MetLife, Inc.s by-laws provide for advance notice
requirements for stockholder proposals and nominations for
director. In addition, pursuant to the provisions of both the
certificate of incorporation and the by-laws, action may not be
taken by written consent of stockholder. Rather, any action
taken by the stockholders must be effected at a duly called
meeting. Moreover, the stockholders do not have the power to
call a special meeting. Only the chief executive officer or the
secretary pursuant to a board resolution or, under some
circumstances, the president or a director who also is an
officer, may call a special meeting. These provisions make it
more difficult for a stockholder to place a proposal or
nomination on the meeting agenda and prohibit a stockholder from
taking action without a meeting, and therefore may reduce the
likelihood that a stockholder will seek to take independent
action to replace directors or with respect to other matters
that are not supported by management for stockholder vote.
Limitations
on Director Liability
MetLife, Inc.s certificate of incorporation contains a
provision that is designed to limit the directors
liability to the extent permitted by the Delaware General
Corporation Law and any amendments to that law. Specifically,
directors will not be held liable to MetLife, Inc. or its
stockholders for an act or omission in their capacity as a
director, except for liability as a result of:
|
|
|
|
|
a breach of the duty of loyalty to MetLife, Inc. or its
stockholders;
|
|
|
|
acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law;
|
|
|
|
payment of an improper dividend or improper repurchase of
MetLife, Inc.s stock under Section 174 of the
Delaware General Corporation Law; or
|
|
|
|
actions or omissions pursuant to which the director received an
improper personal benefit.
|
18
The principal effect of the limitation on liability provision is
that a stockholder is unable to prosecute an action for monetary
damages against a director of MetLife, Inc. unless the
stockholder can demonstrate one of the specified bases for
liability. This provision, however, does not eliminate or limit
director liability arising in connection with causes of action
brought under the federal securities laws. MetLife, Inc.s
certificate of incorporation also does not eliminate the
directors duty of care. The inclusion of the limitation on
liability provision in the certificate may, however, discourage
or deter stockholders or management from bringing a lawsuit
against directors for a breach of their fiduciary duties, even
though such an action, if successful, might otherwise have
benefited MetLife, Inc. and its stockholders. This provision
should not affect the availability of equitable remedies such as
injunction or rescission based upon a directors breach of
the duty of care.
MetLife, Inc.s by-laws also provide that MetLife, Inc.
shall indemnify its directors and officers to the fullest extent
permitted by Delaware law. MetLife, Inc. is required to
indemnify its directors and officers for all judgments, fines,
settlements, legal fees and other expenses reasonably incurred
in connection with pending or threatened legal proceedings
because of the directors or officers position with
MetLife, Inc. or another entity, including Metropolitan Life
Insurance Company, that the director or officer serves at
MetLife, Inc.s request, subject to certain conditions, and
to advance funds to MetLife, Inc.s directors and officers
to enable them to defend against such proceedings. To receive
indemnification, the director or officer must succeed in the
legal proceeding or act in good faith and in a manner reasonably
believed to be in or not opposed to the best interests of
MetLife, Inc. and with respect to any criminal action or
proceeding, in a manner he or she reasonably believed to be
lawful.
Supermajority
Voting Requirement for Amendment of Certain Provisions of the
Certificate of Incorporation and By-Laws
Some of the provisions of MetLife, Inc.s certificate of
incorporation, including those that authorize the board of
directors to create stockholder rights plans, that set forth the
duties, election and exculpation from liability of directors and
that prohibit stockholders from taking actions by written
consent, may not be amended, altered, changed or repealed unless
the amendment is approved by the vote of holders of 75% of the
then outstanding shares entitled to vote at an election of
directors. This requirement exceeds the majority vote of the
outstanding stock that would otherwise be required by the
Delaware General Corporation Law for the repeal or amendment of
such provisions of the certificate of incorporation. MetLife,
Inc.s by-laws may be amended, altered or repealed by the
board of directors or by the vote of holders of 75% of the then
outstanding shares entitled to vote in the election of
directors. These provisions make it more difficult for any
person to remove or amend any provisions that have an
anti-takeover effect.
Business
Combination Statute
In addition, as a Delaware corporation, MetLife, Inc. is subject
to Section 203 of the Delaware General Corporation Law,
unless it elects in its certificate of incorporation not to be
governed by the provisions of Section 203. MetLife, Inc.
has not made that election. Section 203 can affect the
ability of an interested stockholder of MetLife,
Inc. to engage in certain business combinations, including
mergers, consolidations or acquisitions of additional shares of
MetLife, Inc. for a period of three years following the time
that the stockholder becomes an interested
stockholder. An interested stockholder is
defined to include any person owning, directly or indirectly,
15% or more of the outstanding voting stock of a corporation.
The provisions of Section 203 are not applicable in some
circumstances, including those in which (1) the business
combination or transaction which results in the stockholder
becoming an interested stockholder is approved by
the corporations board of directors prior to the time the
stockholder becomes an interested stockholder or
(2) the interested stockholder, upon
consummation of such transaction, owns at least 85% of the
voting stock of the corporation outstanding prior to such
transaction.
Restrictions
on Acquisitions of Securities
The insurance laws and regulations of New York, the jurisdiction
in which MetLife, Inc.s principal insurance subsidiary,
Metropolitan Life Insurance Company, is organized, may delay or
impede a business combination involving MetLife, Inc. In
addition to the limitations described in the immediately
preceding paragraph, the New York Insurance Law prohibits any
person from acquiring control of Metropolitan Life Insurance
Company, either
19
directly or indirectly through any acquisition of control of
MetLife, Inc., without the prior approval of the New York
Superintendent of Insurance. That law presumes that control
exists where any person, directly or indirectly, owns, controls,
holds the power to vote or holds proxies representing 10% or
more of MetLife, Inc.s outstanding voting stock, unless
the New York Superintendent, upon application, determines
otherwise. Even persons who do not acquire beneficial ownership
of more than 10% of the outstanding shares of MetLife,
Inc.s common stock may be deemed to have acquired such
control, if the New York Superintendent determines that such
persons, directly or indirectly, exercise a controlling
influence over MetLife, Inc.s management or policies.
Therefore, any person seeking to acquire a controlling interest
in MetLife, Inc. would face regulatory obstacles which may
delay, deter or prevent an acquisition.
The insurance holding company law and other insurance laws of
many other states also regulate changes of control (generally
presumed upon acquisitions of 10% or more of voting securities)
of domestic insurers (including insurers owned by MetLife, Inc.)
and insurance holding companies such as MetLife, Inc.
Stockholder
Rights Plan
In September 1999, MetLife, Inc.s board of directors
adopted a stockholder rights plan. The stockholder rights plan
expired at the close of business on April 4, 2010 and was
not renewed.
MetLife
Policyholder Trust
Under a plan of reorganization adopted in September 1999,
Metropolitan Life Insurance Company converted from a mutual life
insurance company to a stock life insurance company subsidiary
of MetLife, Inc. MetLife established the MetLife Policyholder
Trust to hold the shares of common stock allocated to eligible
policyholders. A total of 494,466,664 shares of common
stock were distributed to the MetLife Policyholder Trust on the
effective date of the plan of reorganization. As of
September 30, 2010, the trust held 225,909,098 shares
of MetLife, Inc.s common stock. Because of the number of
shares held by the trust and the voting provisions of the trust,
the trust may affect the outcome of matters brought to a
stockholder vote.
The trustee will generally vote all of the shares of common
stock held in the trust in accordance with the recommendations
given by MetLife, Inc.s board of directors to its
stockholders or, if the board gives no such recommendation, as
directed by the board, except on votes regarding certain
fundamental corporate actions. As a result of the voting
provisions of the trust, MetLife, Inc.s board of directors
will effectively be able to control votes on all matters
submitted to a vote of stockholders, excluding those fundamental
corporate actions described below, so long as the trust holds a
substantial number of shares of MetLife, Inc.s common
stock.
If the vote relates to fundamental corporate actions specified
in the trust, the trustee will solicit instructions from the
beneficiaries and vote all shares held in the trust in
proportion to the instructions it receives, which would give
disproportionate weight to the instructions actually given by
trust beneficiaries. These actions include:
|
|
|
|
|
an election or removal of directors in which a stockholder has
properly nominated one or more candidates in opposition to a
nominee or nominees of MetLife, Inc.s board of directors
or a vote on a stockholders proposal to oppose a board
nominee for director, remove a director for cause or fill a
vacancy caused by the removal of a director by stockholders,
subject to certain conditions;
|
|
|
|
a merger or consolidation, a sale, lease or exchange of all or
substantially all of the assets, or a recapitalization or
dissolution of MetLife, Inc., in each case requiring a vote of
MetLife, Inc.s stockholders under applicable Delaware law;
|
|
|
|
any transaction that would result in an exchange or conversion
of shares of common stock held by the trust for cash, securities
or other property; and
|
|
|
|
any proposal requiring MetLife, Inc.s board of directors
to amend or redeem the rights under the stockholder rights plan,
other than a proposal with respect to which MetLife, Inc. has
received advice of nationally-recognized legal counsel to the
effect that the proposal is not a proper subject for stockholder
action under Delaware law.
|
20
DESCRIPTION
OF DEPOSITARY SHARES
The following outlines some of the general terms and provisions
of the depositary shares. Further terms of the depositary shares
and the applicable deposit agreement will be stated in the
applicable prospectus supplement. The following description and
any description of the depositary shares in a prospectus
supplement may not be complete and is subject to and qualified
in its entirety by reference to the terms and provisions of the
deposit agreement, a form of which has been or will be filed as
an exhibit to the registration statement of which this
prospectus forms a part.
The particular terms of the depositary shares offered by any
prospectus supplement and the extent to which the general
provisions described below may apply to such depositary shares
will be outlined in the applicable prospectus supplement.
General
MetLife, Inc. may choose to offer fractional interests in debt
securities or fractional shares of common stock or preferred
stock. MetLife, Inc. may issue fractional interests in debt
securities, common stock or preferred stock, as the case may be,
in the form of depositary shares. Each depositary share would
represent a fractional interest in a security of a particular
series of debt securities or a fraction of a share of common
stock or of a particular series of preferred stock, as the case
may be, and would be evidenced by a depositary receipt.
MetLife, Inc. will deposit the debt securities or shares of
common stock or preferred stock represented by depositary shares
under a deposit agreement between MetLife, Inc. and a depositary
which will be named in the applicable prospectus supplement.
Subject to the terms of the deposit agreement, as an owner of a
depositary share, you will be entitled, in proportion to the
applicable fraction of a debt security or share of common stock
or preferred stock represented by the depositary share, to all
the rights and preferences of the debt security, common stock or
preferred stock, as the case may be, represented by the
depositary share, including, as the case may be, interest,
dividend, voting, conversion, redemption, sinking fund,
repayment at maturity, subscription and liquidation rights.
Interest,
Dividends and Other Distributions
The depositary will distribute all payments of interest, cash
dividends or other cash distributions received on the debt
securities, common stock or preferred stock, as the case may be,
to you in proportion to the number of depositary shares that you
own. In the event of a distribution other than in cash, the
depositary will distribute property received by it to you in an
equitable manner, unless the depositary determines that it is
not feasible to make a distribution. In that case, the
depositary may sell the property and distribute the net proceeds
from the sale to you.
Redemption
of Depositary Shares
If a debt security, common stock or series of preferred stock
represented by depositary shares is redeemed, the depositary
will redeem your depositary shares from the proceeds received by
the depositary resulting from the redemption. The redemption
price per depositary share will be equal to the applicable
fraction of the redemption price per debt security or share of
common stock or preferred stock, as the case may be, payable in
relation to the redeemed series of debt securities, common stock
or preferred stock. Whenever MetLife, Inc. redeems debt
securities or shares of common stock or preferred stock held by
the depositary, the depositary will redeem, as of the same
redemption date, the number of depositary shares representing,
as the case may be, fractional interests in the debt securities
or shares of common stock or preferred stock redeemed. If fewer
than all the depositary shares are to be redeemed, the
depositary shares to be redeemed will be selected by lot,
proportionately or by any other equitable method as the
depositary may determine.
Exercise
of Rights under the Indentures or Voting the Common Stock or
Preferred
Upon receipt of notice of any meeting at which you are entitled
to vote, or of any request for instructions or directions from
you as holder of fractional interests in debt securities, common
stock or preferred stock, the depositary will mail to you the
information contained in that notice. Each record holder of the
depositary shares on the record date will be entitled to
instruct the depositary how to give instructions or directions
with respect to the
21
debt securities represented by that holders depositary
shares or how to vote the amount of the common stock or
preferred stock represented by that holders depositary
shares. The record date for the depositary shares will be the
same date as the record date for the debt securities, common
stock or preferred stock, as the case may be. The depositary
will endeavor, to the extent practicable, to give instructions
or directions with respect to the debt securities or to vote the
amount of the common stock or preferred stock, as the case may
be, represented by the depositary shares in accordance with
those instructions. MetLife, Inc. will agree to take all
reasonable action which the depositary may deem necessary to
enable the depositary to do so. The depositary will abstain from
giving instructions or directions with respect to your
fractional interests in the debt securities or voting shares of
the common stock or preferred stock, as the case may be, if it
does not receive specific instructions from you.
Amendment
and Termination of the Deposit Agreement
MetLife, Inc. and the depositary may amend the form of
depositary receipt evidencing the depositary shares and any
provision of the deposit agreement at any time. However, any
amendment which materially and adversely affects the rights of
the holders of the depositary shares will not be effective
unless the amendment has been approved by the holders of at
least a majority of the depositary shares then outstanding.
The deposit agreement will terminate if:
|
|
|
|
|
all outstanding depositary shares have been redeemed;
|
|
|
|
if applicable, the debt securities and the preferred stock
represented by depositary shares have been converted into or
exchanged for common stock or, in the case of debt securities,
repaid in full; or
|
|
|
|
there has been a final distribution in respect of the common
stock or preferred stock, including in connection with the
liquidation, dissolution or
winding-up
of MetLife, Inc., and the distribution proceeds have been
distributed to you.
|
Resignation
and Removal of Depositary
The depositary may resign at any time by delivering to MetLife,
Inc. notice of its election to do so. MetLife, Inc. also may, at
any time, remove the depositary. Any resignation or removal will
take effect upon the appointment of a successor depositary and
its acceptance of such appointment. MetLife, Inc. must appoint
the successor depositary within 60 days after delivery of
the notice of resignation or removal. The successor depositary
must be a bank or trust company having its principal office in
the United States and having total assets of not less than
$1,000,000,000.
Charges
of Depositary
MetLife, Inc. will pay all transfer and other taxes and
governmental charges arising solely from the existence of the
depositary arrangements. MetLife, Inc. will pay charges of the
depositary in connection with the initial deposit of the debt
securities or common stock or preferred stock, as the case may
be, and issuance of depositary receipts, all withdrawals of
depositary shares of debt securities or common stock or
preferred stock, as the case may be, by you and any repayment or
redemption of the debt securities or preferred stock, as the
case may be. You will pay other transfer and other taxes and
governmental charges, as well as the other charges that are
expressly provided in the deposit agreement to be for your
account.
Miscellaneous
The depositary will forward all reports and communications from
MetLife, Inc. which are delivered to the depositary and which
MetLife, Inc. is required or otherwise determines to furnish to
holders of debt securities, common stock or preferred stock, as
the case may be. Neither MetLife, Inc. nor the depositary will
be liable under the deposit agreement to you other than for its
gross negligence, willful misconduct or bad faith. Neither
MetLife, Inc. nor the depositary will be obligated to prosecute
or defend any legal proceedings relating to any depositary
shares, debt securities, common stock or preferred stock unless
satisfactory indemnity is furnished. MetLife, Inc. and the
depositary may rely upon written advice of counsel or
accountants, or upon information provided by persons presenting
debt securities or shares of common stock or preferred stock for
deposit, you or other persons believed to be competent and on
documents which MetLife, Inc. and the depositary believe to be
genuine.
22
DESCRIPTION
OF WARRANTS
MetLife, Inc. may issue warrants to purchase debt securities,
preferred stock, common stock or other securities described in
this prospectus, or any combination of these securities, and
these warrants may be issued independently or together with any
underlying securities and may be attached or separate from the
underlying securities. MetLife, Inc. will issue each series of
warrants under a separate warrant agreement to be entered into
between MetLife, Inc. and a warrant agent. The warrant agent
will act solely as MetLife, Inc.s agent in connection with
the warrants of such series and will not assume any obligation
or relationship of agency for or with holders or beneficial
owners of warrants.
The following outlines some of the general terms and provisions
of the warrants. Further terms of the warrants and the
applicable warrant agreement will be stated in the applicable
prospectus supplement. The following description and any
description of the warrants in a prospectus supplement may not
be complete and is subject to and qualified in its entirety by
reference to the terms and provisions of the warrant agreement,
a form of which has been or will be filed as an exhibit to the
registration statement of which this prospectus forms a part.
The applicable prospectus supplement will describe the terms of
any warrants that MetLife, Inc. may offer, including the
following:
|
|
|
|
|
the title of the warrants;
|
|
|
|
the total number of warrants;
|
|
|
|
the price or prices at which the warrants will be issued;
|
|
|
|
the currency or currencies investors may use to pay for the
warrants;
|
|
|
|
the designation and terms of the underlying securities
purchasable upon exercise of the warrants;
|
|
|
|
the price at which and the currency, currencies, or currency
units in which investors may purchase the underlying securities
purchasable upon exercise of the warrants;
|
|
|
|
the date on which the right to exercise the warrants will
commence and the date on which the right will expire;
|
|
|
|
whether the warrants will be issued in registered form or bearer
form;
|
|
|
|
information with respect to book-entry procedures, if any;
|
|
|
|
if applicable, the minimum or maximum amount of warrants which
may be exercised at any one time;
|
|
|
|
if applicable, the designation and terms of the underlying
securities with which the warrants are issued and the number of
warrants issued with each underlying security;
|
|
|
|
if applicable, the date on and after which the warrants and the
related underlying securities will be separately transferable;
|
|
|
|
if applicable, a discussion of material United States federal
income tax considerations;
|
|
|
|
the identity of the warrant agent;
|
|
|
|
the procedures and conditions relating to the exercise of the
warrants; and
|
|
|
|
any other terms of the warrants, including terms, procedures and
limitations relating to the exchange and exercise of the
warrants.
|
Warrant certificates may be exchanged for new warrant
certificates of different denominations, and warrants may be
exercised at the warrant agents corporate trust office or
any other office indicated in the applicable prospectus
supplement. Prior to the exercise of their warrants, holders of
warrants exercisable for debt securities will not have any of
the rights of holders of the debt securities purchasable upon
such exercise and will not be entitled to payments of principal
(or premium, if any) or interest, if any, on the debt securities
purchasable upon such exercise. Prior to the exercise of their
warrants, holders of warrants exercisable for shares of
preferred stock or common stock will not have any rights of
holders of the preferred stock or common stock purchasable upon
such
23
exercise and will not be entitled to dividend payments, if any,
or voting rights of the preferred stock or common stock
purchasable upon such exercise. Prior to the exercise of their
warrants, holders of warrants exercisable for other securities
described in this prospectus will not have any rights of holders
of such securities purchasable upon such exercise.
Exercise
of Warrants
A warrant will entitle the holder to purchase for cash an amount
of securities at an exercise price that will be stated in, or
that will be determinable as described in, the applicable
prospectus supplement. Warrants may be exercised at any time up
to the close of business on the expiration date set forth in the
applicable prospectus supplement. After the close of business on
the expiration date, unexercised warrants will become void.
Warrants may be exercised as set forth in the applicable
prospectus supplement. Upon receipt of payment and the warrant
certificate properly completed and duly executed at the
corporate trust office of the warrant agent or any other office
indicated in the prospectus supplement, MetLife, Inc. will, as
soon as practicable, forward the securities purchasable upon
such exercise. If less than all of the warrants represented by
such warrant certificate is exercised, a new warrant certificate
will be issued for the remaining warrants.
Enforceability
of Rights; Governing Law
The holders of warrants, without the consent of the warrant
agent, may, on their own behalf and for their own benefit,
enforce, and may institute and maintain any suit, action or
proceeding against MetLife, Inc. to enforce their rights to
exercise and receive the securities purchasable upon exercise of
their warrants. Unless otherwise stated in the prospectus
supplement, each issue of warrants and the applicable warrant
agreement will be governed by, and construed in accordance with,
the internal laws of the State of New York, without regard to
its principles of conflicts of laws.
DESCRIPTION
OF PURCHASE CONTRACTS
As may be specified in a prospectus supplement, MetLife, Inc.
may issue purchase contracts obligating holders to purchase from
MetLife, Inc., and MetLife, Inc. to sell to the holders, a
number of debt securities, shares of common stock or preferred
stock, or other securities described in this prospectus or the
applicable prospectus supplement at a future date or dates. The
purchase contracts may require MetLife, Inc. to make periodic
payments to the holders of the purchase contracts. These
payments may be unsecured or prefunded on some basis to be
specified in the applicable prospectus supplement.
The prospectus supplement relating to any purchase contracts
will specify the material terms of the purchase contracts and
any applicable pledge or depositary arrangements, including one
or more of the following:
|
|
|
|
|
The stated amount that a holder will be obligated to pay under
the purchase contract in order to purchase debt securities,
common stock, preferred stock, or other securities described in
this prospectus or the formula by which such amount shall be
determined.
|
|
|
|
The settlement date or dates on which the holder will be
obligated to purchase such securities. The prospectus supplement
will specify whether the occurrence of any events may cause the
settlement date to occur on an earlier date and the terms on
which an early settlement would occur.
|
|
|
|
The events, if any, that will cause MetLife, Inc.s
obligations and the obligations of the holder under the purchase
contract to terminate.
|
|
|
|
The settlement rate, which is a number that, when multiplied by
the stated amount of a purchase contract, determines the number
of securities that MetLife, Inc. or a trust will be obligated to
sell and a holder will be obligated to purchase under that
purchase contract upon payment of the stated amount of that
purchase contract. The settlement rate may be determined by the
application of a formula specified in the prospectus supplement.
If a formula is specified, it may be based on the market price
of such securities over a specified period or it may be based on
some other reference statistic.
|
24
|
|
|
|
|
Whether the purchase contracts will be issued separately or as
part of units consisting of a purchase contract and an
underlying security with an aggregate principal amount equal to
the stated amount. Any underlying securities will be pledged by
the holder to secure its obligations under a purchase contract.
|
|
|
|
The type of underlying security, if any, that is pledged by the
holder to secure its obligations under a purchase contract.
Underlying securities may be debt securities, common stock,
preferred stock, or other securities described in this
prospectus or the applicable prospectus supplement.
|
|
|
|
The terms of the pledge arrangement relating to any underlying
securities, including the terms on which distributions or
payments of interest and principal on any underlying securities
will be retained by a collateral agent, delivered to MetLife,
Inc. or be distributed to the holder.
|
|
|
|
The amount of the contract fee, if any, that may be payable by
MetLife, Inc. to the holder or by the holder to MetLife, Inc.,
the date or dates on which the contract fee will be payable and
the extent to which MetLife, Inc. or the holder, as applicable,
may defer payment of the contract fee on those payment dates.
The contract fee may be calculated as a percentage of the stated
amount of the purchase contract or otherwise.
|
The descriptions of the purchase contracts and any applicable
underlying security or pledge or depository arrangements in this
prospectus and in any prospectus supplement are summaries of the
material provisions of the applicable agreements and are subject
to and qualified in their entirety by reference to the terms and
provisions of the purchase contract agreement, pledge agreement
and deposit agreement, forms of which have been or will be filed
as exhibits to the registration statement of which this
prospectus forms a part.
DESCRIPTION
OF UNITS
As specified in the applicable prospectus supplement, MetLife,
Inc. may issue units comprised of one or more of the other
securities described in this prospectus in any combination. Each
unit may also include debt obligations of third parties, such as
U.S. Treasury securities. Each unit will be issued so that
the holder of the unit is also the holder of each security
included in the unit. Thus, the holder of a unit will have the
rights and obligations of a holder of each included security.
The prospectus supplement will describe:
|
|
|
|
|
the designation and terms of the units and of the securities
comprising the units, including whether and under what
circumstances the securities comprising the units may be held or
transferred separately;
|
|
|
|
a description of the terms of any unit agreement governing the
units;
|
|
|
|
a description of the provisions for the payment, settlement,
transfer or exchange of the units; and
|
|
|
|
whether the units will be issued in fully registered or global
form.
|
The descriptions of the units and any applicable underlying
security or pledge or depositary arrangements in this prospectus
and in any prospectus supplement are summaries of the material
provisions of the applicable agreements and are subject to, and
qualified in their entirety by reference to, the terms and
provisions of the applicable agreements, forms of which have
been or will be filed as exhibits to the registration statement
of which this prospectus forms a part.
DESCRIPTION
OF TRUST PREFERRED SECURITIES
The following outlines some of the general terms and provisions
of the trust preferred securities. Further terms of the trust
preferred securities and the amended and restated declarations
of trust will be stated in the applicable prospectus supplement.
The prospectus supplement will also indicate whether the general
terms described in this section apply to that particular series
of trust preferred securities. The following description and any
description of the trust preferred securities and amended and
restated declarations of trust in a prospectus supplement may
not be complete and are subject to and qualified in their
entirety by reference to the terms and provisions of the amended
and restated declarations of trust, forms of which have been or
will be filed as exhibits to the registration statement of which
this prospectus forms a part.
25
General
Each trust may issue only one series of trust preferred
securities having terms described in the prospectus supplement.
The declaration of trust of each trust will authorize the
administrative trustees, on behalf of the trust, to issue the
trust preferred securities of the trust. The trusts will use all
of the proceeds they receive from the sale of trust preferred
securities and common securities to purchase debt securities
issued by MetLife, Inc. The debt securities will be held in
trust by the trusts property trustee for the benefit of
the holders of the trust preferred securities and common
securities.
The trust preferred securities of each trust will have such
terms as are set forth in the trusts declaration of trust,
including as relates to distributions, redemption, voting,
liquidation rights and the other preferred, deferral and special
rights and restrictions. A prospectus supplement relating to the
trust preferred securities being offered will include specific
terms relating to the offering. These terms will include some or
all of the following:
|
|
|
|
|
the distinctive designation of the trust preferred securities;
|
|
|
|
the number of trust preferred securities issued by the trust;
|
|
|
|
the total and per-security liquidation amount of the trust
preferred securities;
|
|
|
|
the annual distribution rate, or method of determining such
rate, for trust preferred securities of the trust;
|
|
|
|
the date or dates on which distributions will be payable and any
corresponding record dates;
|
|
|
|
whether distributions on the trust preferred securities will be
cumulative;
|
|
|
|
if the trust preferred securities have cumulative distribution
rights, the date or dates, or method of determining the date or
dates, from which distributions on the trust preferred
securities will be cumulative;
|
|
|
|
the amount or amounts that will be paid out of the assets of the
trust to the holders of the trust preferred securities of the
trust upon voluntary or involuntary dissolution,
winding-up
or termination of the trust;
|
|
|
|
the obligation, if any, of the trust to purchase or redeem the
trust preferred securities;
|
|
|
|
if the trust is to purchase or redeem the trust preferred
securities:
|
|
|
|
the price or prices at which the trust preferred securities will
be purchased or redeemed in whole or in part;
|
|
|
|
the period or periods within which the trust preferred
securities will be purchased or redeemed, in whole or in part;
|
|
|
|
the terms and conditions upon which the trust preferred
securities will be purchased or redeemed, in whole or in part;
|
|
|
|
the voting rights, if any, of the trust preferred securities in
addition to those required by law, including:
|
|
|
|
|
|
the number of votes per trust preferred security; and
|
|
|
|
any requirement for the approval by the holders of trust
preferred securities as a condition to specified action or
amendments to the trusts declaration of trust;
|
|
|
|
|
|
the rights, if any, to defer distributions on the trust
preferred securities by extending the interest payment period on
the related debt securities;
|
|
|
|
if the trust preferred securities may be converted into or
exercised or exchanged for MetLifes common stock or
preferred stock or any other securities, the terms on which
conversion, exercise or exchange is mandatory, at the option of
the holder or at the option of each trust, the date on or the
period during which conversion, exercise or exchange may occur,
the initial conversion, exercise or exchange price or rate and
the circumstances or manner in which the amount of common stock
or preferred stock or other securities issuable upon conversion,
exercise or exchange may be adjusted;
|
|
|
|
the terms upon which the debt securities may be distributed to
holders of trust preferred securities;
|
26
|
|
|
|
|
whether the preferred securities are to be issued in book-entry
form and represented by one or more global certificates;
|
|
|
|
certain U.S. federal income tax considerations;
|
|
|
|
if applicable, any securities exchange upon which the trust
preferred securities shall be listed;
|
|
|
|
provisions relating to events of default and the rights of
holders of trust preferred securities in the event of default;
|
|
|
|
other agreements or other rights including upon the
consolidation or merger of the trust; and
|
|
|
|
any other relative rights, preferences, privileges, limitations
or restrictions of the trust preferred securities not
inconsistent with the trusts declaration of trust or
applicable law.
|
All trust preferred securities offered will be guaranteed by
MetLife, Inc. to the extent set forth under Description of
Guarantees. Any material United States federal income tax
considerations applicable to an offering of trust preferred
securities will be described in the applicable prospectus
supplement.
In connection with the issuance of preferred securities, each
trust will issue one series of common securities. The
declaration of each trust authorizes the administrative trustees
to issue on behalf of such trust one series of common securities
having such terms including distributions, redemption, voting,
liquidation rights or such restrictions as shall be set forth
therein. The terms of the common securities issued by the trust
will be substantially identical to the terms of the preferred
securities issued by such trust and the common securities will
rank equally, and payments will be made thereon pro rata, with
the preferred securities. However, upon an event of default
under the declaration of trust, the rights of the holders of the
common securities to payment in respect of distributions and
payments upon liquidation, redemption and otherwise will be
subordinated to the rights of the holders of the preferred
securities. Except in certain limited circumstances, the common
securities will also carry the right to vote, and appoint,
remove or replace any of the trustees of a trust. MetLife, Inc.
will own, directly or indirectly, all of the common securities
of each trust.
Enforcement
of Certain Rights by Holders of Trust Preferred
Securities
If an event of default occurs, and is continuing, under the
declaration of trust of any of the trusts, the holders of the
preferred securities of that trust would typically rely on the
property trustee to enforce its rights as a holder of the
related debt securities against MetLife, Inc. Additionally,
those who together hold a majority of the liquidation amount of
the trusts preferred securities will have the right to:
|
|
|
|
|
direct the time, method and place of conducting any proceeding
for any remedy available to the property trustee; or
|
|
|
|
direct the exercise of any trust or power that the property
trustee holds under the declaration of trust, including the
right to direct the property trustee to exercise the remedies
available to it as a holder of MetLife, Inc.s debt
securities.
|
If the property trustee fails to enforce its rights under the
applicable series of debt securities, to the fullest extent
permitted by law, a holder of trust preferred securities of such
trust may institute a legal proceeding directly against MetLife,
Inc. to enforce the property trustees rights under the
applicable series of debt securities without first instituting
any legal proceeding against the property trustee or any other
person or entity.
Notwithstanding the foregoing, if an event of default occurs and
the event is attributable to MetLife, Inc.s failure to pay
interest or principal on the debt securities when due, including
any payment on redemption, and this debt payment failure is
continuing, a preferred securities holder of the trust may
directly institute a proceeding for the enforcement of this
payment. Such a proceeding will be limited, however, to
enforcing the payment of this principal or interest only up to
the value of the aggregate liquidation amount of the
holders preferred securities as determined after the due
date specified in the applicable series of debt securities.
27
DESCRIPTION
OF GUARANTEES
The following outlines some of the general terms and provisions
of the guarantees. Further terms of the guarantees will be
stated in the applicable prospectus supplement. The prospectus
supplement will also indicate whether the general terms
described in this section apply to those guarantees. The
following description and any description of the guarantees in a
prospectus supplement may not be complete and is subject to and
qualified in its entirety by reference to the terms and
provisions of the guarantee agreements, forms of which have been
or will be filed as exhibits to the registration statement of
which this prospectus forms a part, and the Trust Indenture
Act.
MetLife, Inc. will execute and deliver the guarantees for the
benefit of the holders of the trust preferred securities. Each
guarantee will be held by the guarantee trustee for the benefit
of holders of the trust preferred securities to which it relates.
Each guarantee will be qualified as an indenture under the
Trust Indenture Act. The Bank of New York Mellon
Trust Company, N.A. will act as indenture trustee under
each guarantee for purposes of the Trust Indenture Act.
General
Pursuant to each guarantee, MetLife, Inc. will irrevocably and
unconditionally agree, to the extent set forth in the guarantee,
to pay in full, to the holders of the related trust preferred
securities, the following guarantee payments, to the extent
these guarantee payments are not paid by, or on behalf of, the
related trust, regardless of any defense, right of set-off or
counterclaim that MetLife, Inc. may have or assert against any
person:
|
|
|
|
|
any accrued and unpaid distributions required to be paid on the
trust preferred securities of the trust, but if and only if and
to the extent that the trust has funds legally and immediately
available to make those payments;
|
|
|
|
any distributions of MetLifes common stock or preferred
stock or any of its other securities, in the event that the
trust preferred securities may be converted into or exercised
for common stock or preferred stock, to the extent the
conditions of such conversion or exercise have occurred or have
been satisfied and the trust does not distribute such shares or
other securities but has received such shares or other
securities;
|
|
|
|
the redemption price, including all accrued and unpaid
distributions to the date of redemption, with respect to any
trust preferred securities called for redemption by the trust,
but if and only to the extent the trust has funds legally and
immediately available to make that payment; and
|
|
|
|
upon a dissolution,
winding-up
or termination of the trust, other than in connection with the
distribution of debt securities to the holders of trust
preferred securities of the trust, the lesser of:
|
|
|
|
|
|
the total of the liquidation amount and all accrued and unpaid
distributions on the trust preferred securities of the trust to
the date of payment, to the extent the trust has funds legally
and immediately available to make that payment; and
|
|
|
|
the amount of assets of the trust remaining available for
distribution to holders of trust preferred securities of the
trust in liquidation of the trust.
|
MetLife, Inc. may satisfy its obligation to make a guarantee
payment by directly paying the required amounts to the holders
of the related trust preferred securities or by causing the
related trust to pay such amounts to such holders.
Each guarantee will constitute a guarantee of payments with
respect to the related trust preferred securities from the time
of issuance of the trust preferred securities. The guarantees
will not apply to the payment of distributions and other
payments on the trust preferred securities when the related
trust does not have sufficient funds legally and immediately
available to make the distributions or other payments. If
MetLife, Inc. does not make interest payments on the debt
securities purchased by a trust, such trust will not pay
distributions on the preferred securities issued by such trust
and will not have funds available therefor. The guarantee, when
taken together with MetLife, Inc.s obligations under the
debt securities, the Indentures and the declarations of trust,
will provide a full and unconditional guarantee by MetLife, Inc.
of payments due on the trust preferred securities.
28
MetLife, Inc. will also agree separately, through guarantees of
the common securities, to irrevocably and unconditionally
guarantee the obligations of the trusts with respect to the
common securities to the same extent as the guarantees of the
preferred securities. However, upon an event of default under
the Indentures, holders of preferred securities shall have
priority over holders of common securities with respect to
distributions and payments on liquidation, redemption or
otherwise.
Subordination
MetLife, Inc.s obligation under each guarantee to make the
guarantee payments will be an unsecured obligation of MetLife,
Inc. and, if subordinated debt securities are issued to the
applicable trust and unless otherwise noted in the prospectus
supplement, will rank:
|
|
|
|
|
subordinate and junior in right of payment to all of MetLife,
Inc.s other liabilities, including the subordinated debt
securities, except those obligations or liabilities ranking
equal or subordinate to the guarantees by their terms;
|
|
|
|
equally with any other securities, liabilities or obligations
that may have equal ranking by their terms; and
|
|
|
|
senior to all of MetLife, Inc.s common stock.
|
If subordinated debt securities are issued to the applicable
trust, the terms of the trust preferred securities will provide
that each holder of trust preferred securities, by accepting the
trust preferred securities, agrees to the subordination
provisions and other terms of the guarantee related to
subordination.
Each guarantee will constitute a guarantee of payment and not of
collection. This means that the holder of trust preferred
securities may institute a legal proceeding directly against
MetLife, Inc. to enforce its rights under the guarantee without
first instituting a legal proceeding against any other person or
entity.
Each guarantee will be unsecured and, because MetLife, Inc. is
principally a holding company, will be effectively subordinated
to all existing and future liabilities of MetLife, Inc.s
subsidiaries, including liabilities under contracts of insurance
and annuities written by MetLife, Inc.s insurance
subsidiaries. The guarantee does not limit the incurrence or
issuance of other secured or unsecured debt by MetLife, Inc.
Amendments
and Assignment
For any changes that materially and adversely affect the rights
of holders of the related trust preferred securities, each
guarantee may be amended only if there is prior approval of the
holders of more than 50% in liquidation amount of the
outstanding trust preferred securities issued by the applicable
trust. All guarantees and agreements contained in each guarantee
will bind the successors, assigns, receivers, trustees and
representatives of MetLife, Inc. and will inure to the benefit
of the holders of the related trust preferred securities of the
applicable trust then outstanding.
Termination
Each guarantee will terminate and will have no further force and
effect as to the related trust preferred securities upon:
|
|
|
|
|
distribution of debt securities to the holders of all trust
preferred securities of the applicable trust; or
|
|
|
|
full payment of the amounts payable upon liquidation of the
applicable trust.
|
Each guarantee will continue to be effective or will be
reinstated, as the case may be, if at any time any holder of the
related trust preferred securities must restore payment of any
sums paid with respect to the trust preferred securities or
under the guarantee.
Events of
Default
Each guarantee provides that an event of default under a
guarantee occurs upon MetLife, Inc.s failure to perform
any of its obligations under the applicable guarantee.
29
The holders of a majority or more in liquidation amount of the
trust preferred securities to which any guarantee relates may
direct the time, method and place of conducting any proceeding
for any remedy available to the guarantee trustee with respect
to the guarantee or may direct the exercise of any trust or
power conferred upon the guarantee trustee in respect of the
guarantee.
If the guarantee trustee fails to enforce the guarantee, any
holder of the related trust preferred securities may institute a
legal proceeding directly against MetLife, Inc. to enforce the
holders rights under such guarantee without first
instituting a legal proceeding against the trust, the guarantee
trustee or any other person or entity.
Furthermore, if MetLife, Inc. fails to make a guarantee payment,
a holder of trust preferred securities may directly institute a
proceeding against MetLife, Inc. for enforcement of the trust
preferred securities guarantee for such payment.
The holders of a majority or more in liquidation amount of trust
preferred securities of any series may, by vote, on behalf of
the holders of all the trust preferred securities of the series,
waive any past event of default and its consequences.
Information
Concerning the Guarantee Trustee
Prior to an event of default with respect to any guarantee and
after the curing or waiving of all events of default with
respect to the guarantee, the guarantee trustee may perform only
the duties that are specifically set forth in the guarantee.
Once a guarantee event of default has occurred and is
continuing, the guarantee trustee is to exercise, with respect
to the holder of the trust preferred securities of the series,
the same degree of care as a prudent individual would exercise
in the conduct of his or her own affairs. Unless the guarantee
trustee is offered reasonable indemnity against the costs,
expenses and liabilities which may be incurred by the guarantee
trustee by a holder of the related trust preferred securities,
the guarantee trustee is not required to exercise any of its
powers under any guarantee at the request of the holder.
Additionally, the guarantee trustee is not required to expend or
risk its own funds or otherwise incur any financial liability in
the performance of its duties if the guarantee trustee
reasonably believes that it is not assured repayment or adequate
indemnity.
The guarantee trustee is The Bank of New York Mellon
Trust Company, N.A., which is one of a number of banks and
trust companies with which MetLife, Inc. and its subsidiaries
maintain ordinary banking and trust relationships.
Governing
Law
Each guarantee will be governed by, and construed in accordance
with, the internal laws of the State of New York, without
regard to its principles of conflicts of laws.
PLAN OF
DISTRIBUTION
MetLife, Inc. may sell the securities being offered hereby in
one or more of the following ways from time to time:
|
|
|
|
|
to underwriters or dealers for resale to the public or to
institutional investors;
|
|
|
|
directly to institutional investors; or
|
|
|
|
through agents to the public or to institutional investors.
|
The prospectus supplement with respect to each series of
securities will state the terms of the offering of the
securities, including:
|
|
|
|
|
the name or names of any underwriters or agents;
|
|
|
|
the purchase price of the securities and the proceeds to be
received by MetLife, Inc. or the applicable trust from the sale;
|
30
|
|
|
|
|
any underwriting discounts or agency fees and other items
constituting underwriters or agents compensation;
|
|
|
|
any initial public offering price;
|
|
|
|
any discounts or concessions allowed or reallowed or paid to
dealers; and
|
|
|
|
any securities exchange on which the securities may be listed.
|
If MetLife, Inc. or the trusts use underwriters in the sale, the
securities will be acquired by the underwriters for their own
account and may be resold from time to time in one or more
transactions, including:
|
|
|
|
|
negotiated transactions;
|
|
|
|
at a fixed public offering price or prices, which may be changed;
|
|
|
|
at market prices prevailing at the time of sale;
|
|
|
|
at prices related to prevailing market prices; or
|
|
|
|
at negotiated prices.
|
The securities may also be offered and sold, if so indicated in
the prospectus supplement, in connection with a remarketing upon
their purchase, in accordance with a redemption or repayment
pursuant to their terms, or otherwise, by one or more
remarketing firms, acting as principals for their own accounts
or as agents for MetLife, Inc. or the trusts. The prospectus
supplement will identify any remarketing firm and will describe
the terms of its agreement, if any, with MetLife, Inc. or the
trusts and its compensation.
Unless otherwise stated in a prospectus supplement, the
obligations of the underwriters to purchase any securities will
be conditioned on customary closing conditions and the
underwriters will be obligated to purchase all of such series of
securities, if any are purchased.
If MetLife, Inc. sells the securities directly or through agents
designated by it, MetLife, Inc. will identify any agent involved
in the offering and sale of the securities and will list any
commissions payable by MetLife, Inc. to the agent in the
accompanying prospectus supplement. Unless indicated otherwise
in the prospectus supplement, any such agent will be acting on a
best efforts basis to solicit purchases for the period of its
appointment.
MetLife, Inc. may authorize agents, underwriters or dealers to
solicit offers by certain institutional investors to purchase
securities and provide for payment and delivery on a future date
specified in an accompanying prospectus supplement. MetLife,
Inc. will describe any such arrangement in the prospectus
supplement. Any such institutional investor may be subject to
limitations on the minimum amount of securities that it may
purchase or on the portion of the aggregate principal amount of
such securities that it may sell under such arrangements.
Institutional investors from which such authorized offers may be
solicited include:
|
|
|
|
|
commercial and savings banks;
|
|
|
|
insurance companies;
|
|
|
|
pension funds;
|
|
|
|
investment companies;
|
|
|
|
educational and charitable institutions; and
|
|
|
|
such other institutions as MetLife, Inc. may approve.
|
Underwriters, dealers, agents and remarketing firms may be
entitled under agreements entered into with MetLife, Inc.
and/or the
applicable trust, or both, to indemnification by MetLife, Inc.
against certain civil liabilities, including liabilities under
the Securities Act, or to contribution with respect to payments
which the underwriters, dealers, agents and remarketing firms
may be required to make. Underwriters, dealers, agents and
remarketing agents may be customers of, engage in transactions
with, or perform services for MetLife, Inc., any trust,
and/or
MetLife, Inc.s affiliates in the ordinary course of
business.
31
Each series of securities will be a new issue of securities and
will have no established trading market other than the common
stock which is listed on the New York Stock Exchange. Any common
stock sold will be listed on the New York Stock Exchange, upon
official notice of issuance. The securities, other than the
common stock, may or may not be listed on a national securities
exchange. Any underwriters to whom securities are sold by
MetLife, Inc. or any trust for public offering and sale may make
a market in the securities, but such underwriters will not be
obligated to do so and may discontinue any market making at any
time without notice.
Any offering of trust preferred securities will be made in
compliance with Rule 2810 of the Conduct Rules of the
National Association of Securities Dealers, Inc.
LEGAL
OPINIONS
Unless otherwise indicated in the applicable prospectus
supplement, the validity of the securities offered hereby will
be passed upon for MetLife, Inc. by Matthew Ricciardi, Chief
Counsel Public Company and Corporate Law, of
MetLife Group, Inc., an affiliate of MetLife, Inc.
Mr. Ricciardi is paid a salary by an affiliate of MetLife,
Inc., is a participant in various employee benefit plans offered
by MetLife, Inc. and its affiliates to employees generally, is
paid equity-based compensation in accordance with MetLifes
compensation programs and owns MetLife, Inc. common stock.
Certain matters of Delaware law relating to the validity of the
trust preferred securities of MetLife Capital Trust V,
MetLife Capital Trust VI, MetLife Capital Trust VII,
MetLife Capital Trust VIII and MetLife Capital
Trust IX will be passed upon for the trust by Richards,
Layton & Finger, P.A., Wilmington, Delaware, special
Delaware counsel for the trusts.
EXPERTS
The consolidated financial statements and the related financial
statement schedules incorporated in this prospectus by reference
from MetLifes Annual Report on
Form 10-K,
and the effectiveness of MetLifes internal control over
financial reporting for the year ended December 31, 2009,
have been audited by Deloitte & Touche LLP, an
independent registered public accounting firm, as stated in
their reports (which (1) express an unqualified opinion on
the consolidated financial statements and financial statement
schedules and includes an explanatory paragraph regarding
changes in MetLifes method of accounting for the
recognition and presentation of
other-than-temporary
impairment losses for certain investments as required by
accounting guidance adopted on April 1, 2009, its method of
accounting for certain assets and liabilities to a fair value
measurement approach as required by accounting guidance adopted
on January 1, 2008, and its method of accounting for
deferred acquisition costs and for income taxes as required by
accounting guidance adopted on January 1, 2007, and
(2) express an unqualified opinion on MetLifes
effectiveness of internal control over financial reporting),
which are incorporated herein by reference. Such consolidated
financial statements and financial statement schedules have been
so incorporated in reliance upon the reports of such firm given
upon their authority as experts in accounting and auditing.
The audited historical combined financial statements of American
Life Insurance Company, ALICO Services, Inc. and Delaware
American Life Insurance Company and subsidiaries included as
Exhibit 99.1 to MetLife, Inc.s Current Report on
Form 8-K
dated August 2, 2010 and incorporated by reference in this
prospectus have been so incorporated in reliance on the report
of PricewaterhouseCoopers LLP, an independent registered public
accounting firm, given on the authority of said firm as experts
in auditing and accounting.
32